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Background: Effective interventions are needed to prevent cardiovascular disease (CVD) in people with
severe mental illnesses (SMI) because their risk of CVD is higher than that of the general population.
Objectives: (1) Develop and validate risk models for predicting CVD events in people with SMI and
evaluate their cost-effectiveness, (2) develop an intervention to reduce levels of cholesterol and CVD risk in
SMI and (3) test the clinical effectiveness and cost-effectiveness of this new intervention in primary care.
Design: Mixed methods with patient and public involvement throughout. The mixed methods were (1) a
prospective cohort and risk score validation study and cost-effectiveness modelling, (2) development work
(focus groups, updated systematic review of interventions, primary care database studies investigating
statin prescribing and effectiveness) and (3) cluster randomised controlled trial (RCT) assessing the clinical
effectiveness and cost-effectiveness of a new practitioner-led intervention, and fidelity assessment of
audio-recorded appointments.
Setting: General practices across England.
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Participants: All studies included adults with SMI (schizophrenia, bipolar disorder or other non-organic
psychosis). The RCT included adults with SMI and two or more CVD risk factors.
Interventions: The intervention consisted of 8–12 appointments with a practice nurse/health-care
assistant over 6 months, involving collaborative behavioural approaches to CVD risk factors. The
intervention was compared with routine practice with a general practitioner (GP).
Main outcome measures: The primary outcome for the risk score work was CVD events, in the cost-
effectiveness modelling it was quality-adjusted life-years (QALYs) and in the RCT it was level of total cholesterol.
Data sources: Databases studies used The Health Improvement Network (THIN). Intervention development
work included focus groups and systematic reviews. The RCT collected patient self-reported and routine
NHS GP data. Intervention appointments were audio-recorded.
Results: Two CVD risk score models were developed and validated in 38,824 people with SMI in THIN:
the Primrose lipid model requiring cholesterol levels, and the Primrose body mass index (BMI) model with
no blood test. These models performed better than published Cox Framingham models. In health economic
modelling, the Primrose BMI model was most cost-effective when used as an algorithm to drive statin
prescriptions. Focus groups identified barriers to, and facilitators of, reducing CVD risk in SMI including patient
engagement and motivation, staff confidence, involving supportive others, goal-setting and continuity of care.
Findings were synthesised with evidence from updated systematic reviews to create the Primrose intervention
and training programme. THIN cohort studies in 16,854 people with SMI demonstrated that statins effectively
reduced levels of cholesterol, with similar effect sizes to those in general population studies over 12–24 months
(mean decrease 1.2mmol/l). Cluster RCT: 76 GP practices were randomised to the Primrose intervention
(n= 38) or treatment as usual (TAU) (n= 38). The primary outcome (level of cholesterol) was analysed for 137
out of 155 participants in Primrose and 152 out of 172 in TAU. There was no difference in levels of cholesterol
at 12 months [5.4 mmol/l Primrose vs. 5.5 mmol/l TAU; coefficient 0.03; 95% confidence interval (CI) –0.22 to
0.29], nor in secondary outcomes related to cardiometabolic parameters, well-being or medication adherence.
Mean cholesterol levels decreased over 12 months in both arms (–0.22 mmol/l Primrose vs. –0.39 mmol/l TAU).
There was a significant reduction in the cost of inpatient mental health attendances (–£799, 95% CI –£1480
to –£117) and total health-care costs (–£895, 95% CI –£1631 to –£160; p= 0.012) in the intervention group,
but no significant difference in QALYs (–0.011, 95% CI –0.034 to 0.011). A total of 69% of patients attended
two or more Primrose appointments. Audiotapes revealed moderate fidelity to intervention delivery (67.7%).
Statin prescribing and adherence was rarely addressed.
Limitations: RCT participants and practices may not represent all UK practices. CVD care in the TAU arm
may have been enhanced by trial procedures involving CVD risk screening and feedback.
Conclusions: SMI-specific CVD risk scores better predict new CVD if used to guide statin prescribing in
SMI. Statins are effective in reducing levels of cholesterol in people with SMI in UK clinical practice. This
primary care RCT evaluated an evidence-based practitioner-led intervention that was well attended by
patients and intervention components were delivered. No superiority was shown for the new intervention
over TAU for level of cholesterol, but cholesterol levels decreased over 12 months in both arms and the
intervention showed fewer inpatient admissions. There was no difference in cholesterol levels between
the intervention and TAU arms, which might reflect better than standard general practice care in TAU,
heterogeneity in intervention delivery or suboptimal emphasis on statins.
Future work: The new risk score should be updated, deployed and tested in different settings and
compared with the latest versions of CVD risk scores in different countries. Future research on CVD risk
interventions should emphasise statin prescriptions more. The mechanism behind lower costs with the
Primrose intervention needs exploring, including SMI-related training and offering frequent support to
people with SMI in primary care.
Trial registration: Current Controlled Trials ISRCTN13762819.
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Plain English summary
People with severe mental illnesses (SMI), including schizophrenia and bipolar disorder, die earlier fromheart attacks and strokes. This programme of work explored how to best prevent heart attacks or
stroke in people with SMI.
First, a new computerised tool for general practitioner (GP) practices was developed to predict heart
attacks for people with SMI. This was then compared with existing computerised tools and it was found
that this new tool was better. Second, staff and patients were asked for their views on what a service for
reducing the risk of heart attacks should look like. Existing research was reviewed and national data were
used to look at statin prescribing (a medication for lowering levels of cholesterol) for people with SMI. It
was found that statins decreased levels of cholesterol, that physical activity and diet lowered weight, and
that accessing Stop Smoking Services and medications reduced smoking.
This evidence was used to develop a new service to lower levels of cholesterol in people with SMI. Patient
experts were involved in decisions of what to include in the service and in training nurses to review medication,
diet, physical activity, smoking, blood pressure or diabetes mellitus in 8–12 appointments at GP practices.
Third, whether or not patients had lower levels of cholesterol after receiving the new service at their GP
practice when compared with patients receiving GP usual care was assessed. The first large trial was
delivered to improve physical health in SMI in general practices. A total of 327 patients took part in
76 general practices: 38 practices had the new service and 38 did not. The service was delivered well
and people attended. Levels of cholesterol went down for both those who did and those who did not
receive the new service. There was no difference between the groups in terms of levels of cholesterol or
other physical measures. The care provided by the general practices that did not receive the new Primrose
service may have been better than normal general practice care. These general practices still had to identify
people with raised CVD risk factors to take part in the study who might not have been identified if the
general practice had not taken part in the study. This may explain why no differences were found. People
who received the new service had fewer inpatient mental health admissions over the year.
DOI: 10.3310/pgfar07020 PROGRAMME GRANTS FOR APPLIED RESEARCH 2019 VOL. 7 NO. 2
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Osborn et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxi

Scientific summary
Background
People with severe mental illnesses (SMI), including schizophrenia, bipolar disorder and psychosis, die up to
20 years earlier than the general population from cardiovascular disease (CVD). They have increased
risk factors including abnormal lipids, diabetes mellitus, smoking and obesity. They are less likely to be
screened for risk factors or receive interventions for reducing CVD risk. We do not know the most effective
ways to reduce this excess morbidity and mortality.
This programme of research aimed to develop and test better methods to predict and reduce excess CVD
in people with SMI. We developed and validated new CVD risk scores for predicting incident CVD in SMI
and assessed their economic impact if used to decide who should receive a statin prescription.
We also developed and tested the clinical and cost-effectiveness of a new intervention in primary care to lower
levels of cholesterol and reduce CVD risk in SMI, and assessed if the intervention was delivered as intended.
The programme was developed and delivered collaboratively with patient and public involvement
throughout including the research design, intervention development and delivery and interpretation of
results with a Lived Experience Advisory Panel (LEAP).
Objectives
Work package 1
1. To develop and validate a CVD risk prediction score for people with SMI.
2. To determine its cost-effectiveness compared with standard risk scores used for the general population.
Work package 2
1. To identify barriers to, and facilitators of, CVD risk prevention in SMI from the health professional,
patient and carer perspective through focus groups.
2. To evaluate evidence regarding CVD reduction in SMI by updating systematic reviews.
3. To investigate UK statin prescribing and effectiveness among people with SMI.
4. To develop an intervention in which primary care nurses/health-care assistants lower levels of cholesterol
and reduce cardiovascular risk in SMI.
Work package 3
1. To determine the clinical effectiveness of the intervention in a cluster randomised controlled trial (RCT)
in general practice.
2. To determine the cost and cost-effectiveness of the intervention compared with treatment as
usual (TAU).
3. To assess fidelity to intervention delivery.
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Work package 1: development and validation of a cardiovascular disease
risk model
A predictive CVD risk assessment tool was developed and validated for people with SMI using data from
The Health Improvement Network (THIN) UK primary care database on 38,824 people with SMI over a
15-year period. The work was peer reviewed and published in 2015 [Osborn DP, Hardoon S, Omar RZ,
Holt RI, King M, Larsen J, et al. Cardiovascular risk prediction models for people with severe mental illness:
results from the prediction and management of cardiovascular risk in people with severe mental illnesses
(Primrose) research program. JAMA Psychiatry 2015;72:143–51].
Two new risk score models were built, one with serum lipids and another with body mass index (BMI)
and no blood results. The new models used existing risk factors included in CVD risk scores and additional
SMI-specific variables, such as diagnosis and psychotropic medications. Performance of the Primrose
lipid and BMI CVD risk score models were compared in terms of predicting new-onset CVD, using
discrimination statistics and calibration plots. They were then compared with published models from the
USA and also with models we derived from the UK general population. Finally, these different SMI and
general population models were compared in a cost-effectiveness modelling exercise, to see which
performed better when used to determine who should receive statins in terms of net monetary benefit and
quality-adjusted life-years (QALYs).
The results showed that the new Primrose SMI-specific CVD models performed better in terms of
predicting future CVD in people with SMI. Compared with published US CVD prediction models (Cox
Framingham models), D and c-statistics were higher for the Primrose lipid and BMI models for men and
women. The SMI-specific models were also superior in performance than CVD models derived from a UK
general population in primary care.
The health economics modelling showed that the Primrose BMI models had the highest cost savings,
compared with general population-derived CVD risk score models if they were used to guide prescribing
of statins at a high risk score threshold (> 10% 10-year CVD risk). The Primrose BMI model gave 15 extra
QALYs and a saving of £53,000. The corresponding figures for the next best algorithm, a general
population-derived lipid model, were 13 QALYs and £46,000 saved. This work was peer reviewed and
published in 2017 [Zomer E, Osborn D, Nazareth I, Blackburn R, Burton A, Hardon S, et al. Effectiveness
and cost-effectiveness of a cardiovascular risk prediction algorithm for people with severe mental illness
(PRIMROSE). BMJ Open 2017;7:e018181].
Work package 2: developing the intervention
Focus groups and an update of a systematic review were used to inform the design of the Primrose
intervention and training programme. The focus group study was peer reviewed and published in
2015 (Burton A, Osborn D, Atkins L, Michie S, Gray B, Stevenson F, Gilbert H, Walters K. Lowering
Cardiovascular disease risk for people with severe mental illnesses in primary care: a focus group study.
PLOS ONE 2015;10:e0136603).
Focus groups
A total of 14 focus groups with 75 participants identified barriers to and enablers of health professionals
in primary care to deliver CVD risk-lowering interventions to people with SMI. Carers, community mental
health staff, general practitioners (GPs), practice nurses and patients in primary care or community mental
health settings were recruited. They were asked about the training, resources and systems required to
lower CVD risk in SMI, while access to services, motivation and capability to lower CVD risk were explored
with people with SMI. Discussions were audio-recorded. A framework analysis approach was used to
identify themes for the design and delivery of the intervention and training.
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Six themes were identified that needed to be addressed to manage CVD risk in people with SMI: (1) a shift
to focusing on physical health rather than mental health problems in consultations, (2) the view among
some professionals that smoking and weight interventions are not effective for people with SMI, (3) lack
of confidence of nurses working with people with SMI, (4) consideration of the negative side effects of
psychiatric medications, (5) patient motivation to improve physical health and (6) lack of patient engagement
with CVD prevention and primary care services.
Five themes to increase the success of an intervention to manage CVD risk in SMI were identified:
(1) practical suggestions for increasing attendance and service engagement, (2) involving significant others
(family, friends or support workers), (3) seeing the same person at every appointment to ensure continuity,
(4) providing healthy lifestyle advice and (5) working on realistic goals.
Systematic review
We updated existing systematic reviews regarding evidence on pharmacological and behavioural
interventions to lower CVD risk in people with SMI.
A search for published systematic reviews and RCTs on interventions to manage levels of cholesterol,
diabetes mellitus, hypertension, weight, smoking and alcohol was conducted in The Cochrane Library, the
Cochrane schizophrenia and Cochrane depression, anxiety and neurosis group registers. A total of 15
relevant systematic reviews and 28 additional RCTs were identified from 11,028 references.
Pharmacological and behavioural approaches were effective for managing smoking and weight in SMI.
There was limited evidence on reducing alcohol use and no evidence on management of cholesterol levels,
diabetes mellitus, hypertension or multiple CVD risk factors.
Intervention development
The focus group findings were used in the training programme and manualised as strategies to improve
patient engagement and motivation. Findings from the systematic review were used to train health
professionals about effective interventions for weight loss and stopping smoking in people with SMI,
and to direct them to use treatments that are effective in the general population for levels of cholesterol,
blood pressure, hypertension, diabetes mellitus and alcohol misuse.
The intervention was developed collaboratively with a lived experience advisory panel and a lived
experience advisor co-delivered the training. The final intervention involved 2 days of training, and 8–12
appointments with a nurse/health-care assistant (HCA) incorporating a hierarchical approach to effectively
managing CVD risk factors including behavioural theory techniques.
Investigating patterns of statin prescribing
Differences in the prescription of statins were investigated for people with SMI in primary care using
data from 25,246 people with SMI and 125,825 people without SMI between 2005–15 in the UK THIN
database. Results from Poisson regression demonstrated that statin initiation was significantly more
frequent in 30- to 59-year-olds with SMI than in those without SMI; however, rates were similar between
60- to 74-year-olds and significantly lower for those aged ≥ 75 years with schizophrenia [incident rate ratio
(IRR) 0.69, 95% confidence interval (CI) 0.60 to 0.81]. The majority of the study data pre-dated a policy
change recommending prescription of statins above the 10% CVD risk threshold, so we do not know
what has happened to statin prescriptions in SMI since that change.
Estimating the effectiveness of statins
The evidence on the effectiveness of statins for the primary prevention of CVD in SMI was systematically
reviewed. No studies assessing CVD events or associated mortality as outcomes were found. This gap
was addressed with a study assessing the effectiveness of statins in 16,854 people with SMI in the THIN
primary care database. It was found that when statins are prescribed to people with SMI they experience,
a significant reduction in the level of total cholesterol for up to 2 years (of 1.2 mmol/l; p < 0.001). The rate
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of combined myocardial infarction and stroke (IRR 0.89, 95% CI 0.68 to 1.15) and all-cause mortality
(IRR 0.89, 95% CI 0.78 to 1.02) was reduced, but this was not statistically significant. The findings suggest
that statin adherence is sufficient for the effective modification of lipids in people with SMI in UK primary
care. Both statin studies were peer reviewed and published in 2017 (Blackburn R, Osborn D, Walters K,
Nazareth I, Petersen I. Statin prescribing for prevention of cardiovascular disease amongst people with severe
mental illness: Cohort study in UK primary care. Schizophren Res 2018;192:219–225; and Blackburn R,
Osborn D, Walters K, Falcaro M, Nazareth I, Petersen I. Statin prescribing for people with severe mental
illnesses: a staggered cohort study of ‘real-world’ impacts. BMJ Open 2017;77:e013154).
Work package 3: cluster randomised controlled trial
We delivered a cluster randomised, clinical effectiveness and cost-effectiveness trial, comparing a
practitioner-led intervention (Primrose) with TAU in 76 general practices across England. Intervention
arm nurses/HCAs were trained to work with 30- to 75-year-olds with SMI, who had raised levels of
cholesterol and one or more other CVD risk factors, including diabetes mellitus, raised blood pressure,
obesity and smoking. The intervention involved nurses/HCAs setting a goal with each patient to target
behaviours that reduce levels of cholesterol and other CVD risk factors (e.g. adhering to statins, improving
diet, increasing physical activity, stopping or reducing smoking or reducing alcohol intake). Nurses/HCAs
were trained to use eight behaviour change techniques (BCTs) across 8–12 appointments over a 6-month
period to help patients achieve their goal. BCTs included goal-setting, involving supportive others, action
planning, recording and reviewing progress, positive feedback, forming habits and coping with setbacks.
British Heart Foundation leaflets were given to the patient at their first appointment. The intervention was
compared against routine GP practice with British Heart Foundation leaflets.
Clinical effectiveness
The main analysis assessed the primary outcome of total cholesterol level at 12 months, with data available
for 137 out of 155 people with SMI in the intervention arm and 152 out of 172 people with SMI in the TAU
arm. All practices remained in the study at the end. The number with data available exceeded the original
sample size calculation. There were no differences in levels of total cholesterol between the two arms at
12 months (5.4 mmol/l Primrose vs. 5.5 mmol/l TAU; coefficient 0.03, 95% CI –0.22 to 0.29), even after
controlling for baseline cholesterol level, number of appointments attended in the Primrose intervention or
predictors of missing data on the primary outcome. There were also no significant differences in secondary
outcomes including weight, CVD risk scores, blood pressure, body mass index, diet, exercise, well-being and
medication adherence.
A total of 46% of patients in the Primrose intervention arm attended six or more appointments and 23%
attended between two and five appointments. A total of 21% of people did not attend any appointments.
Satisfaction with health care was high in both arms of the trial over the 12 months, and mean cholesterol
levels decreased in both arms (–0.22 mmol/l Primrose vs. –0.39 mmol/l TAU).
There was no difference in the primary outcome measure over and above TAU. This may reflect better than
standard general practice care in the TAU arm, where patients were screened for CVD risk and received
feedback; as well as the difficulty of changing biomedical outcomes in an intervention targeting multiple risk
factors in a heterogeneous sample of people with SMI.
Cost-effectiveness
The economic evaluation assessed whether or not the Primrose intervention was cost-effective compared
with TAU from a health-care cost perspective, over 12 months.
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The total health-care cost for the Primrose intervention group was £1286, with a total cost of £2182 for
TAU (mean difference –895, 95% CI –£1631 to –£160; p = 0.012). These lower health costs were mostly a
result of fewer inpatient mental health costs (£157 in the Primrose intervention vs. £956 in TAU; –£799,
95% CI –£1480 to –£117; p = 0.018). There was no difference in QALYs (Primrose 0.769, 95% CI 0.751
to 0.787; TAU 0.780, 95% CI 0.764 to 0.796).
Fidelity assessment
The extent to which the intervention was delivered to protocol was examined through an assessment of
a random 20% sample of transcribed audio-recordings of intervention appointments. The aims were to
assess whether or not (1) the intervention was delivered as intended, (2) a clinically appropriate behaviour
goal was set, (3) any intervention components were delivered more than others and (4) fidelity differed
between nurses and HCAs.
A total of 67.7% of the intervention components were delivered, suggesting moderate adherence to the
manual and training. None of the sample set a goal addressing statin adherence or initiation. Nurses had
significantly higher fidelity (79.5%) than HCAs (64.3%) [t(20) = 2.23; p = 0.037].
Overall conclusions
l The SMI-specific risk scores are more effective for determining CVD risk and prescribing statins than
general population risk scores.
l Statins are effective in people with SMI with effects on levels of total cholesterol that may translate into
a reduction in CVD events.
l A manualised nurse-led intervention with 8–12 appointments in primary care to reduce levels of
cholesterol showed no superiority in terms of level of total cholesterol or secondary outcomes
over TAU.
l The intervention was attended by participants, and fewer inpatient psychiatric admissions were seen in
the intervention arm.
l Manualised behavioural techniques can be delivered by HCAs/nurses following 2 days of training.
Many health promotion activities occurred in both trial arms but there was limited evidence of statin
initiation or monitoring.
Implications for practice
l General population risk scores can underestimate CVD risk in SMI and a model that does not require
lipid blood results is most beneficial for deciding when to prescribe statins and prevent CVD in SMI.
l Statins are effective for lipid modification in UK people with SMI.
l The intervention was not superior for level of total cholesterol, nor for any of the secondary outcomes;
however, we demonstrated that primary care nurses and HCAs can deliver CVD risk-reducing
interventions to people with SMI despite some initial hesitance. Furthermore, the intervention was
well attended with reduced costs in the intervention arm, and fewer inpatient admissions.
Recommendations for research
l The Primrose risk scores should be validated externally in a separate data set.
l The Primrose risk scores should be updated and compared with newer risk scores.
l Database studies should assess national statin prescribing to people with SMI over time, especially older
age groups who were undertreated in UK practice, and to assess the impact of policy change to
prescribe above 10% CVD risk for people with SMI. Statin initiation was infrequent in both arms of the
RCT and this needs further exploration.
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l Future study designs may require larger sample sizes to determine the impact of statins on mortality
and excess CVD in people with SMI. Discussions around statins and prescribing did not emerge either
as a barrier or as a facilitator for reducing CVD risk in people with SMI in our focus group work. This
requires further research to establish why it did not happen, despite the intervention programme
training nurses/HCAs to explore statin prescription and adherence, and the potential concerns that
patients with SMI might have around taking statins.
l Naturalistic observations in real-life settings should examine organisational, behavioural and
pharmacological CVD risk-reducing interventions and their impact on outcomes for people with SMI.
l The potential effect of increased contact with a primary care health professional on hospital admissions
warrants further investigation.
l Further analysis of the RCT fidelity work should explore the content and communication aspects of the
intervention appointments to help shed light on the lack of difference in results between intervention
and control groups.
l Future work could explore whether or not conversations about statins are happening between
professionals and patients, and the reasons why statins might not be initiated for those who would
benefit. This work could also explore why there may have been a focus on diet, physical activity and
smoking within the consultations.
l Research into future interventions could include mechanisms to ensure that evidence-based CVD risk
reduction strategies are being offered and explained to people with SMI, including reviewing risk scores
and explaining the role of statins.
Trial registration
This trial is registered as ISRCTN13762819.
Funding
Funding for this study was provided by the Programme Grants for Applied Research programme of the
National Institute for Health Research. Professor David Osborn is supported by the University College London
Hospital NIHR Biomedical Research Centre and he was also in part supported by the NIHR Collaboration for
Leadership in Applied Health Research and Care (CLAHRC) North Thames at Barts Health NHS Trust.
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Synopsis
Background
Burden of cardiovascular disease in people with severe mental illnesses
People with severe mental illnesses (SMI), including schizophrenia, bipolar disorder and other psychoses,
make up around 2% of the UK population.1
Cardiovascular disease (CVD) is the most important physical problem in people with SMI,2 and those
aged < 50 years are three times more likely to die from CVD than those without SMI, whereas those aged
50–75 years have a twofold risk.3 People with SMI die from CVD up to 20 years earlier than the general
population3–6 and recent studies have shown that the mortality gap for people with schizophrenia and
bipolar disorder is widening.7,8
The reasons for increased CVD are multifaceted, including increased levels of smoking, diabetes mellitus,
obesity and dyslipidaemia in people with SMI compared with general practice controls.9,10 Systematic
reviews conclude that components of metabolic syndrome (being overweight, abnormal lipids,
hypertension and abnormal glucose) are more common in people with SMI.11 Research has also shown
that people with SMI ate a higher-fat diet, ate less fibre and were less likely to participate in physical
activity.12,13 Antipsychotic medications, such as olanzapine and clozapine, have been linked to increased
appetite and subsequent weight gain as well as abnormalities of lipid and glucose metabolism.14 Another
theory is that long-term stress of SMI exerts cardiovascular risk via the hypothalamic pituitary axis.15
Current NHS provision of cardiovascular disease care in severe mental illness
The majority of people with SMI use primary care services and see a general practitioner (GP) more often
than people without SMI.6,16 Routine annual CVD risk screening for people with SMI is recommended in
national guidelines17,18 and the responsibility for CVD risk prevention is placed within primary care, while
those prescribed antipsychotics should be monitored more regularly.19
The primary care quality outcomes framework pays GPs for providing an annual physical health review
to people with SMI. Indicators for this review have changed over the past few years and glycated
haemoglobin (HbA1c) and cholesterol measurements were retired in 2014/15. The 2017/18 indicators
consist of a recording of blood pressure, smoking status and alcohol consumption.20
Studies have shown that if CVD screening is offered to people with SMI, then they are as likely to attend
the screening as people without SMI.21,22 However, in primary care, people with schizophrenia were
significantly less likely to receive blood pressure or cholesterol screening than practice controls,23 and BMI
and blood pressure recording rates were significantly lower in people with SMI than for those with
diabetes mellitus or chronic kidney disease.24 This study also found that exception reporting rates were
higher for people with SMI.
Cardiovascular disease risk prediction tools for people with severe mental illnesses
Cardiovascular risk tools are widely used clinically to predict an individual’s risk of developing CVD, usually
over a 5- or 10-year period. The risk scores are algorithms of conventional risk factors, such as smoking,
blood pressure and lipids, and the predictive ability of the combined models is greater than that of each
single risk factor. The resulting risk scores are also used to determine thresholds at which different risk
reduction strategies, such as statins, should be employed.
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It is noted in the 2016 National Institute for Health and Care Excellence (NICE) guidelines for CVD disease,
risk and reduction that people with SMI constitute a high-risk group for CVD and existing risk prediction
tools may underestimate their CVD risk, a picture similar to that observed in South Asian people and
people aged < 40 years.25 Ethnicity-adjusted risk scores have been developed as a result,26 but this has not
yet been done for SMI. People with SMI were excluded from the original cohorts, such as the Framingham
cohort, from which existing risk scores have been derived. The 10-year risk needs to be accurately
determined for CVD scores for people with SMI in order to decide the thresholds at which to intervene.
Evidence for treatments to reduce cardiovascular risk in severe mental illness
Although the evidence shows that there are higher rates of CVD risk factors and higher mortality in people
with SMI, we know far less about interventions to decrease this risk. There is a lack of high-quality
evidence on CVD risk-reduction strategies in people with SMI.
Statins have been found to reduce severe dyslipidaemia in people with SMI in small studies focused on
particularly high-risk populations.27,28 The best trials of smoking cessation show small changes in smoking
and quit rates,29 and studies have shown that medication and behavioural interventions are effective for
weight loss.30,31 A feasibility trial in secondary care to improve screening for CVD risk factors, testing a
nurse-led service working across primary and secondary care, improved screening rates, but was too
short in duration to reduce CVD risk.32 Systematic reviews of interventions to increase uptake of lifestyle
behaviours found some beneficial impact on CVD risk factors; however, the methodological quality of
many of the included studies was low.33–35
Most studies target single-risk factors and do not seek to address the full CVD risk profile of patients
with SMI. Only one trial was found that tested a life goals collaborative care intervention involving
management strategies for mental health symptoms and CVD risk factors. The findings were that the
intervention improved the primary outcome of quality of life (physical health) compared with usual
care. CVD risk factors were measured only as secondary outcomes with significantly lower levels of
low-density lipoprotein (LDL) cholesterol in the intervention arm than usual treatment at follow-up, but no
significant differences in blood pressure, BMI, waist circumference or other lipid parameters.36
The Primrose programme overview
The aim of this National Institute for Health Research (NIHR) programme was to develop and test better
methods to predict and reduce the risk of excess CVD in people with SMI across three work packages.
The research was carried out between May 2011 and July 2017. In years 1–2 (May 2011 to May 2013),
we developed and validated a CVD risk score tool specifically for people with SMI. We then developed an
intervention in primary care to lower levels of cholesterol and reduce CVD risk factors in people with SMI
through an update of a systematic review of the literature, focus groups and workshops with clinical and
lived experience advisors (years 1–3: June 2011 to December 2013). We also explored statin prescription
rates and the effectiveness of statins on lowering levels of cholesterol and preventing CVD in people with
SMI using primary care databases (years 2–5: October 2012 to December 2015). Finally, we tested the
clinical effectiveness and cost-effectiveness of the new intervention in a cluster randomised controlled trial
(RCT) and assessed the extent to which the intervention was delivered as intended (years 3–6: January
2014 to February 2017). The links between the three work packages are summarised in Figure 1.
Project management
The programme was overseen by a Programme Management Group (PMG) consisting of all authors of this
report. The PMG met every 6 months. Subgroups that were drawn from the PMG members met more regularly
to deliver each individual work package. A trial management group was formed to oversee the trial delivery
and met every 3–6 months. An external trial steering committee was also formed to monitor the conduct of
the trial and the trial was supported by the UCL PRIMENT clinical trials unit (www.ucl.ac.uk/priment).
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FIGURE 1 Overview of the Primrose programme.
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Work package 1: development and
validation of a risk model for predicting
cardiovascular disease events in people
with severe mental illnesses
Work package 1 aimed to address the following research aims during the first 2 years of the Primroseresearch programme:
l to develop a CVD risk score tool, specifically for people with SMI and compare its performance with
that of existing general population CVD risk tools.
l to evaluate the cost-effectiveness of the CVD risk score tool.
Effectiveness of a cardiovascular risk prediction algorithm for people
with severe mental illnesses
The work package was completed on time and the results have been published in one of the highest-impact
international psychiatry journals (JAMA Psychiatry) in 2015 (with an impact factor of 16.6 at the time of
writing).37 To date, this has been cited 30 times on Web of Science and 42 times on Google Scholar.
The link to this paper can be found in Appendix 3, Work package 1.37 The algorithm has been developed
and published as a web-based tool [www.ucl.ac.uk/primrose-risk-score (accessed 5 September 2018)].
The published work closely followed the proposed methods in our original funding application. It was a
risk score development and validation study.
We used The Health Improvement Network (THIN) UK GP research database to identify a large cohort
of 38,824 people with a GP-recorded diagnosis of schizophrenia, other psychoses or bipolar disorder,
between 1995 and 2010. We identified 2324 new-onset cardiovascular events within this cohort.
We built a model to predict new-onset CVD using standard regression techniques. We included all the
variables usually present in traditional risk scores (e.g. smoking, diabetes mellitus and cholesterol level)
and then added SMI-specific variables in addition. These included use of first- and second-generation
antipsychotics, use of antidepressants, type of SMI diagnosis and heavy alcohol use.
We developed one model that included blood test results for levels of cholesterol and high-density
lipoprotein (HDL) cholesterol: the ‘Primrose lipid model’. We created another ‘Primrose BMI model’, which
did not require these results. We compared these new models with the most widely used international
models: the Cox Framingham models. We used a variety of methods to assess the performance of our new
models in forecasting CVD, using a variety of accepted techniques to create multiple imputed data sets,
and by dividing the data up into sections to allow ‘internal cross-validation’.
The validation results demonstrated that the new Primrose models performed better than the existing Cox
Framingham models, in both men and women, in predicting future CVD events. In men, the D-statistic for
the Primrose lipid model was 1.92 [95% confidence interval (CI) 1.80 to 2.03] and the c-statistic was 0.80
(95% CI 0.76 to 0.83). For published Framingham scores in men, the D-statistic was 1.74 (95% CI 1.54 to
1.86) and the c-statistic was 0.78 (95% CI 0.75 to 0.82). In women, the D-statistic for the Primrose lipid
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model was 1.87 (95% CI 1.76 to 1.98) and the c-statistic was 0.80 (95% CI 0.76 to 0.83). For published
Framingham scores in women, the c-statistic was 1.58 (95% CI 1.48 to 1.68) and the D-statistic was 0.76
(95% CI 0.72 to 0.80).
To assess whether or not this superiority of the new Primrose models reflected a difference in international
models (between the US Framingham model and the UK Primrose model), a UK general population risk
score model was created from the THIN database. This model would be very similar to UK models, such
as QRISK® (University of Nottingham, Nottingham, UK and EMIS Health, Leeds, UK), for which the
parameters were not available at the time. The Primrose models still performed better than the UK general
population models, which suggested that SMI-specific models are best, although all models performed
quite well.
It is concluded that the new Primrose models were the most accurate, but that better evidence is needed
regarding their potential impact before they could be recommended for replacing scores, such as the
QRISK score or Cox Framingham, as these were models performing at an acceptable level in the SMI
cohort and great effort would be required to implement new models across the clinical landscape. The
inferior performance of general population algorithms has now been highlighted in clinical guidelines for
managing the physical health of people with SMI. Examples are the NHS England Lester tool38 and the
British Association for Psychopharmacology (BAP) guidelines on antipsychotic induced weight gain.39
A limitation of the study was that there may be more missing predictor variables within routine clinical
data than in data collected for the purpose of research. In addition, the effectiveness of the CVD risk score
models was not evaluated for people from different ethnic backgrounds owing to poor recording.
One risk score study is not sufficient to implement a full change in policy and screening practice for CVD.
Therefore, in the Primrose cluster randomised trial, tested in work package 3, our data collection included
the variables and calculations for the QRISK score as well as the Primrose new risk scores. Neither risk score
was used to determine participant eligibility for the trial, but the risk score work was reassuring that either
of the risk scores could be used within the trial for determining 10-year risk and relevant interventions in
people with SMI. The risk scores were also used as secondary outcome measures in the trial.
We conducted a further health economics analysis to compare which of Primrose, QRISK or Framingham
CVD risk scores would be most cost-effective if combined with statin prescriptions for people with a CVD
risk of > 10% over 10 years. The results are outlined in the next section and they show some superiority
for the Primrose BMI model in terms of quality-adjusted life-years (QALYs) and net monetary benefit (NMB).
Cost-effectiveness of a cardiovascular risk prediction algorithm for
people with severe mental illnesses
The aim of this work package was to evaluate the 10-year cost-effectiveness of the SMI-specific risk
algorithm (Primrose) described in the previous section37 compared with a general population CVD risk
algorithm. To evaluate this, a 10-year decision model of costs was developed and consequences of CVD
in patients with SMI in the UK primary care population were assessed. The full manuscript for this work
package has been published in BMJ Open in 2017.40 The link to this paper can be found in Appendix 3,
Work package 1.40
A patient-level simulation was developed to hypothetically model the progress of people with SMI over
10 years, which was composed of (1) a decision tree to identify those at a risk of CVD over 10 years
and eligible for statin therapy and (2) a Markov state transition model of 10 1-year cycles. The patient
population in the model was composed of a random sample of 1000 real primary care patients extracted
from the THIN UK GP research database.
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A CVD risk score was calculated for each of the 1000 patients using four different CVD risk algorithms in
four separate analyses.40 The risk algorithms assessed were:
1. a general population lipid algorithm
2. a general population BMI algorithm
3. a SMI-specific lipid algorithm
4. a SMI-specific BMI algorithm.40
Algorithms (1) and (2) were based on an adaptation of the widely used Cox Framingham algorithm,41
herein referred to as the general algorithm, which was created and validated using THIN data.40 Algorithms
(3) and (4) were derived from UK SMI patients in THIN, aged 30–90 years.37,40 The primary analysis was
based on a CVD risk threshold of 10%. The primary CVD prevention strategy used was prescription of a
statin for patients above the risk threshold. A fifth analysis using no CVD risk algorithm was included to
estimate the costs and consequences of not intervening.
The patient-specific probability of having a primary CVD event and the probability of dying in each cycle
were based on algorithms developed using the same data set that was used to develop the Primrose risk
algorithm37 (38,824 people in THIN with SMI and aged > 18 years). The probability of having a secondary
CVD event was calculated from the model in the Reduction of Atherothrombosis for Continued Health
Registry.42
The benefits of statin therapy were modelled by applying the relative risk reduction of CVD from statin
use from a Cochrane review (0.73 and 0.78 for coronary heart disease and stroke respectively)43 to the
predicted risks of CVD for all patients newly prescribed statins. Costs included in our model were the cost
of administering the CVD risk algorithm, CVD risk management and CVD events. All costs were reported
in Great British pounds at 2012/13 values, inflated using conversion rates in Curtis (2013).44
The mortality and morbidity impact was evaluated using QALYs as recommended by NICE,45 in which
patients were allocated a utility score assigned to patients with SMI whose symptoms are being managed
(0.865).46 If a patient had a non-fatal CVD event, a utility decrement was applied. All future benefits
(QALYs) and costs were discounted at 3.5% per annum.45
Cost-effectiveness was calculated using the NMB approach47 and probabilistic sensitivity analysis to
calculate the probability that each option was cost-effective for a willingness to pay (WTP) for a QALY.
The SMI-specific BMI algorithm classified the highest number of patients as at a ‘high risk’ of CVD (326
patients at 10% and 117 patients at 20%) and resulted in the greatest number of new statin prescriptions
(255 patients at 10% and 81 patients at 20%).40 The general BMI algorithm classified the lowest number
of patients as ‘high risk’ (222 patients at 10% and 65 patients at 20%) and generated the lowest number
of new statin prescriptions (175 patients at 10% and 44 patients at 20%).40 The general SMI-specific BMI
algorithm also prevented the greatest number of primary CVD events (13 events), equivalent to a 4–6%
reduction in primary CVD events, and the highest NMB than the general lipid algorithm, and all other
algorithms.40
The results show that the provision of a relatively low-cost identification tool (the Primrose risk algorithm)
and relatively low-cost intervention (statins) compared with the high cost of CVD events means that
these combined interventions save up to £53,000 per 1000 patients over 10 years, or £53 per patient
administered the Primrose CVD risk algorithm. The Primrose BMI model also gave 15 extra QALYs. The
general population-derived lipid model was the next best performing algorithm with 13 extra QALYs and
£46,000 saved.
A limitation of the study was that it was not possible to compare the performance of the Primrose models
with that of the UK QRISK model, as the algorithm parameters were not available.
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Work package 2: development of a
practice nurse-/health-care assistant-led
intervention for lowering levels of
cholesterol and reducing cardiovascular
disease risk in people with severe
mental illnesses
Work package 2 aimed to address the following research questions using three different methodologies:
l What are the barriers to, and facilitators of, lowering cardiovascular risk in people with SMI?
(Focus groups.)
l What evidence is there for effective pharmacological and behavioural interventions to manage
cardiovascular risk factors in people with SMI? (Update of a systematic review.)
l What are the patterns of statin prescribing for people with SMI and the general population?
(Primary care database study.)
l What is the effectiveness of statins in people with SMI? (Systematic review and primary care
database study.)
The findings from the systematic review and focus group studies were brought together to inform the
development of a CVD risk-lowering intervention and training programme for practice nurses and HCAs in
primary care (Primrose intervention).
Focus groups with health professionals, patients and carers on the
barriers to, and facilitators of, cardiovascular disease prevention in
primary care for people with severe mental illnesses
Focus groups were conducted to explore current practices, barriers to, and facilitators of, delivering and
accessing CVD risk-lowering interventions for people with SMI in primary care. This work was delivered
according to the original programme protocol and was published in the journal PLOS ONE in 2015.48
The link to this paper can be found in Appendix 3, Work package 2.48 The findings were used to inform
the development of the Primrose intervention and training programme.
A total of 14 focus groups were run with 75 participants, including 32 health professionals working in
general practices, 11 staff from community mental health settings, 25 service users with SMI and 7 carers
of people with SMI. Topic guides were used to guide the focus group discussions and were developed
using domains from an established theoretical domains framework (TDF) for identifying facilitators and
barriers to intervention delivery and behaviour change in health-care settings.49 For this study, the TDF was
used to design questions that would help elicit the barriers to, and facilitators of, lowering CVD risk for
people with SMI from both the health-care professional and the patient perspective. More specifically, the
topic guides were used to explore the resources, systems and training required by health professionals to
lower CVD risk in SMI and, to explore with people with SMI and their carers the accessibility of services,
motivation and capability to lower their CVD risk. All participants provided written informed consent
to participate in the study and focus groups were audio-recorded, transcribed and analysed using a
framework analysis approach.50
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A number of factors were identified that may prevent but also encourage people with SMI to access and
engage with CVD risk-lowering interventions in general practice. A need for more systematic approaches
to delivering CVD risk prevention in this setting was identified; however, the majority of people
interviewed agreed that CVD risk monitoring and intervention delivery was the responsibility of health
professionals working in general practice.
A number of barriers to CVD risk prevention were identified, including difficulties delivering preventative
physical health care because of consultations focusing on mental health rather than physical health
problems, scepticism among some health professionals about the effectiveness of stop smoking and
weight loss interventions for people with SMI, and limited confidence and training for practice nurses to
work with people with SMI. The negative side effects of psychiatric medications, a lack of motivation due
to mental health problems and a lack of engagement with CVD risk-lowering interventions and primary
care services were all identified as barriers to enacting CVD risk-lowering behaviours in people with SMI.
Potential facilitators were also identified that sought to address some of the barriers. These included
practical ideas to increase attendance and engagement (e.g. afternoon appointments, appointment
reminders); to involve family members, friends or support workers; to have a named contact at the general
practice to ensure continuity; to provide healthy lifestyle advice during appointments; and to agree on and
work towards realistic goals.
Stakeholders from different backgrounds and both urban and rural locations attended the focus groups,
making the findings applicable to UK general practice. The service users who attended the focus groups
may not have been representative of all service users, as they were active participants in their use of health
services. It is likely that for people who are not well or not engaged, attending primary care services may
be more difficult.
Systematic review of pharmacological and behavioural interventions
for reducing cardiovascular disease risk in people with severe
mental illnesses
To inform the development of the intervention, we planned to update existing systematic reviews, rather
than conduct a review de novo. The updated review was presented and published as a conference abstract
at The Lancet Public Health Science Conference51 and the results of the review were incorporated into the
Primrose intervention training programme to inform health professionals about effective interventions for
losing weight and stopping smoking in people with SMI.
A systematic review was conducted to evaluate and narratively synthesise evidence from published
systematic reviews and individual RCTs on the effectiveness of pharmacological and behavioural
interventions for reducing modifiable CVD risk factors in people with SMI. A meta-analysis of findings from
individual RCTs was not possible because of the heterogeneity of reporting of interventions and outcome
measures (see Appendix 1).31,52–100
The Cochrane Library was searched for existing systematic reviews. The Cochrane Schizophrenia and
Cochrane Depression, Anxiety and Neurosis Group Trial Registers were then searched between 1966 and
2014 for additional RCTs not included in the identified reviews. Interventions to manage the following were
searched: levels of cholesterol, diabetes mellitus, hypertension, weight, smoking and alcohol consumption.
Fifteen systematic reviews and 28 additional RCTs were included in the review, from 11,028 references.
The synthesised data demonstrated that bupropion and nicotine replacement therapy were effective
interventions for smoking cessation, or reduction, as was a standardised smoking cessation programme.
There was evidence that metformin and topiramate were effective pharmacological interventions for
weight loss, and that behavioural interventions aimed at individuals (rather than groups) addressing diet
DEVELOPMENT OF A PRACTICE NURSE-/HEALTH-CARE ASSISTANT-LED INTERVENTION
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and physical activity were most effective in reducing BMI. Only three trials reported effective interventions
to reduce alcohol intake. No trials were found on interventions targeting levels of cholesterol, diabetes
mellitus or hypertension as the primary outcome.
Study limitations were that the setting for most of the trials was secondary care, which limits their
generalisability to primary care. It was also difficult to synthesise evidence from a wide range of
intervention studies that targeted different CVD risk factors and measured outcomes in different ways.
Evidence was found that CVD risk attributable to weight and smoking can be managed effectively in
people with SMI using pharmacological and behavioural approaches; however, limited or no evidence on
the effectiveness of interventions to manage levels of cholesterol, diabetes mellitus, hypertension, alcohol
misuse or multiple CVD risk factors was identified in this population. These findings were taken forward
into the development work and used within the training programme.
Investigating patterns of statin prescribing among people with, and without, severe
mental illnesses
The aim of this study was to explore the statin prescription rate in people with SMI compared with people
without SMI in primary care. This work was published in the journal Schizophrenia Research in 2017
(with an impact factor of 3.958 at the time of writing).101 The link to this paper can be found in Appendix 3,
Work package 2.101
The uptake of physical health checks in primary care among people with SMI has increased substantially
over time, reflecting the introduction of policies and incentives, such as the Quality Outcomes Framework.20
However, the impact on cardiovascular interventions, such as statin prescribing, was unknown. We used data
from THIN to examine the rate of new statin prescriptions in people with, and without, SMI over a 10-year
time period. Overall, rates of initiating a statin were at least doubled in people aged 30–59 years with SMI
than in those without, even after adjusting for cardiovascular risk factors. Among people 60–74 years, rates
were generally similar for people with and without SMI. However, among the oldest (aged ≥ 75 years) with
schizophrenia (but not bipolar disorder), the rate of statin prescribing was around 20% lower (IRR 0.81, 95% CI
0.66 to 0.98) relative to those without SMI. These findings suggest that older individuals with schizophrenia
are less likely to be initiated on a statin than people of a comparable age without SMI, and that this group may
therefore benefit from additional measures to prevent CVD. The higher rate of statin prescribing among 30- to
59-year-olds with SMI (relative to people with SMI) demonstrates that statin prescribing is an important element
of CVD prevention for this group and highlights the need for further evaluation.
Estimating the effectiveness of statin prescribing for people with severe
mental illnesses
This study aimed to examine the effectiveness of statins for people with SMI through a systematic review
of existing evidence and a series of staggered cohort studies designed to estimate the effectiveness of
statins for the prevention of CVD and for modifying lipids in people with SMI.102 This study was published
in the journal BMJ Open in 2017.102 The link to this paper can be found in Appendix 3, Work package 2.102
Although statins form a core part of CVD primary prevention in the general population, this evidence base
was not readily transferable to people with SMI. This is because it is not known whether or not patterns
of medication adherence differ. Furthermore, some antipsychotic agents interact with sterol regulatory
binding elements (which control lipid synthesis) and might therefore counteract the cholesterol-lowering
action of statins. In addition, some of the largest statin trials have excluded participants with psychological
conditions or excluded individuals perceived as less likely to be compliant with treatment.
Therefore, a systematic review was undertaken to examine the effectiveness of statins for primary
prevention of CVD among people with SMI. This review did not identify any information on CVD events,
mortality or long-term statin use in people with SMI. However, two studies provided evidence that statin
therapy is associated with significant reductions in levels of total cholesterol (decreases of 11%28 and 35%27
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for pravastatin and rosuvastatin, respectively) and LDL cholesterol (decreases of 20%28 and 49%27 for
pravastatin and rosuvastatin, respectively) over 12 weeks in 60–100 individuals with SMI. These findings
suggested that a large-scale study to evaluate the long-term impact of statin prescribing, particularly on
CVD outcomes, was needed.
To explore the effectiveness of prescribing statins to people with SMI, we used UK primary care data from
THIN to develop a series of cohort studies. These cohorts included 16,854 people aged 40–84 years who
had a diagnosis of schizophrenia or bipolar disorder, and did not have pre-existing CVD. Cardiovascular
outcomes of statin users and non-users were compared for (1) combined first myocardial infarction (MI)
and stroke (primary outcome), (2) all-cause mortality and (3) change in total cholesterol concentration at
1 and 2 years after initiating a statin. We adjusted our results for a wide range of characteristics (such as
blood pressure) that are associated with being prescribed a statin and the risk of developing CVD. In the
main analysis we used multiple imputation to estimate the value of unobserved data and also conducted a
complete-case analysis (for individuals with fully observed data), which produced very similar results to the
analysis of the imputed data.
We did not identify statistically significant reductions in the rate of combined MI and stroke [incident rate
ratio (IRR) 0.89, 95% CI 0.68 to 1.15] or all-cause mortality (IRR 0.89, 95% CI 0.78 to 1.02) associated
with statin prescribing. However, it was found that statin prescribing was associated with statistically
significant reductions (equivalent to a 20% decrease) in the level of total cholesterol 2 years after initiating
a statin (IRR 1.2 mmol/l, 95% CI 1.1 to 1.3 mmol/l). This finding is similar to the reduction in cholesterol
level observed in trial participants without SMI (IRR 1.1 mmol/l, 95% CI 0.8 to 1.4 mmol/l) and suggests
that medication adherence in people with SMI is sufficient to support effective lipid modification. This
translates to approximately a 25% decrease in mortality and 30% decrease in CVD events.103
The study investigated a wide range of confounders for which data were captured in THIN; however, we
cannot exclude the possibility of residual confounding due to factors (such as diet and exercise) that were
unmeasured within our data set. Of note, our estimates of effect for statins were compatible with those
from randomised trials examining non-SMI populations, suggesting that the likely impact of unmeasured
confounding on our results may be small.
Bringing the evidence together to develop and test the Primrose trial
intervention and training programme
The following section describes the development of the Primrose intervention manual and training
programme for health professionals working in primary care.
First, the barriers to, and facilitators of, enacting both health professional and patient behaviours for
lowering CVD risk in SMI were identified in the focus group work, described in Conclusions and
recommendations, Focus groups with health professionals, patients and carers on the barriers and
facilitators to cardiovascular disease prevention in primary care for people with severe mental illness, using
questions derived from a theory-informed approach for identifying the causes of behaviour (TDF).49 The
identified barriers and facilitators were then mapped to potential intervention components that sought to
overcome the identified barriers and harness the facilitators (see Appendix 4, Table 15).
This evidence was supplemented with findings from the systematic review described in Conclusions and
recommendations, Systematic review of pharmacological and behavioural interventions for reducing
cardiovascular disease risk in people with severe mental illness, and recommendations from workshops
with academic, health professionals and lived experience experts. Key intervention components were
combined to form an intervention manual and training programme. The key components of the
intervention and training programme are described in this section, and supporting tables and figures can
be found in Appendix 4. The intervention manual developed as a result of the evidence synthesis can be
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downloaded on the project web page [(www.ucl.ac.uk/primrose/primrose_manual (accessed
5 September 2018)].
A subgroup consisting of experts in mental health, primary care, behaviour change, expertise from
experience and health service research was formed to bring together the evidence into a study manual and
2-day training programme. A logic model was developed by the group to explain the relationship between
factors that might influence the effectiveness and implementation of a primary care nurse-HCA-delivered
behaviour change intervention. This was also used to guide the clinical and practical aspects of the
intervention development and training content (see Appendix 4, Figure 4).
An evidence-based, theory-informed approach (the TDF)49 for identifying factors that might influence
behaviour was used to map the barriers and facilitators for lowering CVD risk for people with SMI
identified by focus group participants, to potential intervention components. Intervention components
were then selected using an established taxonomy of behaviour change techniques104 as well as practical
suggestions to address the barriers and incorporate the facilitators identified by the focus group discussions
(see Appendix 4, Table 15).
The findings from the systematic review were used in the training programme to educate health
professionals on effective interventions for weight reduction and stopping smoking in people with SMI.
Additional workshops were run with academic clinicians and lived experience advisors to elicit expert views
on the final design of the intervention and training programme [see Patient and public involvement for a
list of recommendations incorporated into the final intervention and training programme from the Lived
Experience Advisory Panel (LEAP)].105 A review of relevant policy and clinical guidelines was also undertaken
to ensure that the intervention followed best clinical practice on CVD prevention in SMI with the aim of
addressing the proximal outcomes (behaviours) identified in our logic model (see Appendix 4, Figure 4).
Piloting the Primrose trial intervention and training programme
Seven practice nurses/HCAs attended a pilot session of the training programme before the start of the
trial. Some minor changes were suggested that were incorporated into the final training programme,
including more opportunities for role play of Primrose appointments and more simplified explanations of
the theoretical frameworks used to explain behaviour change.
The first intervention appointment was then piloted with two members of the LEAP. The practice nurse
responsible for delivering the training met with each LEAP member and conducted the appointment using
the study manual. Feedback from these sessions was incorporated into the final version of the manual and
training programme. This included an emphasis on goals being patient led and a need to consider and
understand aspects of the person’s life that may make behaviour change difficult.
The Primrose trial intervention and training components
The final intervention consisted of 8–12 appointments with a practice nurse/HCA over 6 months.
Nurses/HCAs were trained to support patients to identify and monitor progress with goals on cardiovascular
health, including taking medication, improving diet, increasing physical activity, stopping smoking or
reducing drinking. They were encouraged to compile a local resource directory and refer patients on to
existing support services if available in the local area (e.g. weight management or Stop Smoking Services),
or provide support directly if services were unavailable or if the patient requested one-to-one support.
They were also encouraged to actively follow-up and monitor attendance at services and progress made
towards achieving health goals.
Nurses/HCAs were given a manual to take away with them, which included step-by-step appointment
delivery flow charts, help sheets on managing different CVD risk factors and help sheets on strategies to
help patients to stay motivated and engaged. A health plan was also given to patients to take away and
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use in between appointments. The health plan was used to record chosen goals, create an action plan
and record progress towards achieving the goal.
The training programme was delivered to between four and eight practice nurses and HCAs at one of
six training sessions by a practice nurse with expertise in mental health, a health psychologist, a lived
experience trainer and the programme manager. The training comprised lectures and active learning
through group discussion and role play of appointments. There were 2 days of learning, which were
2 weeks apart so that the nurses/HCAs could deliver an appointment between sessions and bring any
difficulties they might have experienced or areas they felt less confident with to practise at session 2.
Training session 1 consisted of (1) discussing the link between CVD risk and SMI, (2) mental health
awareness, (3) effective interventions for lowering CVD risk, (4) behaviour change techniques and
(5) practical strategies to encourage motivation and engagement. Appendix 4, Table 16, contains a more
detailed description of the content of training session 1. Training session 2 was led by the trainees and
involved discussing the appointments that they had delivered and practising strategies and appointment
delivery through role play and discussion.
In conclusion, an evidence-based manual and training programme was developed using clinician, patient
and clinical academic advice from focus groups and workshops alongside reviews of the best available
evidence in both policy and RCTs of CVD risk-lowering interventions. The resulting manual and training
programme were piloted with health professionals and patients and found to be acceptable and
deliverable. The intervention was then tested in a cluster RCT described in Work package 3.
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Work package 3: evaluation of a
practice nurse-/health-care assistant-led
intervention for lowering levels of
cholesterol and reducing cardiovascular
disease risk in people with severe
mental illnesses in primary care – a
cluster randomised controlled trial
This work package evolved from the development work in work package 2 that integrated publishedevidence, the focus groups and then the work of the PMG and lived experience advisory group (LEAP)
to design the nurse-/HCA-led intervention.
Work package 3 took this intervention and subjected it to a full clinical and economic evaluation in a
cluster randomised trial, as planned in the original Programme Grants for Applied Research (PGfAR)
funding application.
Work package 3 had the following research aims:
l to establish whether or not the new Primrose intervention reduces levels of total cholesterol in people
with SMI over a 12-month period compared with treatment as usual (TAU)
l to determine whether or not the intervention improves other CVD risk factors over a 12-month period
compared with TAU
l to determine whether or not the intervention is cost-effective when compared with TAU
l to assess the fidelity of intervention delivery in the Primrose intervention arm.
Clinical effectiveness of an intervention for lowering levels of
cholesterol and reducing cardiovascular disease risk for people with
severe mental illnesses
The full trial protocol for the cluster randomised trial106 was published in Trials in 2016. This protocol
included the final sample size calculations for the trial as well as a description of the interventions and all
trial procedures. The link to the protocol paper can be found in Appendix 3, Work package 3.106
The trial was published in the journal Lancet Psychiatry in 2018.107 The link to this paper can be found in
Appendix 3, Work package 3.107
The methods and results from the analysis of the cluster randomised trial in terms of clinical effectiveness
are summarised below.
Methods
We successfully delivered a cluster randomised trial within which 76 GP practices across England were
recruited and then randomised to either the Primrose intervention (n = 38) or the TAU (n = 38) arm. This
total number of practices was larger than specified in the original grant application as the numbers of
participants (cluster size) recruited in each practice was smaller than expected (mean 4.3 participants).
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Participants in the trial were aged 30–75 years with a GP record of SMI, in line with the definitions already
outlined in this report. They had a raised lipid profile defined as a cholesterol level of > 5.0 mmol/l or a
total-to-HDL cholesterol ratio of > 4 mmol/l; and they needed to have one other cardiovascular risk factor,
including hypertension, smoking, obesity, raised HbA1c levels or diabetes mellitus.
For the practices in the intervention arm, allocated nurses or HCAs were trained on two occasions to
deliver the Primrose intervention that was developed in the earlier stages of the research programme
(work package 2). Briefly, this involved arranging up to 12 appointments with each participant to target
the most relevant CVD risk factor and using agreed evidence-based approaches, and established
behavioural techniques to maximise the chance of successful risk reduction. In the treatment-as-usual arm,
the nurses were not trained in the intervention but they were allowed to offer standard treatment for CVD
risk factors in line with routine practice.
Patients and staff could not be masked to the intervention, but researchers were not informed of the
allocation. The analysis plan was predetermined and random-effects linear regression (adjusting for
baseline characteristics) was performed on the primary outcome of total cholesterol level at 12 months to
account for clustering within general practice. Secondary outcomes included CVD risk scores and other
cardiometabolic parameters including glucose, smoking, blood pressure and diabetes mellitus as well as
BMI. We also included validated measures of well-being, diet and physical activity, patient satisfaction with
services and adherence to both psychotropic and physical health medication.
Results
We recruited 327 participants with SMI: 155 participants in the 38 practices within the Primrose
intervention arm and 172 participants within the TAU arm. Attrition in the study at 12 months was lower
than predicted (12% as opposed to 20%) so that the total number of patients with follow-up data at
12 months (for the primary outcome of total cholesterol level) was greater than the sample size calculation
requirements. In general, the patients had a high level of CVD risk factors, as would be expected by the
inclusion criteria. For instance, half were current smokers and the mean BMI was above the threshold for
obesity in both arms.
For the primary outcome of total cholesterol level there were no differences between arms at 12 months
(5.4 mmol/l Primrose vs. 5.5mmol/l TAU; coefficient 0.03, 95% CI –0.22 to 0.29). This remained the case
when additional analyses were performed, adjusting for baseline cholesterol levels or for characteristics
that differed between arms at baseline. Total cholesterol levels did decrease over 12 months in both arms
(mean decrease Primrose 0.22 mmol/l; mean decrease TAU 0.39 mmol/l).
There were also no differences between arms on the secondary outcomes listed in the methods section
above, including the cardiometabolic parameters, patient satisfaction with services or adherence to
medications. Statin prescriptions were low and did not increase at 12 months in either the Primrose or the
TAU arm.
A total of 30 serious adverse events were reported for 25 people. There were fewer serious adverse events
in the intervention arm (seven events for seven patients, including one death, three psychiatric admissions
and three general admissions) than in the TAU arm (23 events for 18 patients including three deaths,
11 psychiatric admissions for nine people, seven general admissions for six people, one admission to a
crisis house and one diagnosis of cancer).
Participant attendance rates at Primrose appointments were moderately good, with only 32 (21%)
participants attending no appointments. A total of 72 (46%) participants attended more than six
appointments over the 6-month intervention period and 36 (23%) participants attended between two
and five appointments, with the remaining 15 participants (10%) attending one appointment.
EVALUATION OF A PRACTICE NURSE-/HEALTH-CARE ASSISTANT-LED INTERVENTION
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Care in the TAU arm may have been better than standard general practice care as the GP practices in
the study had identified people with raised CVD risk factors, for whom they may have then clinically
intervened. Furthermore, participants and the practices were motivated to take part in the trial and to
reduce CVD risk factors. This may have minimised the chance to show superiority for the more intensive
Primrose intervention.
The choice of primary outcome measure for the trial was a challenge given that the intervention was
designed to target multiple CVD risk factors. Nurses/HCAs were trained to discuss cholesterol levels and
statin intervention and adherence in the first instance and then move on to other goals relevant to CVD
risk reduction; however, this may have been in conflict with goal-setting being patient-led. If other
behavioural goals were chosen instead of statins, then they may have had less impact on levels of
cholesterol. However, differences were not demonstrated in any other CVD risk factors.
Conclusion
Nurses and HCAs were successfully trained in the Primrose intervention and delivered it to the majority of
patients. However, participants in the intervention arm did not do better on the primary or secondary
outcomes than participants in the TAU arm in UK primary care. This may reflect good care in both arms,
as cholesterol levels did decrease over the study period and satisfaction with services on the validated client
satisfaction questionnaire-8 was high in both groups.
This was a pragmatic trial in which participants exhibited a range of clinical characteristics and CVD risk
factors, and it may be that this variability made it less likely that the primary outcome of total cholesterol
level was targeted by the nurses/participants or that the most effective interventions, especially statins,
were chosen. This possibility will be explored in further fidelity and health economics work.
Cost-effectiveness of an intervention for lowering levels of cholesterol
and reducing cardiovascular disease risk for people with severe
mental illnesses
The trial protocol for the cluster RCT106 was published in Trials in 2016 and included the cost-effectiveness
analysis plan. The link to the protocol paper can be found in Appendix 3, Work package 3.106
The full cost-effectiveness analysis was published as supplementary material to the trial in the journal
Lancet Psychiatry in 2018.107 The link to this paper can be found in Appendix 3, Work package 3.107
The methods and preliminary results from this paper are summarised below.
Methods
The aim of the economic evaluation was to evaluate if the Primrose intervention was cost-effective
compared with TAU, for a range of values of WTP for a QALY gained from a health-care cost perspective
over the duration of the trial (12 months).
To calculate QALYs, EuroQol EQ-5D 5 level (EQ-5D-5L) data were collected at baseline, 6 months and
12 months and calculated as the area under the curve adjusting for baseline differences. Data were
collected using patient-completed questionnaires asking about health promotion activities over the past
6 months at baseline, 6 months and 12 months. Health promotion activities included services for
hazardous and harmful drinking, Stop Smoking Services, nicotine replacement therapy, diabetes mellitus
and weight management services. Primary and secondary care resource use was collected from patient
medical records for the duration of the trial. The cost of the Primrose intervention was calculated from
data collected as part of the trial on the number and duration of Primrose appointments attended, missed
appointments and who delivered the intervention (primary care nurse, HCA or GP). Information on the cost
of training was also collected.
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Results
The Primrose intervention arm showed a mean of 0.769 QALYs (95% CI 0.751 to 0.787) compared with a
mean of 0.780 QALYs for TAU (95% CI 0.764 to 0.796). The difference in QALYs was –0.011 (95% CI
–0.034 to 0.011).
The total health-care cost for the Primrose intervention group was £1286, with a total cost of £2182 for
TAU (mean difference –895, 95% CI –£1631 to –£160; p = 0.012). These lower health costs were mostly
a result of fewer mental health inpatient stays and costs (£157 in the Primrose intervention vs. £956 in
TAU; –£799, 95% CI –£1480 to –£117; p = 0.018). The total mean 12-month health-care cost per patient
for the Primrose intervention (including intervention costs but excluding those who did not attend and
training) was £2580 (95% CI £1899 to £3261), with a total mean cost of £3404 (95% CI £2467 to
£4340) for TAU. This gave a cost difference of –£824 (95% CI –£568 to £1079) in favour of Primrose.
The total incremental cost-effectiveness ratio (–£824/–0.011) is £76,245.
There is some uncertainty as to whether or not using the EQ-5D-5L to calculate QALYs is a suitable
methodology for health promotion interventions.
Conclusion
The potential effect of increased contact with a primary care health professional on mental health inpatient
admissions warrants further investigation.
Fidelity assessment of the Primrose intervention delivery
We assessed the extent to which the intervention and training programme were delivered as intended
through an analysis of a randomly selected sample of transcribed audio-recordings of intervention
appointments. The full report of this work can be found in Appendix 2.
Methods
To enhance fidelity in the intervention arm, we developed a study manual in which the detail of each
component of the intervention was described. Nurses/HCAs were trained on delivering the intervention
through strict adherence to the details provided in the manual. This facilitated the standardised delivery of
the intervention across 41 providers in all 38 participating GP practices in the intervention arm.
Nurses/HCAs in the intervention arm were trained in procedures for audio-recording all of their appointments
with recruited Primrose patients. After gaining consent from the patients and nurses/HCAs in the intervention
arm, nurses/HCAs were asked to record all of their Primrose intervention appointments.
A random 20% sample of audio-recordings was selected for the fidelity assessment as specified in the
original grant application. Fidelity was assessed by two independent researchers using first appointment
and subsequent appointment checklists adapted from a reliable fidelity assessment method developed for
behavioural interventions.108,109 A score of ‘2’ was assigned if a provider behaviour was achieved, a score
of ‘1’ when a provider behaviour was achieved to some extent, a ‘0’ when the provider behaviour was
judged appropriate to do but was not delivered, and ‘not applicable’ for provider behaviours judged not
appropriate. This scoring system was applied to the appointment transcripts, deriving a percentage fidelity
score for each intervention component, appointment and provider. We also derived an overall fidelity
percentage score for all sampled appointments and all providers combined. Inter-rater reliability for coding
between the two researchers was 86% with a Cohen’s kappa of 0.668 (95% CI 0.63 to 0.70).
Results
One or more appointment audio files were returned by 33 out of 41 (80.5%) providers for 90 out of
123 (73.1%) patients. Out of 831 attended appointments, 431 (53%) audio-recordings were returned.
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A random selection of 86 out of 431 (20%) audio-recordings covering 23 out of 33 (69.7%) providers
and 52 out of 123 (42.3%) patients were transcribed verbatim.
A total of 67.7% of intervention manual-specified components were delivered across all appointments
indicating moderate fidelity, with considerable variation among activities. Fidelity was higher in appointment
1 (72.5%) than in subsequent appointments (66.6%). Fidelity also varied between intervention components
and was lowest for ‘forming habits’ (47.8%) and highest for ‘reviewing progress’ (90.2%).
Out of 14 first appointments, none of the patients identified a goal that addressed statin adherence or
initiation. Eight (57.1%) patients wanted to address diet or physical activity, three (21.4%) patients set a
goal around reducing smoking, and two (14.3%) patients chose to reduce their alcohol intake. One patient
did not set a goal. Nurses had higher fidelity than HCAs, with 79.5% of intervention components delivered
by nurses compared with 64.3% by HCAs. This difference was significant [t(20) = 2.32; p = 0.037].
A potential limitation of the study was whether or not the fidelity sample of intervention practice nurses/
HCAs was representative of the trial sample. Nurses were over-represented in the fidelity sample (60.9%
vs. 43.9% in the trial) as were providers with previous research experience (52.2% vs. 39% in trial);
however, the fidelity sample was randomly generated by an independent statistician.
Conclusion
Observed fidelity to the Primrose intervention was moderate, with some intervention components being
delivered more than others. These results are comparable to other fidelity assessments of cardiovascular
prevention programmes.110 Statins were not focused on in initial appointments, which concurs with the
main RCT findings in which few statins were initiated. HCAs had a lower fidelity of intervention delivery
than practice nurses, which may have implications for future clinical and research work in this field.
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Conclusions and recommendations
This section brings together the main conclusions from the Primrose research programme. It reflectson the successes and difficulties we faced over the 6 years, in the context of the original aims and
objectives of the funded grant proposal. It then describes the implications of the research findings, the
plans for future research building on the programme, and opportunities for other work in the field of
cardiovascular comorbidity in people with SMI.
Summary of successes and challenges
We achieved all our main research objectives from our final PGfAR proposal and delivered some additional
pieces of work related to cardiovascular health in people with SMI. The risk score work and development
work were all delivered and most of that work has been published in peer-reviewed journals and/or
presented at scientific meetings. The trial was also completed within a revised timeframe for the larger
trial in terms of the increased number of required clusters.
The objectives were achieved despite a number of challenges, especially two major changes in national
GP research infrastructure after funding was awarded, namely the closure of both the Medical Research
Council General Practice Research Framework (MRC GPRF) and then the Primary Care Research Network
(PCRN). We were one of the first research teams to fully run a primary care trial within the new Clinical
Research Network (CRN) structure.
The timeframe for the trial in work package 3 required the Primrose programme to run for an additional
15 months to achieve the numbers required in our sample size calculation, mainly because of the
challenges of recruiting sufficient participants in each general practice. This meant that we needed to
recruit 76 GP practices rather than the original 40. All this was achieved despite a small number of
permanent staff in our budget (one programme manager and one research assistant). It is testimony to
their skills and hard work that the trial achieved its aims with 76 practices recruited across England, all
requiring site initiation, training, liaison with practices and research network staff as well as co-ordination
of follow-up data collection and study closure.
Work package 1: development and validation of a risk model for predicting
cardiovascular disease events in people with severe mental illnesses
The work package 1 risk score work developed new models for predicting CVD in SMI. These were
delivered on time, using all the methods specified in the original proposal. We developed bespoke new
Primrose models for predicting CVD in SMI and these performed well in people with SMI. However,
existing models from the general population also performed fairly well and we did not generate the
objective evidence to suggest that existing CVD risk scores in general practice should be replaced
immediately with the bespoke SMI specific models.
A limitation of the study was that the performance of the CVD risk score models among different ethnic
groups was not assessed, but the availability of routine ethnicity data is limited and this could be a focus of
future work if data quality improves.
Given that a range of guidelines have referenced our work, it is likely that many clinicians are aware that
standard risk scores may underestimate risk in people with SMI.
Work package 1: additional economic modelling work over and above the
original protocol
The health economics modelling work regarding the new Primrose risk scores has recently been peer
reviewed and published.40 It uses the more recently recommended threshold of 10% CVD 10-year risk to
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explore which risk models would be better for people with SMI if used to drive statin prescribing. The
Primrose BMI models provided the best economic results, which may have been a result of its classification
of more individuals at a high risk of CVD and eligible for statin therapy than other algorithms, although
the UK QRISK models also performed well.
Given that there was a small difference between the two tools economically, the decision regarding which
algorithm to use in routine clinical practice becomes one of implementation, advocacy and ease of use.
One could argue in favour of using a general population-derived lipid model as these are already used
in UK general practice and hence require no change. On the other hand, the SMI-specific BMI model,
although potentially requiring additional training and implementation costs, could confer additional benefit
by raising awareness of the need to improve CVD outcomes in people with SMI, and providing a model
that requires no blood test to estimate risk, a limitation of other CVD risk algorithms as many people, with
and without SMI, decline blood tests.111 The ease of implementation and delivery of the SMI-specific BMI
model means it could be used in any setting, including mental health care and non-clinical settings without
blood results. This is particularly important as many people with SMI do not attend primary care and
monitoring of CVD risk factors remains low in other settings.19,111–114 The SMI-specific BMI model provides
an opportunity to target more people with SMI, to increase identification of those at a high risk of CVD
and decrease the physical, social and financial burden associated with CVD.
We have made the Primrose model available on the internet so that it can be used by interested stakeholders.40
Although the Primrose risk score results were delivered (and published) on time, the initial validation results
were not strikingly different from current CVD screening practice for us to include the new algorithms in
the Primrose intervention work or to use them as inclusion criteria for the trial as originally planned.37 This
was partly a timing issue as the risk score work occurred in parallel to the development work packages
2.1–2.3, which involved bringing together this intensive development work to finalise the training and
content of the Primrose intervention.
Work package 2: development of a practice nurse-/health-care assistant-led intervention
for lowering levels of cholesterol and reducing cardiovascular disease in people with
severe mental illnesses
Three major pieces of research were performed to help design the nurse-led intervention for the main trial,
as detailed in our original research protocol.
We also worked closely with our patient and public involvement (PPI) LEAP panel throughout this part of
the programme and won a national prize for our PPI work, from the NIHR Mental Health Research
Network (MHRN).
Focus groups with health professionals, patients and carers on the barriers to, and
facilitators of, cardiovascular disease prevention in primary care for people with severe
mental illnesses
We had always planned to augment our previous work with stakeholders to derive up-to-date information
on the best ways to deliver the Primrose training and the intervention itself in primary care.
We conducted focus groups with nurses, GPs, service users and other stakeholders as planned. This work
was peer reviewed and published in PLOS ONE in 2015.48 We used behavioural science theory49,104 to
identify barriers to, and facilitators of, nurses delivering the intervention to reduce CVD risk in people
with SMI. A range of important factors emerged and these were incorporated into the intervention for
the trial.
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Systematic review of pharmacological and behavioural interventions for reducing
cardiovascular disease risk in people with severe mental illnesses
As there were existing systematic reviews in this field (for single risk factors, such as weight and smoking),
it had only ever been planned to update and summarise this evidence so that the latest research could be
incorporated into the training package and intervention. This evidence would include SMI-specific research
that targeted the main CVD risk factors in people with SMI, namely levels of cholesterol, blood pressure,
dyslipidaemia, raised CVD risk scores, weight/obesity, smoking and diabetes mellitus.
The updated, extensive review was delivered on time and was utilised in the workshops, training and other
activities that informed the final content of our intervention for the trial. It did not find many additional
pieces of evidence to warrant a new publication.
The findings of our review were specifically useful in demonstrating that smoking and weight reduction
interventions have been successful in people with SMI. This was a positive message to incorporate into the
intervention training, particularly aimed at tackling negative attitudes towards behaviour change in people
with SMI.27,115–117
The review was presented at a public health conference and the abstract published in The Lancet.51
Investigating patterns of statin prescribing among people with, and without,
severe mental illnesses
We completed primary care database research that showed that statins are generally being used equitably
(or at higher levels) in people with SMI, compared with age-matched individuals without SMI, except in
older people with schizophrenia for whom there is a disparity and underprescribing of statins. This is an
important finding as this age group has the highest absolute rates of CVD.
This work was emerging as the trial and intervention design was under way; therefore, we maintained
statins at the top of our hierarchy of interventions for the nurses to focus on in the Primrose intervention
arm if the patients met the criteria for statin prescription, which changed to 10% rather than 20% risk at
the beginning of the trial in 2014.25
Additional piece of pharmacological epidemiology: estimating the effectiveness of statin
prescribing for people with severe mental illnesses
This work involved a relatively novel methodological approach to assessing the effectiveness of statins in
real life for people with SMI, again using the UK THIN database.
The staggered cohort design allowed us to show that after adjusting for multiple factors in the analysis,
statins have similar effects on levels of total cholesterol at 12 months, as would be seen in the general
population. In other words, statins do work and people with SMI do seem to take them when they are
prescribed. This is sometimes questioned given issues around adherence and the multiple risk factor
challenges that face people with SMI.
The work has been peer reviewed and published in BMJ Open (with an impact factor of 2.413 at the time
of writing).101,102 The work within work package 2.3 was also the content of a successful PhD awarded to
Ruth Blackburn in 2016 as part of Primrose.118
Bringing the evidence together to develop and test the Primrose trial intervention and
training programme
At the end of the development work packages, we entered an intensive period of work, synthesising the
evidence that we had identified, running workshops and developing the manual and training programme
for the Primrose nurse-led intervention.
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We were able to use a rich combination of existing data, expertise, novel research findings and existing
clinical guidance to create a contemporary evidence-based intervention.
The intervention appointment structure was piloted with two LEAP members and the training programme
was piloted with seven nurses. Feedback was generally positive with suggestions incorporated into the
final versions of the manual and training programme. The final intervention included a structure of 8–12
appointments delivered fortnightly over a 6-month period, a 2-day training programme, the manual for
the nurses and its component instructions. This specified a hierarchy of risk factors to address during the
Primrose appointments, with guidance on how to choose collaborative goals, which were likely to have
an impact on CVD risk. The manual and training programme also addressed a range of behavioural techniques
to guide the nurses/HCAs through each appointment including goal-setting, creating an action plan and
involving supportive others.
Each of the developed products received feedback and input from the full range of Primrose stakeholders
including service users, practitioners, researchers and experts in behavioural science, nursing and cardiovascular
health. Developing a complex intervention involving different stakeholders from a range of backgrounds
was challenging at times, particularly when views on the content of the intervention and training programme
were in conflict. One particular area of contention was around statin prescriptions, with clinicians and policy
favouring statins as a first-line clinically effective treatment for CVD prevention, but patients expressing
concerns about medication and a preference for patient-led behavioural approaches. We decided to maintain
our emphasis on statins and statin adherence as the first-line treatment within the intervention, while also
emphasising the need to work in partnership with the patient to determine how to tackle raised cholesterol
levels and CVD risk, with the option of considering behavioural approaches around diet and physical activity,
smoking and alcohol use.
This development process was very comprehensive and it was felt that the resulting intervention had been
developed extremely thoroughly and included a high level of scientific and practical specification.
Work package 3: evaluation of a practice nurse-/health-care assistant-led intervention
for lowering levels of cholesterol and reducing cardiovascular disease risk in people
with severe mental illnesses – a cluster randomised controlled trial
Ethics approval and trial registration were successfully achieved on time to start the trial in 2013. The trial
protocol was peer reviewed and published in 2016,106 before any analysis occurred.
The trial commenced in the north London locality and it soon became clear that recruitment procedures for
the trial involved large amounts of work to screen for people with SMI in primary care, to check eligibility
in terms of cardiovascular risk factors and to invite them to take part. Some potential participants did not
have all the required information on CVD risk factors, so they needed to be invited to their GP practice to
check eligibility. This was a rate limiting step to recruitment.
We realised that the numbers likely to take part per practice were somewhat smaller than expected, and
required a lot of time and effort in the absence of the MRC GPRF and PCRN infrastructure. We therefore
decided to increase the number of practices from 40 to a final total of 76, which increased the delivery
time of the trial. However, we successfully recruited and retained enough people with SMI and CVD risk
factors to achieve the final number of participants with primary outcome data at the 12-month follow-up
(total n = 289), meeting the requirements of our published sample size calculation.
This was the first fully powered trial of a primary care-based intervention for lowering CVD risk in people
with SMI. The successful delivery demonstrates that there is an appetite for this field in UK primary care
and also that the CRNs were able to support this type of work. The large number of GP practices recruited
and the geographical spread across both rural and urban areas in England is also a strength in terms of
external validity.
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The trial finished follow-up on time within our revised timeline (6 months ahead of the end of the overall
programme funding as planned), allowing time for data cleaning and analysis of the results.
The training and intervention were successfully delivered across the general practices, and seemed
acceptable to providers and participants with almost half attending six or more appointments in the
Primrose intervention arm. This contradicts the negative attitudes that are sometimes voiced about uptake
of this work in SMI.
The main results showed no differences in the primary outcome of total cholesterol levels at the 12-month
follow-up. Furthermore, the trial did not show differences in any of the main secondary outcomes related
to cardiometabolic risk factors, such as blood pressure, glucose, weight or smoking. Diet and exercise
levels were similar in both arms and levels of satisfaction with services were high in both arms.
The richness and volume of the objective medical records data collected for the economic evaluation of the
cluster randomised control trial was a strength of the study, but we did not have the time to conduct all
of the analyses we were interested in. Additional work will include an analysis of 12-month data using
multiple imputation to account for missing data and an analysis of the relationship between health inputs
(health promotion activities) and health outputs (QALYs, reduction in unplanned health-care resource use).
In the assessment of fidelity using the audiotaped appointments, there was evidence that many of the
behavioural techniques had been utilised within the appointments. This was true across providers,
although fidelity seemed even higher for nurses than for HCAs. There was some evidence that when statin
adherence or prescription should have been reviewed and targeted, the participant and provider did not
choose statins as their primary focus.
The initial intervention had been envisaged as a nurse-led intervention, but in practice many GPs were
unable to provide a nurse with time available to be trained in the Primrose intervention, so a health-care
assistant (HCA) was identified instead. These practitioners do deliver CVD screening work to other
populations, therefore, it was agreed that they would be trained in Primrose, partly to reflect real life and
partly to allow the trial to be delivered practically and on time.
There is evidence in the primary care mental health literature that interventions that include supervision
from a physician are more likely to reduce disease risk factors in people with depression,119 but this
approach has not been tested in people with SMI. Future intervention studies may wish to test whether or
not more intensive supervision and support for staff results in improved outcomes for patients; however,
there may be cost implications of additional support.
There were some design issues that are a challenge to the external validity of the trial findings. This
included generalisability, as both the GPs and the participants were people interested in physical health in
SMI but perhaps not representative of the overall UK population and primary care landscape. A second
issue was the cluster design and the fact that practices (and participants) allocated to the TAU arm were
aware that there were Primrose participants with identified CVD risk factors who would not receive the
Primrose intervention. Therefore, these participants may have received superior, or at least different, care
to those undergoing standard care in usual UK general practice, by virtue of the screening process for
the trial. In other words, TAU may not have been a ‘fair’ comparison with the Primrose intervention. The
finding that levels of total cholesterol were reduced in both the intervention and the TAU arms despite a
lack of focus on statins would support this.
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It is interesting that mean total cholesterol levels decreased in both arms of the trial over the 12 months.
The natural course of cholesterol level is to increase with age, so perhaps this decrease in cholesterol level
reflects improvements in CVD risk for people with SMI in both arms and this may be one explanation as to
why there were no differences between arms at 12 months.
The choice of an outcome measure for the trial was always going to be a challenge in a study targeting
multiple CVD risk factors. The level of cholesterol was eventually chosen because the first aim of the
intervention (and the original protocol) was to optimise statin prescribing in the first instance. However, if
other behavioural goals were chosen instead of statins, these goals may have been less likely to have an
impact on the primary outcome. Nonetheless, we did not show any differences in other CVD risk factors,
nor in overall measures of well-being. However, the problem of identifying outcomes in trial settings such
as this has been highlighted in other studies.120 It is also acknowledged that in the longer term, cholesterol
level reduction might not necessarily reduce CVD rates.
Recommendations for future research
Future research related to work package 1: the risk score development work, and work
package 2.3 – the primary care database work
Our bespoke SMI Primrose risk scores have been validated and can be accessed online (www.ucl.ac.uk/
primrose-risk-score/). They have been assessed in terms of economic benefit of using them to guide statin
prescribing and would provide a NMB.
This is a particular benefit when people with SMI do not have a blood test result for lipids or decline to
have one taken. This may apply to 50% of the UK SMI population.21
The Primrose risk scores could be validated externally in a separate data set and updated and also
compared against newer risk scores, including the new QRISK3 score that was published in 2017.121 The
QRISK3 score should be explicitly evaluated for its benefits for people with SMI, especially as QRISK3 uses a
definition of SMI that is inconsistent with the general meaning in UK primary care (i.e. it also includes
depression). The inclusion of depression may be valid, but for now we lack evidence as to whether or not
this new risk score is superior to the Primrose score for people with schizophrenia, bipolar disorder or
other psychoses.
Regarding the statins database research in Primrose,102 it is important that further studies monitor the
national prescribing of statins to people with SMI, especially older age groups who are undertreated in
current UK practice.
Future study designs may be able to assess the impact of statins on the mortality gap and excess CVD in
people with SMI, especially if databases in the UK or internationally achieve larger sample sizes with higher
numbers of CVD events, as is currently planned in primary care research.
Future research related to work package 3: the Primrose cluster randomised
controlled trial
The Primrose intervention was acceptable and deliverable in real-life practice, with patients attending
appointments and behavioural goals being set. However, it was not superior in terms of a difference in
levels of total cholesterol between the two arms of the cluster trial.
Future studies might need to move beyond standard trial designs if we are to understand what works for
people with SMI in terms of reducing CVD risk. Studies might need to use routinely collected clinical data
to assess outcomes for all patients in real-life settings, comparing areas where different interventions are
delivered to different people. These naturalistic evaluations would overcome the restrictions imposed by
trial inclusion criteria, and the unrepresentativeness of people (and practices) who agree to participate in
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trials. This could involve more applied methods where routine data are collected within health-care systems
to evaluate gaps in CVD risk screening and interventions. These studies should explore the delivery of
statins, smoking cessation and weight reduction techniques including pharmacological approaches, such
as metformin and behavioural approaches.
Further analysis of the fidelity work could utilise the full data set and explore the content and conversational
aspects of the appointments in greater detail to help shed light on the lack of difference in results between
intervention and control groups. Future research work should also examine whether or not a conversation
regarding statins is happening between professionals and patients, and explore the reasons why statins
might not be initiated for those who would benefit.
Further analysis of the Primrose trial data set from work package 3 will be able to assess the content of
care within both the intervention arm and the TAU arm and explore what did and did not work, and
any predictors of response. Examples will include demographics, provider characteristics, participant
characteristics, such as diagnosis, the availability of formal or informal support to the participant and
further analysis on service use and prescription data collected for the cost-effectiveness analysis of the trial.
The potential effect of increased contact with a primary care health professional on hospital admissions
also warrants further investigation.
Additional studies emerging from the Primrose programme
A number of additional studies have emerged from the Primrose programme of work and are currently in
application, set-up or analysis phase. This includes:
l An analysis of data from a qualitative study that used semistructured interviews to explore the
experiences of those who delivered and those who took part in the Primrose intervention.
l As part of the data collection for the cluster RCT, participants consented to provide a saliva sample for
deoxyribonucleic acid (DNA) extraction and analysis purposes to determine whether or not any variation
in DNA exists, relevant to both SMI diagnosis and physical health outcomes. Participants were given
the opportunity to opt out of providing the sample without affecting their entry into the trial. DNA
extraction is currently under way with data analysis plans currently being finalised.
l The programme manager is carrying out secondary analyses on data collected through the trial and
fidelity assessments for the purpose of fulfilling a doctorate. The research aims to explore the links
between existing social support and adherence to CVD risk reducing treatments and behaviours for
people with SMI.
l A further, independent study funded by the NIHR School for Public Health Research is being
commenced to explore inequalities in the provision of smoking cessation interventions for people with
SMI, and the effectiveness of interventions in the THIN database 2017–18. This work follows on from
the work in work package 2.3, but for smoking rather than statins.
l Applications are currently being planned for studies to carry out naturalistic evaluations of the different
risk scores in real-life settings as well as local interventions, which have been deployed in different
regions of the UK to integrate physical and mental health care in people with SMI. An example is the
Integrated Practice Unit for psychosis in Camden and Islington Foundation NHS Trust, which brings
together health services and other providers to deliver a holistic approach to mental and physical
health needs.
l A further study is being planned, to explore diet and exercise variables and interventions related to
these, with a NIHR School for Primary Care Research PhD studentship.
l Primary care database studies continue to be used to explore CVD outcomes, risk factors and
interventions in people with SMI, as new (and better-quality) primary care data become available.
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Implications for practice
Work package 1: development and validation of a risk model for predicting
cardiovascular disease events in people with severe mental illnesses
We have demonstrated that general population risk scores can underestimate CVD risk in people with
SMI.37 We have also shown that a model that does not require lipid blood tests is most beneficial for
deciding when to prescribe statins and prevent CVD in people with SMI.40
We are now making this tool available for clinicians and will need to update it with contemporary data as
it becomes available. We will explore integrating these scores into clinical software packages.
Our findings regarding risk scores in SMI have been highlighted in national guidelines, including the
British Association of Psychopharmacology guidelines on weight management in people prescribed
antipsychotics.39
The underperformance of general population risk scores for people with SMI is also highlighted in
the adapted ‘Lester’ tool, an algorithm to help clinicians to manage CVD risk in people with SMI.38
This tool is endorsed by most Royal Colleges and medical/nursing organisations, as well as NICE.17 The
underperformance of general population risk scores in SMI is also recognised in the general 2014 NICE
guidelines on lipid modification.25
In 2017, a new ‘QRISK3’ CVD score was published and it has addressed some of these limitations.121 This
new score included SMI and second-generation antipsychotics. The existing QRISK algorithms do allow
calculation of CVD risk without lipid levels, but this is by assigning an average value. The Primrose models
use multiple imputation in the BMI model and, therefore, should be more accurate when lipids are missing.
There are no data validating the new QRISK3 tool specifically in SMI, and there are some uncertainties
about the new tool as the definition of SMI in the QRISK3 study has needed clarification; it transpires that
the authors include depression in their definition of SMI, which is unusual for this field and may limit the
utility of QRISK3 for people with schizophrenia, bipolar disorder and other psychoses. The results need
further validation and clarification.122 In contrast, the new Primrose models have been validated and
economically evaluated as superior for people with SMI.
Work packages 2.3.1: investigating patterns of statin prescribing, and 2.3.2 – estimating
the effectiveness of statin prescribing for people with severe mental illnesses
Some people with SMI who are older may be less likely to receive statins, so this needs to be addressed in
clinical practice, especially as this group has the highest absolute number of CVD events. It is important
that people with SMI are offered statins, as we have provided robust evidence that they are effective in a
large, representative UK sample of people with SMI.
Work package 3: evaluation of a practice nurse-/health-care assistant-led intervention
for lowering levels of cholesterol and reducing cardiovascular disease risk in people
with severe mental illnesses in primary care – a cluster randomised controlled trial
We demonstrated that a primary care intervention for people with SMI was deliverable across general
practices in England. The training was successfully organised and when the nurses and HCAs organised
appointments, there was good attendance by people with SMI, with almost a half of patients attending six
or more appointments. The providers did deliver the behavioural interventions to a moderate degree
of fidelity. This occurred despite some negative attitudes towards the work when the providers initially
attended the training for Primrose.
There was some evidence that statins were not chosen as the first goal, even when they should have been
initiated or reviewed, but this is preliminary evidence.
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The intervention in its current form was not found to be superior for the chosen primary outcome of total
cholesterol level, nor the secondary outcomes. However, the success of the trial delivery demonstrates the
feasibility of organising care for people with SMI in the primary care setting, at least for a group of people
with SMI, with good levels of satisfaction in both arms. It is also of interest that an intervention in primary
care with regular appointments was associated with fewer serious adverse events and decreased costs in
terms of mental health admissions.
There were some methodological considerations regarding the trial, especially whether or not TAU was
superior to usual UK general practice care, and future research designs may need to be more naturalistic,
using less constraining methods, which are more inclusive of all people and practices, and which can
capture real-life service provision.
In terms of future interventions, our fidelity work demonstrated that behavioural techniques can be
delivered during appointments by HCAs/nurses with a manual and with two brief days of training. Patient
care may be enhanced through mechanisms to ensure that evidence-based CVD risk reduction strategies
are being offered and explained to people with SMI, including reviewing risk scores and explaining the role
of statins.
Dissemination plans
It is planned to disseminate the findings from the programme of work through the following mechanisms:
l Make the CVD risk score available as an online screening tool for use in clinical practice (www.ucl.ac.uk/
primrose-risk-score).
l Communicate key findings through the study website (www.ucl.ac.uk/primrose) and social media
(https://twitter.com/UCLprimrose).
l Publish the trial findings in peer-reviewed academic journals and present the findings at academic
conferences.
l Run workshops with stakeholders who took part in the trial and with leading academics in the field of
CVD prevention and SMI to share findings and consider future research and policy implications.
l Work with the Department of Health and Public Health England to translate the findings into practice.
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Patient and public involvement
There was collaboration with both Rethink Mental Illness and the McPin Foundation in an advisorycapacity and as active partners in the programme of research to ensure that patient involvement was
integrated in the study. An award was received from the MHRN in 2013 for outstanding PPI in the
Primrose programme.
A summary of the processes that were designed to ensure that PPI was appropriately delivered is below.
Each of these activities is then described in more detail, and a reflection on their perceived impact from the
perspective of the study team is provided:
l Patient consultation prior to funding to assist in the design of the study. This was organised through
Rethink Mental Illness. The key service user advisor, Janey Antoniou, died during the study set-up
phase and, unfortunately, did not play a role in the delivery of the research.
l Patient representatives on the management group and as co-applicants in the study (through two
charities, first Rethink Mental Illness and second the McPin Foundation).
l A LEAP during study set up. This group met throughout the life of the programme.
l A public and patient co-ordinator – Dr Ben Gray. This role was active particularly in the development
phases of the programme of research.
l An intervention development group consisting of members of the LEAP and members of the research
team. This group informed the development of the intervention manual and training programme.
l A service user trainer, Vanessa Robinson, was employed to train practice nurses and HCAs drawing on
expertise from experience alongside members of the research team.
l A small qualitative study designed and delivered by the LEAP supported by the research team and staff
at the McPin Foundation.
Design of the study and early development work with the Lived
Experience Advisory Panel
We made use of the Camden and Islington Service User Research Forum (SURF) in the early stages of the
programme to shape the priorities, research aims and research tools for each work package. Service users
consistently endorsed the importance of this work, particularly mentioning weight gain, smoking and
‘diagnostic overshadowing’ whereby physical health is neglected by professionals on account of mental
health diagnoses. SURF supported the development work, especially ensuring that statins were not offered
too aggressively in the clinical trial as the latest ‘miracle cure’, but collaboratively with careful explanation.
The SURF also provided feedback on the development of topic guides for the focus group study.
Shortly after the award of the programme grant, the Independent Service User Consultant co-applicant
and researcher at Rethink Mental Illness sadly died. Our partners at Rethink Mental Illness worked closely
with us and we were joined by a public and patient co-ordinator from Rethink Mental Illness with expertise
in systematic reviews and qualitative work to lead on delivering the PPI arrangements as outlined in the
original application. Within Primrose, this role was known as our PPI co-ordinator post. It was responsible
for the set up and management of a service user advisory panel, a model pioneered by Rethink Mental
Illness and called a LEAP, cofacilitating a service user focus group and assisting in the coding of focus
group transcripts to feed into the development of a thematic framework. The PPI co-ordinator also set up
a blog for service users, carers and members of the public to share their experiences of mental health and
physical health problems and to obtain information on the project. A project website was developed that
contained a dedicated service user and carer involvement page with links to Rethink Mental Illness and the
blog (www.ucl.ac.uk/primrose).
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A ‘virtual’ LEAP of 27 service users and carers with lived experience of mental and physical health problems
was formed and met annually to review progress, influence the content of the programme and comment
on work as needed. We had so much interest in advising the study that we chose to formulate a large
LEAP and smaller face-to-face meetings as needed. The LEAP was co-ordinated by the public and patient
co-coordinator employed by Rethink Mental Illness who updated members via e-mail on developments
within the programme between meetings. At the first meeting, the purposes of the project were shared
and feedback on the development work obtained and incorporated into the protocol. This included
recruiting carers through Rethink Mental Illness to take part in an additional focus group, conducting focus
groups in rural areas and exploring within the focus groups the potential link between primary care and
secondary services in delivering the intervention. Feedback on the development of the project logo was
incorporated into the final design. Comments on study documentation including patient information
sheets, invitation letters and patient questionnaires and ideas to help improve recruitment and retention in
the study were received from panel members in future meetings. This resulted in the redesign of the study
recruitment leaflet and the design of a postcard thanking participants for their involvement in the study
and to remind them of their follow-up assessment. The LEAP also contributed to the development of
the health economics questionnaire for the trial and members were involved in piloting the intervention
appointments.
Programme management group
One way to ensure that PPI was integrated into the study was to monitor PPI progress by having a
standing item on all management meeting agendas. The PPI standing item tended to be an update report
from the PPI co-ordinator, or charity representative. Decisions were taken at these meetings to support PPI,
such as a LEAP request, to develop a user-led qualitative study to understand participant motivations for
consenting to take part in research.
Intervention development group
A smaller, core LEAP intervention subgroup consisting of eight service users and carers was formed from
the larger panel with the remit of translating the findings from the development work packages (focus
groups, policy and systematic review) into the design of the intervention. The subgroup met four times
over 1 year and developed 11 key recommendations, six of which were incorporated in to the intervention
manual and training programme.105 These recommendations were (1) one step at a time goals for
behaviour change, (2) involvement of carers and mental health workers, (3) training of nurses to address
attitudes towards mental illness and stigma, (4) appointment reminders to service users, (5) information to
take away including the next appointment time and (6) involving service users in the training of nurses. For
recommendations that were not incorporated into the intervention, the study team discussed the reasons
with the subgroup members and answered any questions arising from these decisions.
Recognition of patient and public involvement in the Primrose study
The Primrose study received an award from the MHRN for outstanding service user involvement in 2013.
The study was selected as the winner by three judges that were independent of the MHRN. The award
was presented to Professor David Osborn at the annual MHRN Scientific Meeting on 21 March 2013. A
service user from the LEAP took up the offer of a fully funded place (awarded to the Primrose study team)
to attend the scientific meeting.
The Primrose programme manager, public and patient co-coordinator from Rethink Mental Illness and a
member of the LEAP contributed to a case study report written on behalf of the MHRN.123 The case study
documented the impact, experiences and challenges of service user and carer involvement in research.
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Training practice nurses and health-care assistants
A lived experience trainer with experience of mental health problems and CVD risk factors shaped the
development and piloting of the training programme and co-delivered the training to practice nurses
and HCAs. Attendees greatly valued the opportunity to hear the lived experience trainer’s story and ask
questions about the experiences of how the trainer managed both their mental and physical health, and
this was often cited as the most helpful session of the training. A video of the talk was created for use
in the event that the trainer became unwell or was unable to attend, and a written summary document
of the experiences was given to all attendees.
Later work of the Lived Experience Advisory Panel
The programme of research across the life of the project required changes in how we approached the LEAP.
Once we entered the trial phase there were fewer decisions to make requiring lived experience expertise.
We kept in touch with people through a newsletter, and the LEAP met less frequently. One output from the
group after the trial began was a change in design for the patient information leaflet. It was updated with
new text and images as the group felt that the original, on reflection, was unappealing.
The group also designed a plan for how results might be disseminated. Recommendations for bringing
academics together to discuss findings from related studies were made as well as how results would be
fed back to participating GP practices and research participants.
Peer-led qualitative research study
A peer-led qualitative project to explore the reasons why people with SMI choose whether or not to
engage in research studies was conducted by members of the LEAP supported by staff at the McPin
Foundation. This approach is termed Peer Research.105 The idea for the study came from the LEAP group,
and members were asked if they wanted to be involved as service user researchers. We recruited two LEAP
members to design the study and conduct the interviews, supported by the Primrose PPI co-ordinator and
experienced McPin senior researcher.
User-led interviews to explore decision-making among potential
mental health research participants
The study sought to understand how mental health service users living with SMI approach decision-making
with regard to being offered the opportunity to join a research trial. The study used the Primrose trial as
an example. It also explored individuals’ views on and experiences with research and evaluation activities
more generally, considering the impact of these views on specific decisions to take part in trials.
In-depth interviews took place with 12 people who met the criteria for entry into the Primrose trial and
were recruited through voluntary sector networks. Interviews were conducted by a peer researcher, and
the McPin Foundation team, as well as the Primrose programme manager supported analysis and write-up
of findings. The study received research ethics approval from the University College London Ethics
Committee (project ID 6357/001).
The findings from this study are currently being analysed.
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Reflections from the Lived Experience Advisory Panel members
I felt very involved and included as a member of the LEAP from the beginning. It was good that
there was a mix of lived experience of mental distress and carers. We had discussions and I felt my
views and everyone’s was valued. We provided feedback on plans, documentation, leaflets and the
manual to be used by nurses. The study kept us up to date, especially in the early years of the study.
The PPI co-ordinator was excellent at this, along with making sure we all had opportunities to get
involved. The group worked well together and were very supportive, along with not being afraid to
give their views. I think a lot can be learnt regarding PPI from this study as I felt a very good example
of co-production in the true sense. Even with the change from Rethink Mental Illness to McPin
Foundation this continued, especially as the PPI co-ordinator moved on to work at McPin Foundation.
At all the meetings I could bring my lived experience of taking medication that affected my weight,
that left me at greater risk of cardiovascular disease. I could share how I struggled to tackle this,
especially the effect that the medication had on me. This experience I feel helped especially when
information resources were being developed, as getting the right wording for research participants
was so important. I wanted it to be encouraging and supportive, but not telling people, as at the
end of the day any person needed to take the decision that they wanted to achieve certain goals
themselves. I know only too well how hard is it to make those changes, but with some intervention
you never forget what you have learnt and can always return to it further down the line. It would
be good if the GP surgeries involved undertook some follow-ups with patients who were part of
this programme.
Jackie, LEAP experiences
I had recently joined Rethink Mental Illness as a member, and tentatively answered an online piece
regarding research into cardiovascular issues for people with serious mental illness. As I had high
cholesterol and was at the time trying to avoid being prescribed statins, I thought maybe I had
something to offer the team. I ended up in the main LEAP and intervention development group.
We achieved lots in each meeting. I remember the first session we decided on what we considered
was an appropriate logo for the project.
We had a co-ordinator who kept us informed of progress in the study. We would meet, were
encouraged to express our feelings, doubts and fears; and also put forward helpful ideas to further the
research. It may be that the researchers found our input more helpful than we ourselves knew: as we
were just mentioning day-to-day experiences that we come across all the time and more or less take
for granted (e.g. discrimination, being patronised, or diagnostic overshadowing). We agreed that a
gentle approach with a health-care professional at the annual cardiovascular review at the surgery
might work well: regular meetings with the same health-care professional, focusing on one issue at
a time to address rather than a blanket approach of tackling all the issues, like smoking, dieting,
exercise, all at once. And this approach was taken up by the team, into the project and was delivered
to patients at GP surgeries across England.
Susie, LEAP experiences
What was learnt about patient and public involvement
Primrose had a well-resourced and comprehensive PPI programme, but not all elements worked as well as
we would have liked. There were several challenges during the course of the programme.
l First, we lost our PPI co-applicant lead early in the programme. This meant that we did not have
consistency of input from design through to dissemination.
l Our PPI co-ordinator became unwell during the study and was off work for periods of time. We did not
have immediate contingency plans to replace their input into the development work, particularly the
cofacilitation of the service user focus groups. We recruited a service user consultant with experience of
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running focus groups who was able to cofacilitate two of the service user groups. They continued to
co-ordinate LEAP meetings and obtain ad hoc feedback on specific pieces of work including service
use input into the development of the health economics questionnaire for the trial, piloting the
intervention manual and feedback on patient invitation letters. They continued to update the LEAP
members and encourage communication through their blog.
l There were organisational changes during the study with the PPI co-ordinator at Rethink Mental Illness
moving to the McPin Foundation part way through the programme as Rethink Mental Illness closed its
research function.
l During the trial period there was limited work for the LEAP to feedback on, which resulted in less
frequent communication. Towards the end of the trial, a smaller LEAP was reformed and met three
times to explore the study findings and offer insight and recommendations from the service user and
carer perspective on interpreting the results of the trial and qualitative work.
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Appendix 1 Systematic review of
pharmacological and behavioural interventions for
reducing cardiovascular disease risk in people with
severe mental illnesses
This section presents the full report of the methods and results of a systematic review that wasconducted to inform the development of Primrose intervention and training programme.
Summary
Background
People with SMI are at increased risk of developing CVD and die at a younger age than the general
population. This study evaluated and synthesised evidence from published systematic reviews and
individual RCTs on the effectiveness of pharmacological and behavioural interventions for reducing
modifiable CVD risk factors in people with SMI.
Methods
We searched The Cochrane Library for existing systematic reviews. We then searched the Cochrane
Schizophrenia and Cochrane Depression, Anxiety and Neurosis Group Trial Registers between 1966 and
2014 for additional RCTs not included in the identified reviews. We searched for interventions to manage
levels of cholesterol, diabetes mellitus, hypertension, weight, smoking and alcohol consumption.
Findings
Fifteen systematic reviews and 28 additional RCTs were included in the review, from 11,028 references.
The synthesised data demonstrated good evidence of effective pharmacological and behavioural interventions
for weight management and some evidence that combined pharmacological and behavioural interventions
might be more effective than either alone. There was good evidence that pharmacological interventions
were effective for smoking cessation, or reducing smoking, and some evidence for behavioural or combined
interventions. Three studies reported effective interventions to reduce alcohol misuse. No studies were found
on effective interventions targeting levels of cholesterol, diabetes mellitus or hypertension in SMI.
Conclusion
There is evidence that CVD risk attributable to weight and smoking can be managed effectively in SMI,
using pharmacological and behavioural approaches. Future research should determine the effectiveness
of interventions to manage cholesterol levels, diabetes mellitus, hypertension and alcohol misuse in
this population.
Introduction
People with SMI die at a significantly younger age than the general population.124 The majority of these
premature deaths (66%) are due to potentially preventable or treatable CVD.3,5
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Increased mortality risk for CVD is seen in people with SMI compared with the general population.
Those aged 50–75 years have a twofold increased risk of death from CVD, rising to threefold for those
< 50 years old.3 There is evidence that CVD risk screening for people with SMI does not meet international
or national guidelines.23,111
Increased risk for CVD is attributable to metabolic and anthropomorphic effects of antipsychotic medication
as well as lifestyle factors including poor diet, low levels of physical activity, smoking and, in some cases,
higher than recommended levels of alcohol consumption.
The challenge is to design and deliver effective interventions to prevent CVD in this group and this requires
synthesis of evidence about modifying the different risk factors that contribute to CVD in SMI. Our overarching
aim was to identify the best international evidence regarding effective CVD risk management for people with
SMI to allow clinicians, policy-makers and researchers to meet the challenge of implementing and appraising
CVD risk reduction strategies.
In primary care, multiple risk factors for CVD are often addressed in one consultation but existing reviews
of pharmacological or behavioural interventions to reduce CVD risk in people with SMI tend to be limited
to one or two contributing risk factors/behaviours (e.g. smoking52,95 diet and physical activity96–99 or alcohol
use).100 Furthermore much existing research has largely been generated in secondary care rather than
primary care where, in the UK, evidence-based guidelines suggest CVD risk in SMI should be managed.17 One
review has synthesised evidence across CVD risk factors up to 2010.53 We aimed to update and improve on
this review by including (1) more recently published studies, (2) existing systematic reviews and meta-analyses
in addition to individual studies and (3) including only the highest-quality studies using a randomised
experimental design. This review informed the development of a primary care-based intervention to reduce
CVD risk.106
Methods
We searched for published systematic reviews and additional RCTs that were not included in existing
systematic reviews.
Inclusion/exclusion criteria
Studies were included if they met the following criteria: (1) they used a randomised controlled design,
(2) ≥ 50% of participants were adults with a diagnosis of schizophrenia, bipolar disorder or other
non-organic psychotic disorders including schizoaffective disorder, (3) they evaluated interventions aimed
at managing levels of cholesterol, diabetes mellitus, hypertension, weight, smoking and/or alcohol
consumption, (4) title and abstract were written in English (papers were only excluded on the basis of
being written in a non-English language where translation of the full text was not possible) and (5) were
published between 1966 and 2014.
Search strategy
We conducted the search strategy in five stages in the following order: (1) we searched the Cochrane
group publications lists and Cochrane Library database for systematic reviews, (2) an information specialist
from the Cochrane Schizophrenia Group searched the Cochrane Schizophrenia Group Trials Register
for RCTs with schizophrenia and psychosis populations, (3) we searched The Cochrane Library database
for additional RCTs using an adapted search strategy to include populations with bipolar disorder provided
by the Cochrane Depression, Anxiety and Neurosis Group, (4) an expert reference group searched for
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
52
non-peer-reviewed literature, (5) experts in the field were asked to identify any relevant publications not
captured by the electronic search strategies and (6) principal investigators identified on trials registers were
contacted for relevant publications.
The following search terms were used:
Schizophrenia* OR severe mental illness* OR bipolar or mania* OR manic* OR hypomani* OR psychos*
OR psychotic OR postpsychotic OR “post psychotic” OR “rapid cycling” OR schizoaffective OR bipolar OR
mania* OR manic* OR hypomani*
AND
*physical* OR *cardio* OR *metabolic* OR *weight* OR *Tobacc* OR *Smok* OR *medical* OR
*alcohol* OR *nutrition* OR *diet* OR *health* OR *diabete* OR *blood pressure* OR *hypertension*
OR *cholesterol*OR *statin*
Screening
Titles and abstracts of reports of RCTs identified in the electronic searches were screened by four researchers
(LA, AB, MH and VT; see Acknowledgements). References not meeting the inclusion criteria and duplicates
(including individual RCTs in included systematic reviews) were removed. To assess reliability of screening,
reviewers independently screened 10% of each other’s allotted references resulting in < 5% level of
disagreement. Disagreements were resolved by discussion.
Full-text reports were obtained and screened by the same researchers using the criteria described above.
Data were extracted from reports meeting the inclusion criteria.
Data extraction
Data within the RCTs were extracted using a modified template from Methods for the Development of
NICE Public Health Guidance125 to record methodological (publication, design, etc.) and substantive
characteristics (participant, setting, etc.) of included studies.
Quality assessment
The quality of evidence in included reports was assessed using The Cochrane Collaboration’s tool for
assessing risk of bias.126
Data synthesis
Reference lists of published systematic reviews were cross-checked and reviews including the greatest
number of relevant references were summarised. Papers from less comprehensive reviews were also
included if they were not covered by the more comprehensive reviews. A meta-analysis of findings from
individual RCTs was not possible owing to the heterogeneity of reporting, so a narrative synthesis of
findings was created. Findings from RCTs with fewer than 10 participants, which may not be sufficiently
powered to detect change, are summarised separately.
We performed a narrative synthesis of the evidence, first by selecting the most comprehensive systematic
review and summarising this and all the additional trial results.
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Findings
Fifteen systematic reviews and 28 additional individual RCTs of interventions met the inclusion criteria
[Table 1 and Figure 2 for Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
flow diagram of individual RCTs].
No trials or reviews of interventions directly targeting levels of cholesterol, diabetes mellitus or hypertension
in SMI were identified. Systematic reviews and individual RCTs meeting the inclusion criteria were therefore
grouped into three categories of interventions: (1) weight, (2) smoking and (3) alcohol consumption.
In this section, we summarise the main findings of the systematic reviews, grouping the interventions
according to their main target CVD risk factor and whether they were behavioural, pharmacological
or both.
Risk of bias
Risk of bias was assessed in individual RCTs identified through the electronic searches (n = 28) and in an
additional five RCTs that were taken from systematic reviews that were discarded from this review because
the remaining studies had all been included in one of the 15 more comprehensive reviews, making a total
of 33 assessments.
Three RCTs were rated as being at a high risk of bias. Of these, two were open-label studies of
pharmacological interventions54,55 and one had high attrition, which differed across treatment groups.56
Seven RCTs were rated as being at a low risk of bias.57–63
TABLE 1 Systematic reviews and RCTs identified by the search strategy
Target risk factor and type of
intervention
Systematic reviews (number of
RCTs included in each review)
Total number of additional RCTs
identified from electronic searches
Weight
Pharmacological 3 (32, 11, 4) 14
Behavioural 6 (13, 11, 10, 10, 9, 6) 9
Pharmacological or behavioural 1a (23) 0
Combined pharmacological and
behavioural
0 0
Smoking
Pharmacological 0 0
Behavioural 0 0
Combined pharmacological and
behavioural
3 (34, 9, 8) 0
Alcohol
Pharmacological 0 5
Behavioural 1 (32) 0
Combined pharmacological and
behavioural
0 0
Weight, or alcohol or smoking 1 (16) 0
Total 15 (228) 28
a Findings from this review are summarised in the relevant sections on pharmacological or behavioural interventions.
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Records excluded
(n = 453)
Records after
title & abstract screening
(n = 593)
(CSzG = 514, CCDAN = 79)S
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n
Total records identified
through database searching
(n = 11,026)
(CSzG = 3762, CCDAN = 7264)
Additional records identified
through other sources
(n = 0)
Full-text articles assessed for
eligibility
(n = 140) 
(CSzG = 102, CCDAN = 38)
Studies included in narrative
synthesis
(n = 28)
(CSzG = 21, CCDAN = 7)In
cl
u
d
ed
El
ig
ib
ili
ty
• No outcomes of interest, n = 30
• Included in a systematic review
   included in this review, n = 19
• Conference proceeding, n = 16
• Non-intervention study, n = 12
• Non-RCT, n = 8
• Study protocol, n = 6
• Non-SMI, n = 5
• No inferential statistics
   reported, n = 4
• Non-peer review, n = 4
• No relevant subgroup analysis
   presented, n = 3
• Dissertation, n = 2
• Review paper, n = 1
• Not in English language, n = 1
• No between-group analysis, n = 1
Records excluded
(n = 112)
FIGURE 2 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart of additional
individual RCTs. CCDAN, Cochrane Depression, Anxiety and Neurosis Group; CSzG, Cochrane Schizophrenia Group.
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The remaining 23 RCTs were rated as being at an unclear risk of bias. Although all studies reported using
randomisation, 20 of the 23 RCTs did not adequately describe methods of allocation concealment and
17 out of 23 did not describe how participants were randomised.
Systematic reviews and randomised controlled trials targeting weight
Pharmacological interventions targeting weight
Systematic reviews of pharmacological interventions targeting weight
Four systematic reviews were identified which assessed pharmacological interventions to prevent
antipsychotic-related weight gain in people with SMI.31,64,98,99 The most comprehensive review98
is summarised.
Maayan et al.98 included 32 studies (n = 1482 participants) of the effectiveness of 15 different medications
on weight gain for people prescribed olanzapine, clozapine, risperidone, quetiapine or mixed first- or
second-generation antipsychotics. Studies were conducted in the USA, Venezuela, Brazil, the UK, Finland,
Turkey, Israel, Iran, China and South Korea. These studies explored a range of outcomes including weight,
lipids and glucose.
Anthropometric outcomes
A pooled weight change of –1.99 kg (95% CI –2.77 to –1.20 kg) compared with placebo was reported
after a mean of 13 weeks. Although modest and heterogeneous, greatest weight loss was reported for
metformin (7 RCTs, n = 334, –2.94 kg, 95% CI –4.89 to –0.99 kg), followed by d-fenfluramine (1 RCT,
n = 16, –2.60 kg, 95% CI –5.14 to –0.06 kg), sibutramine (2 RCTs, n = 55, –2.56 kg, 95% CI –3.91 to
–1.22 kg) and topiramate (2 RCTs, n = 133, –2.52 kg, 95% CI –4.87 to –0.16 kg).
Metabolic outcomes
Compared with placebo, triglyceride levels decreased significantly more with metformin augmented with
sibutramine (1 RCT, n = 28; weighted mean difference (WMD) –36.8 mg per 100 ml, 95% CI –63.94
to –9.66 mg per 100 ml; p = 0.008); metformin alone (2 RCTs, n = 109; WMD –28.07 mg per 100 ml,
95% CI –53.22 to –2.92 mg per 100 ml; p = 0.04) and fluvoxamine (1 RCT, n = 68, WMD –22.70 mg
per 100 ml, 95% CI –44.59 to –0.81 mg per 100 ml; p = 0.04). Compared with placebo, LDL cholesterol
end-point values were significantly lower only with sibutramine (1 RCT, n = 37, WMD –33.80 mg per
100 ml, 95% CI –60.41 to –7.19 ml; p = 0.01).
No significant effects on glucose levels were identified in placebo-controlled RCTs of metformin, sibutramine,
metformin augmented with sibutramine, or rosiglitazone (Avandia®; GlaxoSmithKline plc, GSK House,
Middlesex, UK).
Additional individual randomised controlled trials of pharmacological interventions
targeting weight
A further 14 RCTs of pharmacological interventions to promote weight loss or prevent antipsychotic-related
weight gain were identified by searching electronic databases.56–60,65–73 Five of these studies were trials of
topiramate, two were of zonisamide and the others evaluated seven other pharmacological interventions.
Findings from these studies, plus an additional study by Afshar et al.,61 included in a different systematic
review64 are summarised below and in more detail (along with effect sizes where available) in Table 2.
Anthropometric outcomes in additional randomised controlled trials (two randomised
controlled trials, n = 55, –2.56 kg, 95% CI –3.91 to –1.22 kg)
Three out of the five RCTs of topiramate reported a significant beneficial effect on BMI and/or weight
loss.57,67,70 Two studies reported no significant effects of topiramate on weight loss or BMI,56,61 one of
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TABLE 2 Summary of findings from additional individual RCTs of pharmacological interventions targeting weight
Author and year
of publication Country
Number of
participants
(diagnosis),
follow-up
Intervention
and comparator
(duration) Setting Risk of bias Weight/BMI Lipids Glucose Blood pressure
a,bAfshar et al.
(2009)61
Iran 32 (schizophrenia),
8 weeks
Topiramate vs.
placebo (8 weeks)
Secondary care
outpatients
Low No significant between-group
differences for BMIc
N/A No significant
between-group
differences (specific
type of glucose
measure not reported)c
No significant between-
group differences (specific
type of blood pressure
measure not reported)c
Roy Chengappa
et al. (2006)57
USA 287 (bipolar
disorder), 12 weeks
Topiramate vs.
placebo (12 weeks)
Secondary care
outpatients
Low BMI change:c intervention:
–0.8 kg/m2 (SD 1.2 kg/m2);
control: 0.1 kg/m2 (SD 1.0 kg/m2)
(p<0.001)
N/A N/A N/A
Weight change:c intervention:
–2.5 kg (SD 3.4 kg); control:
0.2 kg (SD 3.0 kg) (p< 0.001)
Roy Chengappa
et al. (2007)67
USA 48 (schizoaffective
disorder), 8 weeks
Topiramate vs.
placebo (8 weeks)
Secondary care
outpatients
Unclear BMI change:c intervention:
–0.5 kg/m2 (SD 1.3 kg/m2);
control: 1.0 kg/m2 (SD 2.2 kg/m2)
[F(143)=6.5, p<0.02]
N/A N/A N/A
Weight change:c intervention:
–3.3 lb (SD 8.5 lb); control:
6.6 lb (SD 14.2 lb) [F(1,43)=6.5,
p<0.02]
Narula et al.
(2010)70
India 67 (schizophrenia),
12 weeks
Topiramate vs.
placebo (12 weeks)
Secondary care
outpatients
Unclear BMI (baseline; 12 weeks):b
intervention: 20.6 kg/m2
(SD 3.9 kg/m2) – 20.1 kg/m2
(SD 4.0 kg/m2); control:
20.2 kg/m2 (SD 3.9 kg/m2)
– 22.6 kg/m2 (SD 4.1 kg/m2)
(t= 2.4; p= 0.017)
Total cholesterol (baseline;
12 weeks):c intervention:
135 mg% (SD 30mg%)
–133mg% (SD 31mg%);
control: 133mg%
(SD 31mg%) –156
(SD 6mg%) (t= 2.7;
p= 0.008)
Fasting blood glucose
(baseline; 12 weeks):c
intervention: 79.8mg%
(SD 9.4mg%) –78.2
mg% (SD 6.7mg%)
control: 77.8mg% (SD
7.4mg%) –88.5mg%
(SD 12.0mg%) (t=4.3;
p<0.001)
Systolic blood pressure
(baseline; 12 weeks):c
intervention: 118.8mmHg
(SD 7.8mmHg) –117.9mmHg
(SD 7mmHg); control:
119.9mmHg (SD 7.1mmHg)
–122.5mmHg (SD 7.7
mmHg) (t=2.6; p=0.012)
Weight (baseline; 12 weeks):b
intervention: 54 kg (SD 12.9 kg)
52.73 kg (SD 12.9 kg); control:
52.8 kg (SD 12.6 kg) 58.9 kg
(SD 13.1 kg) (t=1.9; p=0.05)
Diastolic blood pressure
(baseline; 12 weeks):c
intervention: 78.6mmHg
(SD 5.7) –77.9mmHg
(SD 4.8mmHg); control:
80.2mmHg (SD 6.3mmHg)
–81.4mmHg (SD 6.2mmHg)
(t= 2.5; p= 0.014)
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TABLE 2 Summary of findings from additional individual RCTs of pharmacological interventions targeting weight (continued )
Author and year
of publication Country
Number of
participants
(diagnosis),
follow-up
Intervention
and comparator
(duration) Setting Risk of bias Weight/BMI Lipids Glucose Blood pressure
McElroy et al.
(2007)56
USA 46 (bipolar disorder
or schizoaffective
disorder with a
BMI of ≥ 30 kg/m2
or ≥ 27 kg/m2 with
concomitant
obesity-related risk
factors), 24 weeks
Topiramate vs.
sibutramine
(24 weeks)
Secondary care
outpatients
High (high
attrition
differing
across
treatment
groups)
No significant between-group
differences for BMIc or weight
lossb
N/A N/A N/A
Ball et al. (2011)65 USA 37 (schizophrenia
or schizoaffective
disorder with
weight gain ≥ 7%
since starting
antipsychotic
medication),
24 weeks
Atomoxetine+weight
management, group
counselling and
physical activity vs.
weight management,
group counselling
and physical activity
(24 weeks)
Tertiary care
outpatients
Unclear No significant between-group
differences for weight or BMIb
No significant between-
group differences
for HDL, LDL, triglycerides,
very-low-density
lipoproteinb
No significant
between-group
differences for fasting
glucosec
No significant between-
group differences for systolic
or diastolic blood pressurec
Borba et al.
(2011)66
USA 20 (schizophrenia
or schizoaffective
disorder with a BMI
of ≥ 30 kg/m2 or
≥ 27 kg/m2 with
evidence of insulin
resistance or any
component of
metabolic
syndrome),
8 weeks
Ramelteon vs.
placebo (8 weeks)
Secondary care
outpatients
Unclear No significant between-group
differences for waist
circumferenceb
Total cholesterol (baseline;
8 weeks):c intervention:
205mg/dl (SD 39mg/dl)
–195mg/dl (SD 42mg/dl);
control: 171mg/dl
(SD 37mg/dl) –175mg/dl
(SD 36mg/dl) [F(1,18)
= 5.26; p= 0.03]
No significant
between-group
differences for fasting
glucosec
N/A
Cholesterol-to-HDL ratio
(baseline; 8 weeks):
intervention: 5.1mg/dl
(SD 1.4mg/dl) –4.9mg/dl
(SD 1.3mg/dl); control:
4mg/dl (SD 1mg/dl)
–4.6mg/dl (SD 1.4mg/dl)
[F(1,17)= 7.57; p= 0.01]
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Author and year
of publication Country
Number of
participants
(diagnosis),
follow-up
Intervention
and comparator
(duration) Setting Risk of bias Weight/BMI Lipids Glucose Blood pressure
Henderson et al.
(2011)69
USA 35 (schizophrenia
or schizoaffective
disorder), 8 weeks
Modafinil vs.
placebo (8 weeks)
Secondary care
outpatients
Unclear No significant between-group
differences for BMI or weightb
No significant between-
group differences for
levels of total cholesterol,
HDL, non-HDL and
triglyceridesc
No significant
between-group
differences for fasting
glucosec
No significant between-
group differences for systolic
or diastolic blood pressurec
McElroy et al.
(2012)58
USA 42 (psychotic or
bipolar disorder
with a BMI of
≥ 22 kg/m2),
16 weeks
Zonisamide vs.
placebo (16 weeks)
Secondary care
outpatients
Low Weight change:c intervention:
0.9 kg (SD 3.3 kg0; control:
5.0 kg (SD 5.5 kg) (mean
difference –4.4 kg (95% CI
–1.5 to –7.4; p= 0.01)
N/A No significant
between-group
differences for fasting
glucosea
No significant between-
group differences for systolic
or diastolic blood pressurea
Ghanizadeh et al.
(2013)59
Iran 41 (schizophrenia),
10 weeks
Zonisamide vs.
placebo (10 weeks)
Outpatient
and inpatient
Low BMI change:c intervention:
–0.3 kg/m2 (SD 0.4 kg/m2);
control: 2.2 kg/m2
(SD 6.9 kg/m2) (p= 0.0001)
N/A N/A N/A
Weight change:c intervention:
–1.1 kg (SD 1.4 kg); control:
1.4 kg (SD 2.2 kg) (mean
difference –4.4 kg
(p= 0.0001)
Elmslie et al.
(2006)68
New
Zealand
n= 60 (bipolar
disorder with a BMI
of > 25 kg/m2),
26 weeks
L-carnitine
supplement+
dietary counselling
sessions vs.
placebo+ dietary
counselling sessions
(26 weeks)
Outpatients Unclear No significant between-group
differences for weight
change,c BMIa or waist
circumference
N/A N/A N/A
Ranjbar et al.
(2013)60
Iran n= 52
(schizophrenia,
schizoaffective and
schizophreniform
disorders),
16 weeks
Ranitidine vs.
placebo (16 weeks)
Inpatients Low No significant between-group
differences for BMI changea
N/A N/A N/A
Poyurovsky et al.
(2013)72
Israel n= 43
(schizophrenia),
6 weeks
Reboxetine+
betahistine vs.
placebo (16 weeks)
Inpatients Unclear BMI change:c intervention:
0.7 kg/m2 (SD 0.8 kg/m2);
control: 1.5 kg/m2
(SD 1 kg/m2) (t= 2.92,
df= 41, p= 0.008)
N/A N/A N/A
Weight change:c intervention:
2 kg (SD 2.4 kg); control:
4.8 kg (SD 3.2 kg) (t= 2.89,
df= 41, p= 0.006)
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TABLE 2 Summary of findings from additional individual RCTs of pharmacological interventions targeting weight (continued )
Author and year
of publication Country
Number of
participants
(diagnosis),
follow-up
Intervention
and comparator
(duration) Setting Risk of bias Weight/BMI Lipids Glucose Blood pressure
Jarskog et al.
(2013)71
USA n= 148
(schizophrenia and
schizoaffective
disorder), 16 weeks
Metformin +weekly
diet and physical
activity intervention
vs. weekly diet and
physical activity
intervention
(16 weeks)
Outpatients Unclear BMI change:a intervention:
–1 kg/m2 (95% CI –1.3 to
–0.7); control: –0.3 (95% CI
–0.7 to 0) (t= –2.27;
p= 0.006)
Triglycerides change:a
intervention: –7.0mg/dl
(95% CI –20.4 to
6.3mg/dl); control:
13.2mg/dl (95% CI
–0.3 to 26.7mg/dl)
(t= –2.11; p= 0.037)
No significant
between-group
differences for fasting
glucosea
N/A
Weight change:c intervention:
–3 kg (95% CI –2 to –4 kg);
control: –1 kg (95% CI –2 to
0 kg) (t= –2.61; p= 0.007)
No significant between-
group differences for
levels of total cholesterol,
HDL, non-HDL and LDLa
Smith et al.
(2013)73
USA n= 44
(schizophrenia and
schizoaffective
disorder), 12 weeks
Pioglitazone+
manualised
diet–exercise
intervention vs.
placebo +
diet–exercise
intervention
(12 weeks)
Not reported Unclear No significant between-group
differences for weight and
BMI changea
Total cholesterol change:c
intervention: 2.3mg/dl
(SD 7.6mg/dl); control:
2mg/dl (SD 8mg/dl)
(F= 2.9; p= 0.048)
Fasting blood glucose
change:c intervention:
0.02mg/dl
(SD 8.1mg/dl);
control: 24.2mg/dl
(SD 8.6mg/dl)
(FL= 3.88; p= 0.016)
N/A
HDL change:c
intervention: 4.6 SD
1.8mg/dl; control: –2.6
SD 2.1mg/dl (F= 6.50,
p= 0.001)
N/A, not applicable; SD, standard deviation.
a Secondary outcome.
b Identified in Ellinger et al.64
c Primary outcome.
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which was in comparison to sibutramine.56 Significant effects on BMI and/or weight and/or waist
circumference were reported in two RCTs of zonisamide,58,59 one RCT of reboxetine plus betashistine72
and a RCT comparing metformin plus weekly diet and physical activity intervention with a weekly diet and
physical activity intervention alone.71 No significant effects on BMI or weight were reported in RCTs of
ramelteon,66 modafinil,69 atomoxetine,65 the supplement L-carnitine,68 ranitidine60 or pioglitazone.73
Metabolic outcomes
Only one of the five RCTs of topiramate examined the effect on lipids and reported a significant effect on
preventing an increase in the level of total cholesterol compared with placebo.70 A single, small (n = 20) RCT
of ramelteon reported a significant effect on reducing levels of cholesterol and reducing the cholesterol-to-
HDL ratio.66 A RCT comparing metformin plus weekly diet and physical activity intervention with a weekly
diet and physical activity intervention alone reported a significant reduction in the level of triglycerides in the
metformin arm, but no effect on the levels of total, HDL, non-HDL and LDL cholesterol.71 A RCT comparing
pioglitazone plus a manualised diet–exercise intervention with placebo plus a manualised diet–exercise
intervention reported a significant effect on the levels of total and HDL cholesterol.73 Placebo-controlled RCTs
of modafinil and atomoxetine reported no significant effect on lipids.65,69
Out of the eight RCTs examining the effect of pharmacological interventions on glucose58,61,65,66,69–71,73
one RCT of topiramate and one RCT of pioglitazone reported significant effects in reducing glucose.70,73
Out of the five RCTs examining the effect of pharmacological interventions on blood pressure,58,61,65,69,70
only one RCT (of topiramate) reported a significant reduction in systolic and diastolic blood pressure.70
Synthesising systematic review and individual randomised controlled trial findings
The most comprehensive systematic review98 reported the greatest effects for metformin on weight loss
and blood lipids. Findings from more recently identified individual RCTs report varied effects for topiramate
on weight management and limited evidence regarding topiramate and ramelteon on blood lipids.
Behavioural interventions targeting weight
Systematic reviews of behavioural interventions targeting weight management
We identified six systematic reviews of physical activity and/or diet interventions.75–78,96,97 The systematic
review and meta-analysis by Bonfioli et al.96 provided the most comprehensive review of the literature
and this is summarised here. Two RCTs identified in other reviews but not included in Bonfioli et al.96
are summarised together with additional individual trials identified by our search.
Bonfioli et al.96 reviewed 13 RCTs of behavioural interventions to prevent weight gain or promote weight
loss. Studies were conducted in the USA (n = 4), Italy (n = 2), the UK (n = 1), Spain (n = 1), Sweden (n = 1),
Switzerland (n = 1), Korea (n = 1), China (n = 1) and Australia (n = 1).
Interventions were delivered to both individuals (n = 4) and groups (n= 9) and included different combinations
of dietary advice and diet programmes, physical activity, self-monitoring techniques (e.g. keeping diaries), goals
and planning techniques (e.g. setting and reviewing goals) as well as general behavioural support approaches,
such as motivational interviewing.
The meta-analysis reported an effect on BMI reduction favouring intervention groups compared with
control (–0.98 kg/m2, 95% CI –1.31 to –0.65 kg/m2).
Subgroup analyses revealed that interventions delivered to individuals (–1.20 kg/m2, 95% CI –1.57 to
–0.83 kg/m2), targeting weight gain prevention (–1.09 kg/m2, 95% CI –1.51 to –0.68 kg/m2) that include
dietary (–1.31 kg/m2, 95% CI –1.78 to –0.83 kg/m2) or physical activity (–1.22 kg/m2, 95% CI –1.59 to
–0.85 kg/m2) components had the greatest effect in reducing BMI.
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Additional individual randomised controlled trials of behavioural interventions
targeting weight
We identified a further nine RCTs of behavioural interventions to promote weight loss or prevent
antipsychotic-related weight gain through searching electronic databases62,79–86 and an additional two RCTs
in other reviews (Scocco et al.87 in Álvarez-Jiménez et al.78 and Jean-Baptiste et al.88 in Cabassa et al.75).
Findings are summarised in more detail in Table 3, apart from four RCTs, which had < 10 participants in
each trial arm and are summarised separately.78–80,88
Anthropometric outcomes
One RCT of a diet and physical activity intervention with behavioural support that also encouraged patients
to use a pedometer reported small but significant effects on reducing baseline measures in the intervention
group of BMI (–0.32 kg/m2), weight (0.8 kg) and waist circumference (3.38 cm).83 A RCT of a diet, physical
activity and behavioural support intervention also reported a significant reduction on waist circumference.79
One trial reporting significant effects on weight and BMI immediately after the intervention period reported
no effect at 12 months.62
Three RCTs, one of a group diet and physical activity intervention, one providing free fruit and vegetables
to participants for 6 months, and one of a nutrition, physical activity and contingency management
intervention [two arms: (1) payment for weight loss and (2) payment for attendance] reported no effect on
weight or BMI.82,84,86
Metabolic outcomes
Two RCTs, one of a nutrition, physical activity and behavioural support intervention, and one of nutrition,
physical activity and contingency management, both reported no effect on the levels of triglycerides or
total cholesterol.79,86
Three RCTs examined the effect of behavioural interventions on glucose: two reported no effect,82,86
and one reported a significant reduction in the intervention arm.62
One RCT examining the effects of interventions on blood pressure reported no effect.79
Randomised controlled trial with < 10 participants in trial arms
One RCT reported significant effects on weight. This involved an intensive, 16-week intervention of diet
(including cooking demonstration, visits to supermarkets) physical activity (participants were given a
pedometer) and behavioural support resulting in a –6.4 lb (–2.9 kg) weight change in the intervention
group;88 however, only eight participants were included in the intervention arm.
Two RCTs reported no effect on BMI, weight or waist circumference80,81 and one of these RCTs did not
have an effect on systolic blood pressure.81 One was an educational programme providing information and
counselling on exercise and nutrition80 and the other was a 12-week exercise programme.81 A third RCT
focusing on diet alone did not find an effect on weight gain.87
Combined pharmacological and behavioural interventions targeting weight
No systematic reviews of combined pharmacological and behavioural interventions targeting weight
were identified.
Additional individual randomised controlled trials of combined pharmacological and
behavioural interventions targeting weight
We did not identify any RCTs of combined pharmacological and behavioural interventions to promote weight
loss or prevent antipsychotic-related weight gain through searching electronic databases, but we did identify
one RCT,63 in a review focusing on behavioural interventions.77 This study compared metformin and a diet
and physical activity intervention alone, in combination and with placebo and reported that diet and physical
activity plus metformin were significantly superior to metformin or diet and physical activity alone in reducing
fasting BMI, weight and fasting glucose.
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TABLE 3 Summary of findings from additional individual RCTs of behavioural or combined pharmacological and behavioural interventions targeting weight
Author and year
of publication Country
Number of participants
(diagnosis), follow-up
Intervention and
comparator Setting Risk of bias Weight/BMI Lipids Glucose Blood pressure
Behavioural interventions
Álvarez-Jiménez
et al. (2010)62
Spain n= 61 (schizophrenia,
schizoaffective disorder,
schizophreniform disorder,
delusional disorder, brief
reactive psychosis, or
psychosis not otherwise
specified), 52 weeks
10–14 individual, face-to-face
sessions delivered over
12 weeks by a clinical
psychologist. Sessions
included psychoeducation,
dietary counselling, physical
activity, and behaviour
therapy vs. usual
care+ advice on weight
monitoring strategies
and general dietary
recommendations
Outpatients
(assumed
secondary care)
Low risk No significant group differences
in weighta or BMIa at 52-week
follow-up
N/A N/A N/A
Cordes et al.
(2011)79
Germany n= 100, (schizophrenia or
schizoaffective disorder
and had gained 1.5 kg
since starting
antipsychotic medication),
48 weeks
12, 90-minute group sessions
delivered over 6 weeks by a
dietitian. Sessions covered
nutrition, physical activity and
behavioural support vs. usual
care
Secondary care
inpatients
Unclear Waist circumference change:b
intervention: 4.6 cm (SD 8.3 cm);
control: 10.1 cm (SD 7.3 cm)
F(8,19.073)= 3.144; p= 0.019)
No significant
between-group
differences for the
levels of total
cholesterol or
triglyceridesb
Fasting glucose change:
intervention: 86.4mg/dl
(SD 21.4mg/dl);
control= 110.9mg/dl
(SD 32.4mg/dl) (t(23)=
2.159; p= 0.042)
No significant
group differences
for blood
pressureb
No significant group differences
in body weight at 24 weeksa
Significant group × time
effects for fasting
glucose: (F(2,26.3)
= 3.97; p= 0.03)
Methapatara and
Srisurapanont
(2011)83
Thailand n= 64 (schizophrenia, BMI
of ≥ 23 kg/m2), 12 weeks
Five, 60-minute group
sessions delivered over
1 week by study researcher.
Sessions included
motivational interviewing,
education on nutrition and
physical activity, information
and practice using a
pedometer+ booster session
at 4 weeks healthy lifestyle
leaflet vs. healthy lifestyle
leaflet
Tertiary care
(intervention
delivered to
inpatients prior
to discharge)
Unclear Weight change:a intervention:
–0.8 kg (SD 3.6 kg); control:
1.4 kg (SD 4.1 kg) (95% CI 4.12
to 0.29, t= –2.30; p= 0.03)
N/A N/A N/A
BMI change: intervention:
–0.3 kg/m2 (SD 1.3 kg/m2);
control: 0.5 kg/m2 (SD 1.6 kg/m2)
(95% CI 1.5 to 0.6, t= –2.2;
p= 0.03)
Waist circumference change:
intervention: –3.4 cm
(SD 4.4 cm); control: 0.9 cm
(SD 5.2 cm) (t= –3.53; p< 0.01)
McCreadie et al.
(2005)82
UK n= 100 (schizophrenia),
78 weeks
Free fruit and vegetables
for 6 months with diet
instructions vs. without
instructions vs. usual care
Community Unclear No significant group differences
for BMIb
N/A No significant group
differences for glucoseb
N/A
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TABLE 3 Summary of findings from additional individual RCTs of behavioural or combined pharmacological and behavioural interventions targeting weight (continued )
Author and year
of publication Country
Number of participants
(diagnosis), follow-up
Intervention and
comparator Setting Risk of bias Weight/BMI Lipids Glucose Blood pressure
Usher et al.
(2013)84
Australia n= 101 (schizophrenia,
bipolar disorder),
12 weeks
12 group sessions, once per
week delivered by a nurse;
sessions included education
and discussion on the healthy
lifestyle topic of the week
(e.g. five food groups),
participants’ progress
implementing components of
the programme into their
everyday life. This session was
followed by a 30-minute
exercise activity vs. healthy
lifestyle booklet
Primary care Unclear No significant group differences
for weighta or BMIa
N/A N/A N/A
Daumit et al.
(2013)85
USA n= 291 (schizophrenia,
bipolar disorder),
18 months
12 group sessions, once per
week delivered by a nurse;
sessions included education
and discussion on the healthy
lifestyle topic of the week
(e.g. five food groups),
participants’ progress
implementing components of
the programme into their
everyday life. This session was
followed by a 30-minute
exercise activity vs. healthy
lifestyle booklet
Primary care Unclear BMI change:a intervention:
–1.2 kg/m2 (95% CI –1.7 to
–0.8 kg/m2); control: –0.1 kg/m2
(95% CI –0.6 to 0.4 kg/m2)
[mean between-group change
–1.1 kg/m2 (95% CI –1.8 to
–0.5 kg/m2; p= 0.001)]
No significant
group differences
for lipidsb
No significant group
differences for glucoseb
No significant
group differences
for diastolic or
systolic blood
pressureb
Weight change:a intervention:
–3.4 kg (95% CI –4.7 to –2.1 kg);
control: –0.2 kg (95% CI –1.7 to
1.3 kg) [mean between-group
change –3.2 kg (95% CI –5.1 to
–1.2 kg; p= 0.002)]
Ratliff et al.
(2012)86
USA n= 30 (schizophrenia,
schizoaffective disorder),
8 weeks
8 individual sessions, once
per week of a standardised
lifestyle programme (SIMPLE
programme) supporting
participants to choose
healthy food and identify
opportunities for physical
activity (e.g. taking stairs
instead of the lift) plus
payment for attendance vs.
SIMPLE programme plus
payment for weight loss vs.
control
Community
mental health
centre
Unclear No significant group differences
for weighta or BMIa
No significant
group differences
for lipidsb
No significant group
differences for glucoseb
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Author and year
of publication Country
Number of participants
(diagnosis), follow-up
Intervention and
comparator Setting Risk of bias Weight/BMI Lipids Glucose Blood pressure
Combined pharmacological and behavioural interventions
Wu et al.,
(2008)63
China n= 128 (schizophrenia),
12 weeks
12-week diet and physical
activity intervention (daily in
week 1, weekly in weeks 2–12)
delivered by dietitian and
exercise psychologist+
metformin alone or in
combination vs. placebo
Secondary care
inpatients
Low risk Significant differences in BMI
change between groups
(diet and physical activity plus
metformin significantly superior to
either alone or placebo in reducing
BMI): diet and physical activity
plus metformin= –1.8 kg/m2
(95% CI –2.3 to –1.3 kg/m2);
metformin= –1.2k g/m2 (95% CI
–0.9 to –1.5 kg/m2); diet and
physical activity= –0.5 kg/m2
(95% CI –0.8 to –0.3 kg/m2);
placebo=1.2 kg/m2 (95% CI
0.9 to 1.5 kg/m2)
N/A Significant differences in
fasting glucose change
between groups (diet
and physical activity plus
metformin significantly
superior to either alone or
placebo in reducing
fasting glucose): diet and
physical activity plus
metformin= –7.2mg/dl
(95% CI –10.8 to
–5.4mg/dl); metformin
= –10.8mg/dl (95% CI
–16.2 to –7.2mg/dl);
diet and physical activity
= –7.2mg/dl (95% CI
–9.0 to –3.6mg/dl);
placebo=1.8mg/dl
(95% CI –1.8 to
3.6mg/dl)
N/A
Significant differences in weight
change between groups (diet and
physical activity plus metformin
significantly superior to either
alone or placebo in reducing
weight): diet and physical activity
plus metformin= –4.7 kg (95% CI
–5.7 to –3.4 kg); metformin=
–3.2 kg (95% CI –3.9 to –2.5 kg);
diet and physical activity= –1.4 kg
(95% CI –2.0 to –0.7 kg);
placebo=3.1 kg (95% CI 2.4 to
3.8 kg)
N/A, not applicable; SIMPLE, simplified intervention to modify physical activity, lifestyle and eating behaviour; SD, standard deviation.
a Primary outcome.
b Secondary outcome.
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Systematic reviews and randomised controlled trials targeting smoking
We identified three systematic reviews of pharmacological, behavioural or combined interventions to
promote smoking cessation or reduction in smoking.52,89,95
Tsoi et al.95 was the most comprehensive review. There was one additional trial included in a different
review which is described later alongside other additional trials we identified.91 Tsoi et al.95 reviewed
34 RCTs of pharmacological and/or behavioural interventions to promote smoking cessation, smoking
reduction or relapse prevention (16 smoking cessation RCTs; nine smoking reduction RCTs; one relapse
prevention RCT and eight RCTs reporting smoking outcomes in interventions aimed at other purposes).
The majority of RCTs (28/34) were conducted in the USA.
Pharmacological interventions targeting smoking
Systematic reviews of pharmacological interventions targeting smoking
Seventeen trials of pharmacological interventions were included in the Tsoi et al.95 review, a meta-analysis
of seven placebo-controlled RCTs of bupropion showed that smoking cessation rates were significantly
higher in treatment groups at the end of treatment [N = 7, n = 340; risk ratio (RR) 3.03, 95% CI 1.69 to
5.42] and a further meta-analysis of five RCTs confirmed this at 6 months (N = 5, n = 214, RR 2.78,
95% CI 1.02 to 7.58).
A meta-analysis of two trials comparing varenicline with placebo reported significantly higher smoking
cessation rates in treatment groups at the end of treatment (N = 2, n = 137, RR 4.74, 95% CI 1.34
to 16.71).
Additional individual randomised controlled trials of pharmacological interventions
targeting smoking
We identified one RCT in a systematic review of pharmacological and/or behavioural interventions.89
The RCT compared nicotine replacement therapy (NRT) with usual care and reported significant effects on
point prevalence abstinence, carbon monoxide (CO) levels and cigarettes smoked per day.90 Findings are
summarised in more detail in Table 4.
TABLE 4 Summary of findings from additional individual RCTs of pharmacological interventions targeting smoking
Reference Country
Number of participants
(diagnosis), duration
(weeks)
Intervention
and comparator
(duration) Setting
Risk of
bias
Smoking
abstinence
Number of cigarettes
per day/cotinine/CO
levels
Pharmacological interventions
aChou et al.
(2004)90
Taiwan n= 68 (schizophrenia),
12 weeks
NRT vs. TAU
(8 weeks)
Secondary care
outpatients
Unclear Point prevalenceb
(3 months):
NRT= 23%,
TAU= 0%
Cigarettes per day:b
significant difference
between groups
(z= –5:8, p< 0.0001)
CO levels:b significant
difference between
groups (z= –8.8,
p< 0.0001)
a Identified in Ferron et al.89
b Primary outcome.
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Behavioural interventions targeting smoking
Systematic reviews of behavioural interventions targeting smoking
Five trials of behavioural interventions were included in Tsoi et al.’s95 review. One trial compared a standard
smoking cessation programme (American Lung Association programme) with a specialised group therapy
intervention for people with schizophrenia and reported significantly higher abstinence rates 6 months
post treatment in the standard programme (17.6% vs. 10.7%, p < 0.03). One trial compared a hospital
staff-delivered group intervention with one lecture on the dangers of smoking and reported a significant
reduction in cigarettes per day at 3 months [F(1,51) = 9.2; p < 0.05]. Other trials compared a single
session of motivational interviewing vs. didactic psychoeducation vs. minimal intervention, active repetitive
transcranial magnetic stimulation vs. sham repetitive transcranial magnetic stimulation, and high-intensity
behaviour support plus NRT vs. low intensity monitoring and information plus NRT. All reported no
significant increase in abstinence or reduction in cigarette use or expired CO levels.
Additional individual randomised controlled trials of behavioural interventions
targeting smoking
No further RCTs were identified.
Combined pharmacological and behavioural interventions targeting smoking
Systematic reviews of combined pharmacological and behavioural interventions
targeting smoking
Three trials of combined pharmacological and behavioural interventions were included in Tsoi et al.95 A
contingent reinforcement intervention plus a nicotine patch was significantly better than both contingent
reinforcement alone and minimal intervention in promoting smoking cessation at 9 months (50% vs. 28%
vs. 10%).
Individual motivational interviewing plus cognitive-behavioural therapy (CBT) plus a nicotine patch was not
effective in promoting smoking cessation compared with usual care but did have a significant effect on
reducing cigarette consumption by 50% at 3 months (intervention vs. control, 42.5% vs. 15.7%; odds
ratio 3.96, 99% CI 1.53 to 10.23; p < 0.001).
A four-arm RCT comparing financial incentives with no incentive and bupropion with placebo reported
significantly reduced biomarkers for cigarette smoking [cotinine levels, F(3,144) = 6.40; p < 0.001)] and
carbon monoxide levels [F(3,144) = 5.02; p < 0.01] in the financial incentive groups, but no added value
of bupropion.
Additional individual randomised controlled trials of combined pharmacological and
behavioural interventions targeting smoking
No further RCTs were identified.
Systematic reviews and randomised controlled trials targeting alcohol
Pharmacological interventions targeting alcohol
Systematic reviews of pharmacological interventions targeting alcohol
No systematic reviews of pharmacological interventions targeting alcohol were identified.
Additional individual randomised controlled trials of pharmacological interventions
targeting alcohol
We identified five RCTs of pharmacological interventions to reduce alcohol misuse in people with
SMI54,55,81,92,93 (Table 5). Two compared naltrexone plus behavioural support with behavioural support alone.
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TABLE 5 Summary of findings from additional individual RCTs of pharmacological and behavioural interventions targeting alcohol
Author and date
of publication Country
Number of participants
(diagnosis), follow-up
(weeks)
Intervention and
comparator (duration) Setting Risk of bias Frequency of alcohol use Quantity of alcohol use
Pharmacological interventions
Petrakis et al.
(2004)91
USA n= 31 (schizophrenia or
schizoaffective disorder
and alcohol dependence),
12 weeks
Naltrexone + behavioural
support (12 × weekly
cognitive behavioural
relapse prevention
support encouraging
abstinence) vs.
placebo + behavioural
support
Secondary care
outpatients
Unclear Drinking days:a
l Naltrexone: 6.2 (SD 8.0) days
l Placebo: 13.5 (SD 15.6) days
[F(1,248)= 13.4; p< 0.0001]
Heavy drinking days:
l Naltrexone: 0.37 (SD 1.1) days
l Placebo: 0.81 (SD 1.4) days
[F(1,248)= 9.32; p= 0.003]
Number of drinks during
treatment:a
l Naltrexone: 56.7
(SD 84.3) days
l Placebo: 83.1
(SD 98.1) days
(No inferential statistics
reported)
Petrakis et al.
(2006)55
USA n= 66 (schizophrenia or
bipolar disorder and
alcohol dependence),
12 weeks
Naltrexone + disulfiram
vs. naltrexone vs.
disulfiram vs. placebo
(12 weeks)
Secondary care
outpatient
High risk
(all conditions
double blind
apart from one
open label due
to the side
effects of
disulfiram)
Total days abstinent:a
l Naltrexone + disulfiram: 77.4
(SD 12.8) days
l Naltrexone: 80.4 (SD 7.0) days
l Disulfiram: 78.8 (SD 8.6) days
l Placebo: 68.4 (SD 18.8) days
(Medication vs. placebo: t = 2.8;
p = 0.01)
Heavy drinking daysa:
l Naltrexone + disulfiram = 6.06
(SD 11.5) days
l Naltrexone = 2.75 (SD 5.7) days
l Disulfiram = 4.16 (SD 10.8) days
l Placebo= 11.57 (SD 15.6) days
(Medication vs. placebo: t = 2.31;
p = 0.02)
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Author and date
of publication Country
Number of participants
(diagnosis), follow-up
(weeks)
Intervention and
comparator (duration) Setting Risk of bias Frequency of alcohol use Quantity of alcohol use
No significant differences between
medications for either outcome
Brown et al.
(2009)92
USA n= 50 (bipolar disorder
and alcohol dependence),
12 weeks
Naltrexone (12 weeks)+
CBT for bipolar disorder
and substance use
(16 sessions delivered
by CBT therapist) vs.
placebo + CBT
Outpatients
(assumed
mixture of
primary and
secondary
care)
Unclear No significant differences between
groups for drinking daysa
No significant differences
between groups for drinks
per daya
Ralevski et al.
(2011)93
USA n= 34 [schizophrenia
(n= 9), schizoaffective
disorder (n = 10),
non-specified psychosis
(n= 4), cocaine and/or
cannabis dependence
(n= 11)], 12 weeks
Acamprosate vs. placebo
(12 weeks)
Secondary care
outpatients
Unclear No significant differences between
groups for drinking daysa or heavy
drinking daysa
No significant differences
between groups for number
of drinks per drinking daya
Tolliver et al.
(2009)54
USA n= 9 (bipolar disorder
and alcohol dependence),
8 weeks
Acamprosate vs. usual
care (8 weeks)
Secondary care
outpatients
High (open label
RCT)
No significant group × time effect
on drinking days per weeka
Drinks per week:a
l Acamprosate:
baseline = 13.9 (SD 17.2);
8 weeks = 5.5 (SD 4.1)
l Usual care: baseline=
17.8 (SD 13.3);
8 weeks = 20.8 SD12.6
Significant group × time effect
[F(1,7) = 11.55; p < 0.02]
No significant time × group
effect on drinks per day
SD, standard deviation.
a Primary outcome.
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They reported contrasting findings: one reported a significant effect on drinking days (number of days on
which participants drank) and number of drinks,91 and one reported no effect on these outcomes.92 A
placebo-controlled RCT of naltrexone plus disulfiram alone or in combination reported a significant increase
on days abstinent and reduction in heavy drinking days (days on which five or more drinks consumed) when
compared with no drug.55 Two RCTs of acamprosate54,93 reported no effect on frequency of alcohol, and one
reported a significant reduction on number of drinks per week54 but included only nine participants.
Behavioural interventions targeting alcohol
Systematic reviews of behavioural interventions targeting alcohol
We identified one systematic review of RCTs of 32 behavioural interventions to reduce alcohol or other
substance misuse (n = 3165).94 Interventions included motivational interviewing and CBT alone and in
combination, integrated and non-integrated models of care and skills training. Studies were conducted
mostly in the USA (n = 19), six in Australia, three in the UK and one each from Denmark, Germany, Ireland
and Switzerland. There were no significant effects of any intervention on outcome measures of alcohol or
substance use apart from one motivational interviewing intervention on alcohol abstinence at 6 months
(n = 28, RR 0.36, 95% CI 0.2 to 0.8; number needed to treat = 2, 95% CI 2 to 5) though this study was
rated as ‘very low quality of evidence’.
Additional individual randomised controlled trials of behavioural interventions
targeting alcohol
No further RCTs were identified.
Combined pharmacological and behavioural interventions targeting alcohol
No systematic reviews or RCTs were identified.
Interpretation
Summary of main findings
We performed a comprehensive review of international evidence regarding interventions to reduce
cardiovascular risk in people with SMI. We included existing systematic reviews as well as more recent
RCTs. We found evidence for effective pharmacological and behavioural interventions to decrease weight
and smoking, but limited evidence on effective interventions to manage alcohol misuse. We did not find
RCT evidence regarding interventions directly targeting cholesterol levels, hypertension, diabetes mellitus or
CVD multiple risk factors.
Regarding pharmacological interventions for managing weight, metformin appeared to be most effective
over an average 13-week period, with a modest weight loss of nearly 3 kg on average.98 Evidence from
the 10 more recent individual trials focused mainly on topiramate, which was also shown to be similarly
effective in managing weight,57,67,70 although adverse effects may limit its tolerability.17 Incidentally, it also
prevented an increase in the level of cholesterol.70
For behavioural interventions for managing weight, those aimed at individuals (rather than groups), with
both dietary and physical activity components were most effective in reducing BMI.96 No trials were
identified that assessed the effectiveness of physical activity alone. The most effective interventions to
reduce BMI were those combining dietary, physical activity and behavioural support.63,83,85 although adverse
effects may limit its tolerability.17 There was some evidence of effectiveness of behavioural interventions on
metabolic outcomes with one of three RCTs reporting a significant effect on plasma glucose levels.62
The one trial of a combined pharmacological and behavioural (diet and physical activity) intervention
was significantly more effective in reducing BMI, weight and fasting glucose than the pharmacological or
behavioural components of the intervention alone.63
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Smoking
A meta-analysis demonstrated significant effects of bupropion on smoking abstinence and reduction.95
One trial of NRT reported significant effects on abstinence, number of cigarettes smoked and CO levels.90
One trial of a standardised smoking cessation programme included in a published review was significantly
more effective than a SMI-tailored intervention in promoting abstinence.95 Limited conclusions can be drawn
from the two RCTs of behavioural interventions identified in this review as their findings conflict: one
reported significant effects on reducing smoking; the other reported no significant effect on abstinence.95
One RCT comparing contingency management and bupropion alone or in combination reported a
significant effect of contingency management on CO levels but no additional effects of bupropion.95
Most of the trials of smoking cessation or reduction interventions included in the review and RCTs
identified by this review were conducted in secondary care. It may be that delivering these interventions
to patients in primary care who are likely to be more stable may result in a better response.
Alcohol
There was less evidence regarding alcohol in SMI. Two trials of acamprosate reported no significant effects
on frequency of alcohol use.54,93 Two RCTs compared naltrexone plus behavioural support with behavioural
support alone; one reported a significant effect in reducing quantity and frequency of use,91 while the other
reported no effect. One RCT reported no differentiation in the effectiveness of naltrexone over disulfiram.55
A published review of 32 interventions reported that only one intervention based on motivational
interviewing was effective in promoting abstinence but was rated as very low quality of evidence.94
Clinical implications
CVD risk could be reduced in people with SMI by delivering combined pharmacological and behavioural
interventions for both smoking and weight reduction. The exact content of interventions could be tailored
to the preference of the individual as a variety of elements have been shown to be effective, mostly for
individuals but also in groups.
There is little specific evidence regarding the effectiveness of interventions to reduce other CVD risk factors
commonly found in SMI, including dyslipidaemia, diabetes mellitus and hypertension; however, there is
evidence from the general population on what interventions might work to reduce and manage CVD risk.
Algorithms are also available to guide treatment recommendations for reducing CVD risk in the general
population in both Australia and the UK.38
Our research findings are in line with recent international guidelines in both England17 and Scotland127
regarding the management of physical health in people with psychosis or bipolar disorder. The lack of
evidence regarding managing lipids, diabetes mellitus and hypertension in SMI requires attention. We need
to know whether this disadvantaged group of people are accessing and receiving the best interventions to
prevent CVD, and then whether interventions, such as statins and antihypertensive drugs, are decreasing
excessive rates of CVD. This will require international research to determine whether or not these effective
interventions are actually being offered and accepted by people with SMI and ultimately to assess whether
or not the stubborn mortality gaps for people with SMI can be diminished in years to come.
Review limitations
It is not straightforward to synthesise all the evidence regarding CVD risk management in SMI. The
individual studies frequently have their own design problems and limitations, and evidence is extremely
heterogeneous in terms of interventions, settings, target groups and outcome measures. Factors limiting
interpretation of findings included small sample sizes, varying or undefined inclusion criteria, setting, short
length of follow-up and completeness of intervention description.
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Nine of the 23 RCTs not included in the systematic reviews of pharmacological or behavioural interventions
to manage weight were tested on SMI patients with a minimum BMI or minimum weight gain since
commencing antipsychotic medication (e.g. BMI of > 25 kg/m2 was one of the inclusion criteria).56–58,65–68,79,83
This limits the generalisability of findings to all SMI patients and highlights a reactive rather than proactive
approach to weight management in SMI.
Most of the trials identified by this review were conducted in secondary care limiting their generalisability
to other settings, such as primary care.
A further limitation is the length of time between intervention end and collection of follow-up data. As is
the nature of pharmacological interventions, follow-up data were collected at the end of the intervention
which was, on average, 13 weeks after baseline assessment (aside from one that collected data 4 weeks
after intervention end). Of the behavioural and combined pharmacological and behavioural interventions
the average length of time between intervention end and collection of follow-up data was 19 weeks.
This is a relatively short amount of time in the lifespan of people with SMI, so conclusions regarding longer
term effectiveness cannot be made.
There was a lack of detail used to describe behavioural interventions. This problem has been acknowledged
in the wider literature on interventions to change behaviour.128 Although guidance exists to promote
detailed reporting to allow replication;129 for some interventions, replication would not be possible based on
the descriptions in published reports we have reviewed.
Conclusion
Although we can be optimistic about the efficacy of interventions to address smoking and weight gain in
SMI, we also reveal a lack of evidence for managing a range of CVD risk factors including lipids, diabetes
mellitus and hypertension as well as a lack of evidence on managing multiple CVD risk factors. These are
the challenges for clinical researchers and service planners alike.
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Appendix 2 Fidelity assessment of the Primrose
intervention delivery
Introduction
In the Primrose cluster RCT, nurses/HCAs were trained to deliver an intervention consisting of simple
behaviour change strategies to help patients identify and make progress with goals to lower their level of
cholesterol and other CVD risk factors using clinically appropriate treatments and interventions. The results
of this trial have been outlined above. This report describes the degree to which the intervention manual
and training programme were adhered to, involving a fidelity assessment of audiotapes of the intervention
appointments returned by the nurses/HCAs who delivered the intervention.
Treatment fidelity refers to the extent to which a treatment or intervention is delivered as planned and
specified to protocol.130 Bellg et al.131 argue that without a thorough fidelity assessment, it is not possible
to determine how much and why any given intervention may be the cause of any observed changes in
outcomes. In order to assess fidelity, ongoing monitoring of the intervention and reliable and valid measuring
of treatment components is essential.132 Audio or videotaping intervention sessions is considered to be the
gold standard when monitoring fidelity of treatment delivery.130 Guidance from the Medical Research Council
also emphasises the importance of a systematic approach to process evaluation.133
Fidelity should therefore be assessed and reported, as recommended in both the MRC framework for
developing and evaluating complex interventions134 and the Consolidated Standards of Reporting Trials
(CONSORT) statement for reporting RCTs.129
The concept of fidelity sits within a broader framework for health behaviour change trials, such as that
developed by the National Institutes of Health Behaviour Change Consortium,131 and involves evaluating
whether or not intervention components were delivered as intended over the duration of the intervention.
However, a systematic review of psychosocial treatments found that only 3.5% of studies conducted any
evaluation of fidelity of treatment delivery.135
In addition to evaluating the extent of delivery of a behavioural intervention, it is also important to
recognise and understand the active ingredients of an intervention.136 Interventions encompassing different
behaviour change elements are often complex and comprise many potentially interrelating components
which address different aspects of the behaviour being targeted for change.134 The precise components
of such interventions are difficult to establish as there is a lack of standardised language and confusions
may arise when different labels are used to identify the same behaviour change techniques, or different
techniques are identified by the same label.137
In response to this lack of standardised language, a taxonomy of behaviour change techniques (BCTs) has
been developed to systematically describe specific elements of behaviour change interventions. BCTs are
defined as the components of an intervention aimed at changing behaviour which are observable and
replicable. Goal-setting, positive feedback and action planning are all examples of BCTs.
This BCT taxonomy has been modified for use in various health behaviour contexts, such as behavioural
support for smoking cessation,138 weight management,139 and physical activity and healthy eating
behaviours.140 We used this taxonomy to inform the development of intervention components for lowering
levels of cholesterol and other CVD risk factors in people with SMI (Primrose).106
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The Primrose cluster randomised controlled trial
A total of 326 patients and 76 GP practices were recruited to the trial between January 2014 and January
2016. Patients with a diagnosis of schizophrenia, bipolar disorder or other psychosis, aged 18–75 years, with
raised levels of cholesterol and one or more other CVD risk factors were recruited to the study through the
UK CRN. GP practices were randomised to receive training and deliver the Primrose intervention or standard
care. The primary outcome of interest was the level of total cholesterol at the 12-month follow-up.
Nurses, HCAs and one GP (providers) from 38 GP practices were randomly allocated to deliver the Primrose
intervention and attend 2 days of training. The training days were delivered 2 weeks apart to enable the
providers to deliver an appointment in between training sessions and rehearse any aspects that they felt
less confident with at training session 2. Providers were given a study manual that included help sheets for
each intervention component and clinical outcome, appointment flow charts and practical advice on
preparing for and organising appointments.
Providers were trained to identify the patient’s primary CVD risk factors at the first intervention appointment
and to work collaboratively with the patient to set a behavioural goal targeting the CVD risk factor.
Providers were given a flow chart that set out the procedure for deciding on an appropriate behavioural
goal. The flow chart detailed potential interventions and behaviours that would have the largest impact on
lowering levels of cholesterol, through to blood pressure, pre-diabetes, diabetes mellitus, smoking, weight
and alcohol misuse. To lower levels of cholesterol, the provider was guided to begin the consultation by
checking whether or not the patient was adhering to their statin prescription (if prescribed). If the patient
was on a statin but was not taking it regularly, the suggested goal was to help the patient improve their
statin adherence. If the patient had been prescribed a statin and was adherent, the next appropriate
intervention was to set a goal around improving diet and increasing physical activity.
The training was delivered by a health psychologist, a practice nurse with mental health expertise, a lived
experience trainer and the programme manager and covered the rationale for the study and intervention
design, SMI and role play of appointments using the following eight BCTs: (1) setting a behavioural goal,
(2) involving supportive others, (3) action planning, (4) recording progress towards the goal, (5) reviewing
progress, (6) giving positive feedback, (7) coping with setbacks and (8) forming habits.
Study aim
The aim of this study was to assess the fidelity of delivery (adherence to the manual and training programme)
of the Primrose intervention. The study also aimed to identify whether or not there were differences in the
extent to which key intervention components were delivered.
Objectives
1. To assess whether or not pre-specified intervention components of the Primrose intervention are
delivered by nurses and HCAs.
2. To assess whether or not appropriate behavioural goals that targeted cholesterol level were set in the
first appointment.
3. To determine whether or not particular intervention components are delivered more than others.
4. To assess whether or not there is a difference in fidelity of delivery between nurses and HCAs.
Method
A fidelity assessment of audio-recorded Primrose intervention appointments. The intervention was designed
to lower levels of cholesterol and other CVD risk factors in people with SMI in primary care and its
effectiveness tested in a cluster RCT (Primrose programme).
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Sample
A random 20% sample of received audio files were selected for the fidelity assessment as specified in the
original funding application.
Data collection
Patients and providers were asked to provide written consent to audio-record all Primrose intervention
appointments. Providers were requested to spend 60 minutes delivering the first appointment and
15–20 minutes on subsequent appointments and were supplied with a digital audio-recorder and written
instructions on operating and returning the audio files to the study team. Providers were asked to audio-
record all appointments with participants who had given consent and to upload each file via a secure data
protection system (IDHS Safe Haven, University College London, London, UK).
Measures
Fidelity of delivery
Appointment fidelity checklists were developed by the study authors to assess fidelity of delivery of the
intervention, along with coding guidelines and examples, using a procedure that has been found to
be effective in other fidelity studies.108 The checklists consisted of intervention components, provider
behaviours necessary to perform each activity and scoring criteria for each provider behaviour. First
appointment checklists (Table 6) consisted of three main sections: (1) introduction (explaining the purpose
of Primrose), (2) delivery of six behaviour change strategies (setting a relevant behavioural goal, involving
supportive others, developing an action plan, recording behaviour, forming habits and providing positive
feedback) and (3) finishing the appointment (arranging the next appointment and allowing the
opportunity for the patient to ask questions).
TABLE 6 First appointment checklist
First appointment checklist
Patient ID number:
Intervention
component Provider behaviour
Scoring criteria (2= done, 1= done to some extent,
0= judged appropriate to do but not done, N/A= judged
not appropriate to do) Score
Introduction The purpose of the
Primrose service is
explained
2= The purpose of the Primrose service was explained to the
patient
1= The purpose of the Primrose service was partially explained to
the patient e.g.
l The nurse asked the patient if they understood the purpose
but did not explain further
l The purpose was explained but it did not accurately reflect the
Primrose service objectives
0= The purpose of the Primrose service was not explained to the
patient
1. Set a relevant
behavioural goal
What is the patient’s
primary risk factor(s)?
Cholesterol
Blood pressure
Pre-diabetes
Diabetes mellitus
Smoking
Weight
Alcohol
continued
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TABLE 6 First appointment checklist (continued )
First appointment checklist
Patient ID number:
Intervention
component Provider behaviour
Scoring criteria (2= done, 1= done to some extent,
0= judged appropriate to do but not done, N/A= judged
not appropriate to do) Score
What risk factor was
targeted?
Cholesterol
Blood pressure
Pre-diabetes
Diabetes mellitus
Smoking
Weight
Alcohol
Is the patient’s CVD risk
profile discussed?
2= The patient’s full CVD risk profile was discussed
1= Some but not all of the patient’s CVD risk profile was discussed
(e.g. only one risk factor discussed when more are present)
0= The patient’s CVD risk profile was not discussed
Is the patient asked
which area of physical
health they would like
to work on?
2= The patient was asked about which aspect of their physical
health they would like to work on
0= The patient was not asked about which aspect of their physical
health they would like to work on
Is a behavioural or
outcome goal set?
2= A goal was set
0= A goal was not set
What was the goal that
was set?
Adherence
Diet
Exercise
Smoking
Alcohol
Other
Is the goal relevant to
the patient’s primary or
a relevant risk factor?
2= If the risk score is > 10% and/or the patient is on a statin the
goal made was on taking or starting medication. If the risk score is
< 10% and/or the patient is not on a statin the goal made was on
diet and/or physical activity
1= If the risk score is > 10% and/or the patient is on a statin the goal
made was on diet and/or physical activity. If the risk score is < 10%
and/or the patient is not on a statin the goal made was targeting a
different but relevant risk factor (e.g. the patient was a smoker and
the goal was stop smoking)
0= The goal was not relevant to any of the patient’s risk factors
Is the goal SMART? 2= The goal was SMART (e.g. walk to the park for
30 minutes a day)
1= The goal was S, M, A, R or T but did not cover
all 5 components
0= The goal was not SMART (e.g. lose weight,
lower levels of cholesterol)
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TABLE 6 First appointment checklist (continued )
First appointment checklist
Patient ID number:
Intervention
component Provider behaviour
Scoring criteria (2= done, 1= done to some extent,
0= judged appropriate to do but not done, N/A= judged
not appropriate to do) Score
2. Involve
supportive others
Is the patient asked
whether they would like
to involve anyone in
their care?
2= The patient was asked if they would like to involve someone in
their care
0= The patient was not asked if they would like to involve
someone in their care
Is there an exploration
of how they would
they like them to be
involved?
2= There was an exploration of how the supportive other might
be involved or this was not applicable as the patient did not want
to involve anyone
0= There was no exploration of how the supportive other might
be involved
3. Develop an
action plan
Is an action plan made? 2= An action plan was made
0= An action plan was not made
Does the action plan
include:
2= The action plan included when, where and with whom
(if applicable) the goal would be performed. If whom is not
applicable still award a score of two if the other two components
were addressed1. When?
2. Where? 1= The action plan included when, where or with whom
(if applicable) the goal would be performed but did not cover all three
components. If whom is not applicable award a score of one if one of
the other two components was not addressed
3. With whom the
behaviour would be
performed?
0= The action plan did not include when, where or with whom
(if applicable) the goal would be performed (None of the elements)
4. Record behaviour Is there a discussion on
how progress would be
recorded?
2= There was a discussion on how progress would be recorded
(e.g. recording number of cigarettes smoked, food diary, daily
physical activity, daily medication taking)
0= There was no discussion on how progress would be recorded
Is the patient
encouraged to record
progress in ‘My Health
Plan’?
2= Yes
0= No
5. Form habits Is the patient
encouraged to form a
habit by linking the
action plan to activities
that they do regularly?
2= The patient was encouraged to form a habit by linking the
action plan to activities that they do regularly (e.g. walking to the
shops rather than getting the bus, taking medication when they
brush their teeth)
1= The patient was encouraged to form a habit but there was no
discussion with them on how to do it
0= The patient was not encouraged to form a habit
6. Positive feedback Is positive feedback
given for attending the
appointment?
2= Positive feedback was given for attending the appointment
(e.g. thank you for coming, it is good to see you, well done for
coming)
0= No positive feedback was given for attending the appointment
Is the patient asked if
they are happy with the
decisions made?
2= The patient was asked whether they are happy with the
decisions made
0= The patient was not asked whether they are happy with the
decisions made
continued
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Subsequent appointment checklists (Table 7) included two sections: (1) delivery of seven behaviour change
strategies (reviewing progress with behavioural goals, coping with setbacks, developing an action plan,
recording behaviour, forming habits, providing positive feedback, following up supportive others) and
(2) finishing the appointment.
Manual-specified intervention components, such as the ‘introduction’ and ‘forming habits’, in appointment
1 constituted a single-provider behaviour, whereas ‘setting a relevant behavioural goal’ constituted up to
five different provider behaviours, such as ‘was a goal set?’ and ’was the goal relevant to the patient’s
CVD risk factors?’. All other intervention components contained two required provider behaviours. In
the subsequent appointments, all possible intervention components consisted of two required provider
behaviours apart from ‘forming habits’ and ‘involving supportive others’, which consisted of one provider
behaviour. ‘Coping with setbacks’ consisted of four provider behaviours.
TABLE 6 First appointment checklist (continued )
First appointment checklist
Patient ID number:
Intervention
component Provider behaviour
Scoring criteria (2= done, 1= done to some extent,
0= judged appropriate to do but not done, N/A= judged
not appropriate to do) Score
7. Finishing the
appointment
Is the patient given the
opportunity to ask
questions?
2= The patient was asked whether they had any questions and the
questions were addressed
1= The patient was asked whether they had any questions but the
questions were not addressed
0= The patient was not asked whether they had any questions
Is the next appointment
arranged?
2= The date and time of the next appointment was arranged
0= The date and time of the next appointment was not arranged
TABLE 7 Subsequent appointment checklist
Subsequent appointments checklist
Patient ID number: Appointment number:
Intervention
component Provider behaviour
Scoring Criteria (2= done, 1= done to some extent,
0= judged appropriate to do but not done,
N/A= judged not appropriate to do) Score
1. Review progress
with behavioural
goal
Is progress with goals
discussed?
2= Progress with goals was discussed
1= Progress was discussed however closed questions were asked,
‘Did you do X?’ rather than open questions ‘How did you get on?’
0= Progress with goals was not discussed
Is the goal reviewed? 2= If the goal was achieved either another goal was set or the
goal was maintained. If the goal was partly achieved or not
achieved the goal was reduced or a new goal was set
0= The goal was reviewed but there was no discussion about
setting a new goal, maintaining or reducing the goal
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TABLE 7 Subsequent appointment checklist (continued )
Subsequent appointments checklist
Patient ID number: Appointment number:
Intervention
component Provider behaviour
Scoring Criteria (2= done, 1= done to some extent,
0= judged appropriate to do but not done,
N/A= judged not appropriate to do) Score
2. Cope with
setbacks
Are setbacks identified? 2= Set backs were identified if the goal was not achieved or only
partly achieved. If the goal was achieved potential setbacks were
explored
0= Set backs were not identified. If the goal was achieved
potential setbacks were not explored
[N/A=Goal was completely accomplished and so it was not
applicable to discuss setbacks]
Is the patient told that
setbacks are part of the
process?
2= The patient was told that setbacks are part of the process
0= The patient was not told that setbacks are part of the process
Is the patient
encouraged to see
setbacks as a learning
opportunity?
2= The patient was encouraged to see setbacks as a learning
opportunity
0= The patient was not encouraged to see setbacks as a learning
opportunity
Are strategies agreed
with the patient for
coping with situations
that could lead
to a setback?
2= Strategies were discussed and agreed for coping with
situations that could lead to a setback
1= Strategies for coping with situations that could lead to a
setback were discussed but not agreed
0= Strategies were neither discussed or agreed for coping with
situations that could lead to a setback
3. Develop an
action plan
Is an action plan made? 2=An action plan was made
0=An action plan was not made
Does the action plan
include:
2= The action plan included when, where and with whom
(if applicable) the goal would be performed. If whom is not
applicable still award a score of two if the other two components
were addressed
When? 1= The action plan included when, where or with whom
(if applicable) the goal would be performed but did not cover all
three components. If whom is not applicable award a score of one
if one of the other two components was not addressed
Where? 0= The action plan did not include when, where or with whom
(if applicable) the goal would be performed (None of the elements)
With whom the
behaviour would be
performed?
4. Record behaviour Is there a discussion on
how progress would be
recorded?
2= There was a discussion on how progress would be recorded
(e.g. recording number of cigarettes smoked, food diary, daily
physical activity, daily medication taking)
0= There was no discussion on how progress would be recorded
Is the patient
encouraged to record
progress in ‘My Health
Plan’?
2= Yes
0=No
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Scoring
The checklists were applied to the transcripts and a score was generated for each intervention component.
The scoring methods of Hardeman et al.109 were used. The total number of behaviours delivered within an
appointment, were divided by the maximum score possible on the checklist.
A score of ‘2’ was given for provider behaviours that were performed; a ‘1’ for provider behaviours that
were ‘performed to some extent’; a ‘0’ for provider behaviours that were judged appropriate to do but
were not performed; and ‘not applicable’ for provider behaviours judged not appropriate to perform.
The scoring criteria for strategies that were ‘done to some extent’ were developed iteratively by two
researchers reviewing the transcripts and comparing their individually assigned codes.
TABLE 7 Subsequent appointment checklist (continued )
Subsequent appointments checklist
Patient ID number: Appointment number:
Intervention
component Provider behaviour
Scoring Criteria (2= done, 1= done to some extent,
0= judged appropriate to do but not done,
N/A= judged not appropriate to do) Score
5. Form habits Is the patient
encouraged to form a
habit by linking the
action plan to activities
that they do regularly?
2= The patient was encouraged to form a habit by linking the
action plan to activities that they do regularly (e.g. walking to the
shops rather than getting the bus, taking medication when they
brush their teeth)
1= The patient was encouraged to form a habit but there was no
discussion with them on how to do it
0= The patient was not encouraged to form a habit
6. Positive feedback Is positive feedback
given for attending the
appointment?
2= Positive feedback was given for attending the appointment
(e.g. thank you for coming, it is good to see you, well done for
coming)
0= No positive feedback was given for attending the appointment
Is positive feedback
given for any attempts
or progress towards
achieving their goal?
2= Positive feedback was given on progress towards achieving the
goal
1= Positive feedback was given for some but not all achievements
0= Positive feedback was not given on progress towards achieving
the goal
7. Follow-up
supportive others
Was there follow-up on
whether the patient
would like to involve
anyone in their care and
how they would like
them to be involved?
2= There was discussion on how the supportive other has been
involved
0= There was no discussion on involving supportive others
8. Finishing the
appointment
Is the next appointment
arranged?
2= The date and time of the next appointment was arranged
0= The date and time of the next appointment was not arranged
Is the patient given the
opportunity to ask
questions?
2= The patient was asked whether they had any questions and the
questions were addressed
1= The patient was asked whether they had any questions but the
questions were not addressed
0= The patient was not asked whether they had any questions
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Scoring for ‘setting a behavioural goal’
For each of the 14 initial appointments selected for the fidelity assessment, a descriptive analysis was
conducted to (1) determine each patient’s CVD risk factor profile, (2) identify which risk factor was
then targeted by the provider at the first appointment and (3) identify whether or not the subsequent
behavioural goal was appropriate to the risk factor. A score of ‘2’ was given if the goal was relevant to
the patient’s primary risk factor and an appropriate goal was agreed. A score of ‘1’ was given if a goal
was set that was relevant to the patient’s risk factor, but not the primary risk factor of cholesterol level.
For example, a score of 1 was given if a goal was set around reducing alcohol consumption (a patient’s
secondary risk factor) but their primary risk factor of cholesterol level was not targeted by either statin
prescription or adherence (as per clinical guidelines, statin prescription is recommended if a patient has a
QRISK2 score of > 10%), improving diet or by increasing physical activity. Finally a score of ‘0’ was given to
providers who did not set a goal or where no relevant (primary or otherwise) risk factor was targeted.
Analysis
Audio files were transcribed verbatim and anonymised by a professional third-party transcription service.
All transcripts were checked by members of the research team to ensure content accuracy and anonymity.
Each transcript was then coded independently by two researchers and scores were compared to determine
the reliability of the scoring system. Any disagreements or variations in coding were resolved through
discussion between researchers until a final score was agreed on.
Researchers scored intervention components as ‘missing’ when there was insufficient information available
in the transcript to be able to allocate a score of ‘0’, ‘1’, ‘2’ or ‘N/A’. All fields scored as ‘missing’ or ‘N/A’
were excluded from the denominator in the final analysis.
The fidelity score for each appointment was expressed as the total mean percentage of overall manual-
specified intervention components that were delivered in the appointment divided by the total number of
activities deemed applicable. In addition, to allow for comparisons between intervention components and
to determine whether or not some activities were delivered more than others, the mean total percentage
score for each individual intervention component was calculated across all appointments included in the
fidelity assessment. A higher percentage score indicates greater fidelity of delivery. We adopted thresholds
used in other intervention fidelity work,141,142 where 81–100% constituted high fidelity, 51–80% was
moderate fidelity and ≤ 50% constituted low fidelity.
Results
Out of a total of 813 appointments attended, 431 audio files (53%) were received by the study team.
One or more appointment audio files were returned by 33 providers (80.5%) for 90 patients (73.1%).
A number of appointments were not audio-recorded although patients’ consent had been given;
providers gave the following reasons: telephone appointment, audio-recorder batteries ran out, faulty
audio-recorder, provider forgot to record and patient retracted consent to record the appointment.
For the purpose of this study, we randomly sampled 20% of first appointment audio files (n = 14) and 20%
of all subsequent appointment audio files (n = 72) to assess whether or not the intervention was delivered to
protocol. Table 8 presents the total sample and the fidelity sample for patients, providers and audio files.
TABLE 8 Intervention and fidelity samples for patients, providers and audio files
Sample Patients Providers Audio files
Total, n 123 41 431
Fidelity, n (%) 52 (42) 23 (56) 86 (20)
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Provider characteristics
A total of 41 providers (18 nurses, 22 HCAs and one GP) from 38 GP practices were randomised to
receive training to deliver the Primrose intervention to all recruited patients at their GP practice. In three
GP practices, only two members of staff were trained because the original staff member left the practice
part way through the study. All providers gave their consent to be audio-recorded.
Twenty-three providers were included in the fidelity analysis, of whom 13 (57%) were nurses, 9 (39%)
were HCAs and one was a GP (4%). The majority of providers were female (95.7%) and of white ethnic
background (95.7%). The mean age of providers was 45.9 years (range 30–60 years) and the average
length of experience working as a nurse, HCA or GP was 10 years (range 10 months to 27 years).
Eleven providers (48%) had no previous experience of being involved in research. Table 9 presents the
characteristics of the fidelity and trial samples.
TABLE 9 Characteristics of intervention providers in the fidelity assessment and overall trial samples
Characteristic
Sample, n (%)
Fidelity (N= 23) Trial (N= 41)
Provider type
HCA 9 (39.1) 22 (53.7)
Nurse 13 (56.5) 18 (43.9)
GP 1 (4.3) 1 (2.4)
Ethnicity
White 22 (95.7) 39 (95.12)
Asian 1 (4.3) 2 (4.88)
Age (years)
> 25 0 (0) 1 (2.4)
25–35 5 (21.7) 8 (19.5)
36–45 5 (21.7) 9 (22)
46–55 7 (30.4) 15 (36.6)
56–65 6 (26.1) 8 (19.5)
> 65 0 (0) 0 (0)
Gender
Female 22 (95.7) 39 (95.1)
Male 1 (4.3) 2 (4.9)
Length of experience (as nurse or HCA) (years)
> 1 1 (4.35) 1 (2.44)
1 to 2 3 (13.04) 4 (9.76)
3 to 5 4 (17.39) 9 (21.95)
6 to 10 6 (26.09) 10 (24.39)
11 to 15 2 (8.70) 5 (12.20)
16 to 20 2 (8.70) 6 (14.63)
21 to 30 4 (17.39) 5 (12.20)
Missing 1 (4.35) 1 (2.44)
Previous experience of research
Yes 12 (52.2) 16 (39)
No 11 (47.8) 25 (61)
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
82
Patient characteristics
A total of 155 patients were randomised to receive the intervention and 139 patients (89.7%) gave their consent
to be audio-recorded. A total of 123 (79.4%) patients attended one or more intervention appointments and
one or more appointments were included in the fidelity sample for 52 patients (42.3%). Table 10 presents the
characteristics of the fidelity and overall intervention samples. The samples appear to be evenly matched with
the exception of a lower number of patients in the ≥ 70-year age category in the fidelity sample compared with
the overall intervention sample. The majority of patients in the fidelity sample were female (54%) and of white
ethnic background (90%). The mean age of patients was 51 years in both groups with most patients falling into
the 40- to 49-year age category (29%) and 46% of patients had a diagnosis of bipolar disorder.
Intervention appointment characteristics
The mean length of the first appointments in the fidelity sample was 28 minutes (range 19–42 minutes)
and in subsequent appointments 14 minutes (range 4–32 minutes). More than half of the fidelity sample
appointments (n = 49, 57%) were delivered by a practice nurse, 36 (41.9%) by HCAs and one (1.2%)
appointment was delivered by a GP.
Fidelity
A total of 67.7% (median of 65.2%) of intervention manual-specified activities were delivered across
all appointments, although there was considerable variation among activities. Mean fidelity to specific
intervention components ranged from 47.8% for ‘forming habits’ to 90.2% for ‘reviewing progress’ across
all appointments. Average inter-rater reliability for coding was 86% with a Cohen’s kappa of 0.668 (95% CI
0.63 to 0.70). Table 11 presents the percentage adherence to each specified intervention component in
appointment 1, subsequent and all appointments.
TABLE 10 Characteristics of intervention patients in the fidelity assessment and overall intervention samples
Characteristic
Sample, n (%)
Fidelity subset (N= 52) All intervention (N= 155)
Ethnicity (n = 154)a
White 47 (90) 134 (87)
Black 3 (6) 11 (7)
Asian 1 (2) 5 (3)
Other 1 (2) 4 (3)
Age (years)
30–39 9 (17) 25 (16)
40–49 15 (29) 48 (31)
50–59 14 (27) 38 (25)
60–69 13 (25) 32 (21)
≥ 70 1 (2) 12 (8)
Gender
Female 28 (54) 88 (57)
Male 24 (46) 67 (43)
Diagnosis
Schizophrenia/schizoaffective disorder 20 (38) 54 (35)
Bipolar disorder 24 (46) 71 (46)
Other psychosis 8 (15) 30 (19)
a One patient’s ethnic background was unknown.
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Missing and not applicable intervention components
In total, 8.2% of all intervention components were not applicable and 4.8% were ‘missing’. Table 12
provides a breakdown of not applicable and missing scores by intervention component. Follow-up of
supportive others had the highest amount of missing information in subsequent appointments, whereas
‘coping with setbacks’ was the intervention component that was the most likely to be not applicable.
TABLE 11 Adherence to intervention components in appointment 1 and subsequent appointments
Intervention component
Adherence n/N (%)
Appointment 1 Subsequent appointments All appointments
Introduction 17/28 (60.7) N/Aa 17/28 (60.7)
Finishing the appointment 24/56 (42.9) 190/276 (68.8) 214/332 (64.5)
Goal-setting 112/140 (80) N/Ab 112/140 (80)
Involve supportive others 34/48 (70.8) 60/64 (93.8) 94/112 (83.9)
Develop an action plan 43/54 (79.6) 161/260 (61.9) 204/314 (65)
Record behaviour 50/56 (89.3) 158/260 (61) 208/316 (65.8)
Form habits 18/28 (64.3) 68/152 (44.7) 86/180 (47.8)
Positive feedback 40/56 (71.4) 229/286 (80.1) 269/342 (78.7)
Review progress N/A 220/244 (90.2) 220/244(90.2)
Cope with setbacks N/A 203/394 (51.5) 203/394 (51.5)
Total 338/466 (72.5) 1289/1936 (66.6) 1627/2402 (67.7)
N/A, not applicable.
a The introduction component involved explaining the purpose of the Primrose intervention and was therefore only
applicable in the first appointment.
b Goal-setting was not applicable in subsequent appointments, as this was explored within ‘reviewing progress’.
TABLE 12 Number of appointment intervention components that were not applicable or missing
Intervention component N/A, n ‘Missing’, n
Introduction 0 0
Finishing the appointment 1 0
Goal-setting 0 0
Follow-up supportive others 4 40
Develop an action plan 2 11
Record behaviour 2 15
Form habits 3 0
Positive feedback 3 0
Review progress 3 0
Cope with setbacks 95 0
Total, n/N (%) 113/1376 (8.2) 66/1376 (4.8)
N/A, not applicable.
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Fidelity to setting a behavioural goal
‘Setting a behaviour goal’ was specified as an intervention component in appointment 1 and, therefore,
only the CVD risk factors and agreed goals for the appointment 1 sample (n = 14) were explored.
Table 13 presents each patient’s primary CVD risk factor, the risk factor that was targeted in appointment 1,
the goal that was actually set, the goal that we would have expected to have been set and the awarded
score.
Eight (57.1%) patients set a goal around behaviours that had an impact on lowering levels of cholesterol,
while three (21.4%) patients set a goal around smoking cessation, two (14.3%) patients set a goal around
reducing alcohol intake and one (7.1%) patient did not set a goal. No patients addressed statin adherence
or initiation (Table 14).
TABLE 13 Patient CVD risk factors and goals set in appointment 1
Patient
Primary CVD
risk factor(s) QRISK (%)
CVD risk factor
targeted Goal set
Goal that should
have been set
Score
given
1 Cholesterol 6.6 Cholesterol/weight Improve diet and increase
physical activity
Improve diet 2
2 Cholesterol 1.1 Smoking Stop smoking Improve diet 1
3 Cholesterol/on
statin
19.8 Alcohol Reduce alcohol consumption Statin adherence 1
4 Cholesterol/on
statin
31.8 Cholesterol/weight Increase physical activity Statin adherence 1
5 Cholesterol 2.0 Alcohol/weight Reduce alcohol consumption Improve diet 1
6 Cholesterol 20.5 None None Statin prescription 0
7 Cholesterol/on
statin
17.6 Cholesterol/weight Improve diet Statin adherence 1
8 Cholesterol/
pre diabetes
4.5 Weight Improve diet Improve diet 2
9 Cholesterol/on
statin
8.0 Smoking Stop smoking Statin adherence 1
10 Cholesterol/
pre diabetes
3.9 Cholesterol Improve diet Improve diet 2
11 Cholesterol 1.8 Cholesterol Improve diet and increase
physical activity
Improve diet 2
12 Cholesterol 3.4 Smoking Stop smoking Improve diet 1
13 Cholesterol/on
statin
13.5 Weight Improve diet Improve dieta 2
14 Cholesterol 13.4 Weight Increase physical activity Statin prescription 1
a The provider reviewed the patient’s statin adherence in the appointment and referred the patient on to phlebotomy for
a cholesterol level check. As the patient was happy managing their own statin adherence, the appropriate goal was to
improve diet.
TABLE 14 Health behaviours targeted in appointment 1
Goal category
Lower level of cholesterol
Statin prescription/
adherence
Improve
diet
Increase physical
activity
Stop
smoking
Reduce alcohol
intake
No goal
set Total
Number of
patients (%)
0 (0.0) 6 (42.9) 2 (14.3) 3 (21.4) 2 (14.3) 1 (7.1) 14 (100)
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Fidelity by appointment number
Higher adherence to intervention components was seen in appointment 1 (72.5%) than in subsequent
appointments (66.6%) and adherence within individual appointments varied from 40% (appointment 12,
n = 1) to 81.4% (appointment 8, n = 5) (Figure 3).
Fidelity by provider type
A mean of 79.5% of intervention manual specified activities were delivered during appointments by nurses
(n = 13) in comparison to 64.3% in appointments delivered by HCAs (n = 9). The GP was excluded from this
analysis. The difference in fidelity scores between nurses and HCAs was significant [t(20) = 2.32; p = 0.037].
Discussion
Summary of findings
This study presents a thorough assessment of fidelity to a behaviour change intervention for lowering
levels of cholesterol and other CVD risk factors delivered in a primary care trial (Primrose).
In response to the first objective of whether or not the intervention components of the Primrose
intervention were delivered as specified, our results showed that fidelity was 67.7%. This score indicates
moderate fidelity to the intervention.141,142 This result is comparable to similar fidelity assessments of
behavioural interventions including an assessment of a cardiovascular prevention programme110 but higher
than the fidelity of delivery of a physical activity intervention (44%).109 The fidelity observed in this study
was slightly lower than for an intervention to increase attendance at a stop smoking service (71.3%);143
however, it was recognised by the authors that the sessions were delivered by two advisors who created
a sense of shared responsibility, mitigated feelings of nervousness and encouraged higher adherence to
the protocol in an environment where one assessor was being observed by the other.
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The second objective sought to determine whether or not a relevant behavioural goal targeting cholesterol
level was set at the first appointment. All 14 patients sampled for the first appointment assessment had a
primary CVD risk factor of raised cholesterol levels and should have been supported by the provider to set a
behavioural goal which would have had a direct impact on lowering levels of cholesterol. Although six of the
patients had a risk score that exceeded the threshold for statin prescription (> 10%) and five of those patients
were already prescribed a statin, none of these patients set a goal around increasing adherence to statins.
Only eight (57.1%) patients set a goal related to behavioural modification (e.g. diet or physical activity)
to lower levels of cholesterol, while three (21.4%) patients set a goal on smoking cessation, two (14.3%)
patients on reducing alcohol intake and one (7.1%) patient did not set a goal.
As behavioural goals were intended to be patient-led with the support of the provider, the patient may
have declined to work on reducing their levels of cholesterol and instead chose to set a goal that they felt
was more relevant to their health profile and could produce more tangible results on their health, such as
stopping smoking or reducing alcohol.
For the third objective, investigating whether or not particular intervention components were delivered
more than others, the highest adherence was seen for ‘reviewing progress with goals’ (90.2%) and the
lowest for ‘forming habits’ (47.8%). Providers may have been more comfortable reviewing patient progress
as they may already be familiar with providing short-term support in usual practice, such as monitoring
blood test results, weight change and blood pressure. Longer-term monitoring and support for behavioural
change in primary care is perhaps less common because of short consultation times, limited resources
and less continuity of care, which could explain why providers may have found it difficult to address
habit formation. This finding may also suggest that if forming habits is considered a crucial element for
behaviour change then low adherence to this activity may lead to decreased effectiveness of the
intervention on health outcomes over time.
‘Goal-setting’ (80%) was discussed in depth at the start of the intervention training, whereas those BCTs
with the lowest adherence scores (‘forming habits’ and ‘coping with setbacks’) were covered towards the
end of the training in less detail. It is possible that providers remembered the earlier, more detailed aspects
of the training over later topics when fatigue may have set in. A way of improving adherence to these
techniques could be to revisit these BCTs at the start of the second training day or include specific role-play
activities which explore their applicability in more detail.
The fourth research question assessed whether or not there was a difference in fidelity between provider
types. Nurses were more adherent than HCAs, suggesting that the previous experience and skills of providers
may need to be taken into consideration for future intervention training programmes. The Primrose trial
originally aimed to train practice nurses as intervention providers but, owing to a shortage of nurses in some
GP practices and the increasing involvement of HCAs in CVD prevention work, HCAs were trained to deliver
the intervention to recruited patients if a nurse was unavailable. If the intervention was delivered solely by
nurses, as originally intended, then adherence to the intervention may have been higher, clinical goals may
have been more relevant and the intervention may have had a stronger impact on study outcomes.
First appointments were on average 28 minutes (range 19–42 minutes) in duration. This was less than half
the time that providers were asked to spend with patients at the first appointment (60 minutes). This
observation could be used to explain the moderate fidelity as there may not have been enough time to
cover all of the specified components of the intervention.
Strengths
A strength of this study was the robust methodology. Transcripts were double coded and anonymised to
remove potential bias. Inter-rater reliability of scoring between two researchers was 86% with a Cohen’s
kappa of 0.668 (95% CI 0.63 to 0.70), indicating a moderate level of agreement between raters.144 Our
assessment of a random 20% of the sample is also seen as the recommended amount for fidelity studies.145
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An audio file return rate of 53% was achieved but the number of data provided was large. Health
professionals with limited research experience and who had limited time for administrative tasks and a lack
of technological support were responsible for operating the recorders and uploading the files rather than
trained researchers. The complexity of co-ordinating the return of audio files across 41 providers in 38 GP
practices must also be taken into consideration.
A further strength of the study was its external validity. Assessing the fidelity of delivery of an intervention
in a real-world primary care setting with primary care nurses and HCAs, rather than in an artificial research
setting with trained intervention specialists may increase the ability to apply the results of this study to
training and intervention recommendations for health professionals working in primary care.
Limitations
A potential limitation of the study was the representativeness of the fidelity sample compared with the
trial sample of intervention providers. There was an over-representation of nurses in the fidelity sample
(60.9% compared with 43.9% in the trial) as well as an over-representation of providers who had
previous experience of research (52.2% compared with 39% in trial). Although the sample was randomly
generated by a statistician not involved in the fidelity analysis, the over-representation of nurses could be
explained by a higher return of audio files and a greater number of overall appointments being delivered
by nurses than being delivered by HCAs, meaning that nurses comprised a larger proportion of the sample
in the fidelity study than in the trial. Similarly, those involved in previous research may also have been
more likely to return audio files meaning they were more likely to appear in our fidelity sample. Future
intervention training may need to be adapted to troubleshoot potential barriers for HCAs and those with
limited research experience for providing the suggested number of intervention appointments to patients
and returning the audio files.
Another limitation of the study was that, owing to a decreasing number of subsequent appointments from
appointment nine onwards, the potential pool of audio files that the sample could be chosen from was
small and for some appointments only one audio file was randomly selected for the fidelity assessment.
Interpretation of the results of these subsequent appointments should therefore be treated with caution.
The Primrose intervention included up to 17 provider behaviours across seven different intervention
components in the first appointment and 16 provider behaviours across eight different intervention
components in subsequent appointments. Furthermore, patients presented with a range of CVD risk
factors meaning that providers had to tailor the intervention to each individual. This was a complex
intervention and previous research has shown that intervention complexity has a negative impact on
fidelity.146 This might contribute to the moderate score that was observed.
The structure and content of the intervention training could have been another contributing factor to
explain the moderate fidelity score as the training may not have been detailed enough, or even too
complex for providers who had little previous experience of delivering behaviour change interventions.147
Providers were instructed to complete their first intervention appointments soon after having attended
the intervention training sessions which could explain why overall adherence was higher in the first
appointment (72.5%) than in subsequent appointments (66.6%).
Future work could take into consideration the wider content and conversational aspects of the intervention
appointments, which were beyond the scope of this study.
Conclusion
This study presents the preliminary findings from an analysis of data collected from a cluster randomised trial
to assess fidelity of delivery of an intervention for lowering CVD risk in people with SMI in primary care. The
findings from this fidelity assessment suggest that moderate fidelity was achieved, particular intervention
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components were delivered more than others, and nurses were more adherent than HCAs to intervention
delivery. None of the goals that were set targeted the most effective interventions and behaviours for
lowering levels of cholesterol (statin prescription and/or statin adherence). Future research on similar
interventions should ensure that there is enhanced support and supervision throughout the intervention
period and greater consideration of the existing clinical skills of those delivering the intervention. These
findings now need to be integrated with the overall trial results and used to help to explain and disseminate
the results of the Primrose cluster RCT.
DOI: 10.3310/pgfar07020 PROGRAMME GRANTS FOR APPLIED RESEARCH 2019 VOL. 7 NO. 2
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Osborn et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
89

Appendix 3 Links to full text of published studies
Work package 1
Cooper SJ, Reynolds GP, Barnes T, England E, Haddad PM, Heald A, et al. BAP guidelines on the management
of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic
drug treatment. J Psychopharmacol 2016;30:717–48. https://doi.org/10.1177/0269881116645254
Osborn DP, Hardoon S, Omar RZ, Holt RI, King M, Larsen J, et al. Cardiovascular risk prediction models for
people with severe mental illness: results from the prediction and management of cardiovascular risk in
people with severe mental illnesses (PRIMROSE) research program. JAMA Psychiatry 2015;72:143–51.
https://doi.org/10.1001/jamapsychiatry.2014.2133
Zomer E, Osborn D, Nazareth I, Blackburn R, Burton A, Hardoon S, et al. Effectiveness and cost-effectiveness
of a cardiovascular risk prediction algorithm for people with severe mental illness (PRIMROSE). BMJ Open
2017;7:e018181. https://doi.org/10.1136/bmjopen-2017-018181
Work package 2
Blackburn R, Osborn D, Walters K, Nazareth I, Petersen I. Statin prescribing for prevention of cardiovascular
disease among people with severe mental illness: cohort study in UK primary care. Schizophr Res
2018;192:219–25. https://doi.org/10.1016/j.schres.2017.05.028
Blackburn R, Osborn D, Walters K, Falcaro M, Nazareth I, Petersen I. Statin prescribing for people with
severe mental illnesses: a staggered cohort study of ‘real-world’ impacts. BMJ Open 2017;7:e013154.
https://doi.org/10.1136/bmjopen-2016-013154
Blackburn R. Exploring the Effectiveness of Statins for Primary Prevention of Cardiovascular Disease
in People with Severe Mental Illness. PhD dissertation. London. University College London; 2016.
URL: http://discovery.ucl.ac.uk/1476263 (accessed 24 April 2018).
Burton A, Osborn D, Atkins L, Michie S, Gray B, Stevenson F, et al. Lowering cardiovascular disease risk for
people with severe mental illnesses in primary care: a focus group study. PLOS ONE 2015;10:e0136603.
https://doi.org/10.1371/journal.pone.0136603
Burton A, Walters K, Atkins L, Howard M, Michie S, Peveler R, et al. Barriers, facilitators, and effective
interventions for lowering cardiovascular disease risk in people with severe mental illnesses: evidence from
a systematic review and focus group study. 2016, National Conference on Public Health Science, Cardiff, UK.
Lancet 388(Suppl. 2):30.
Work package 3
Osborn D, Burton A, Walters K, Nazareth I, Heinkel S, Atkins L, et al. Evaluating the clinical and cost
effectiveness of a behaviour change intervention for lowering cardiovascular disease risk for people with
severe mental illnesses in primary care (PRIMROSE study): study protocol for a cluster randomised
controlled trial. Trials 2016;17:80. https://doi.org/10.1186/s13063-016-1176-9
DOI: 10.3310/pgfar07020 PROGRAMME GRANTS FOR APPLIED RESEARCH 2019 VOL. 7 NO. 2
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Osborn et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
91
Osborn D, Burton A, Hunter R, Marston L, Atkins L, Barnes T, et al. Clinical and cost-effectiveness of an
intervention for reducing cholesterol and cardiovascular risk for people with severe mental illness in English
primary care: a cluster randomised controlled trial. Lancet Psychiatr 2018;5:145–54.
Other outputs arising from the programme
Atkins L, Michie S. Changing eating behaviour: what can we learn from behavioural science? Nutr Bull
2013;8:30–5. https://doi.org/10.1111/nbu.12004
Gray B, Larsen J, Faulkner A. Third sector facilitation of lived experience in research: a case study of service
user and carer involvement in the Primrose project. JMHTEP 2013;8:141–51. https://doi.org/10.1108/
JMHTEP-03-2013-0008
Hardoon S, Hayes JF, Blackburn R, Petersen I, Walters K, Nazareth I, Osborn DP. Recording of severe
mental illness in United Kingdom primary care, 2000–2010. PLOS ONE 2013;8:e82365. https://doi.org/
10.1371/journal.pone.0082365
Staley K. A Series of Case Studies Illustrating the Impact of Service User and Carer Involvement on Research.
London: NIHR Network: Mental Health; 2013. URL: www.nihr.ac.uk/nihr-in-your-area/mental-health/
documents/Impact-of-service-user-and-carer-involvement%20PDF.pdf (accessed 5 May 2018).
Conference proceedings
Atkins L, Michie S. Using Theoretical Domains Framework to Inform an Intervention to Manage CVD
Risk in People with Severe Mental Illness: Primrose Programme. Paper presented at Workshop Exploring
the Theoretical Domains Framework in Behaviour Change Research, Ottawa, ON, December 2012.
URL: https://ktcanada.ohri.ca/workshop_tdf/TDF_Atkins.pdf (accessed 19 November 2018).
Atkins L, Burton A, Walters K, Michie S, Osborn D. Developing a Theory-based Intervention to Reduce
Cardiovascular Disease Risk in People with Severe Mental Illness: Findings from a Systematic Review and
Focus Group Study. University of Oxford, Oxford: UK Society of Behavioural Medicine; 2013.
Burton A, Osborn D. Developing an Intervention to Manage and Reduce Cardiovascular Disease (CVD) Risk
in People with Severe Mental Illness: A Focus Group Study. University College London, London: Qualitative
Health Conference; 2013.
Burton A, Osborn D, Atkins L, Michie S, Gray B, Stevenson F, et al. Developing an Intervention To Manage
Cardiovascular Disease Risk in People with Severe Mental Illness: A Focus Group Study. University of
Manchester, Manchester: Primary Care Mental Health Conference; 2013.
Blackburn R, Osborn D, Walters K, Petersen I, Nazareth I. Inequalities in Statin Prescribing for Primary
Prevention of Cardiovascular Disease in People with Severe Mental Illness. University of Exeter, Exeter:
Primary Care Mental Health Conference; 2014.
Blackburn R, Osborn D, Petersen I, Walters K, Nazareth I. Statin Prescribing for the Primary Prevention of
Cardiovascular Disease in People with Severe Mental Illness. Edinburgh: Society for Academic Primary Care
(SAPC); 2014.
Blackburn R, Osborn D, Petersen I, Walters K, Nazareth I. Systematic Review of the Evidence for the
Effectiveness of Statins for the Primary Prevention of Cardiovascular Disease in People with Severe Mental
Illness. Edinburgh: Society for Academic Primary Care (SAPC); 2014.
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
92
Blackburn R, Osborn D, Petersen I, Walters K, Nazareth I. Patterns of Statin Prescribing for the Primary
Prevention of Cardiovascular Disease in People with Severe Mental Illness. Taipai, Taiwan: International
Society for Pharmacoepidemiology; 2014.
Blackburn R, Osborn D, Petersen I, Walters K, Nazareth I. Statin Prescribing Cardiovascular Disease
Prevention in People with Severe Mental Illness. New York, NY: North American Primary Care Research
Group (NAPCRG); 2014.
Burton A, Osborn D, Atkins L, Michie S, Gray B, Stevenson F, et al. Development of a Theory and Evidence
Based Intervention to Manage Cardiovascular Disease Risk in People with Severe Mental Illnesses in Primary
Care (Primrose). University of Exeter, Exeter: Primary Care Mental Health Conference; 2014.
Osborn D. CVD Risk Assessment – Evidence from Primrose Regarding Who and What to Assess/Manage.
Malaga: European Network for Mental Health Service Evaluation (ENMESH). 2015. URL: http://enmesh.eu/
BookOfAbstracts.pdf (accessed 29 January 2017).
Blackburn R, Osborn D, Petersen I, Walters K, Nazareth I. Reducing Inequalities in Cardiovascular Health in
People with Severe Mental Illness: Evaluating the Real-Life Impact of Statin Prescribing. Warwick University,
Coventry: Public Health England Applied Epidemiology Scientific Conference; 2016.
Burton A, Heinkel S, Osborn D. Lowering Cardiovascular Risk for People with Severe Mental Illnesses
(Primrose). A Cluster Randomised Controlled Trial in Primary Care. Middlesbrough: Clinical Research
Network North East and North Cumbria (CRN NENC) Primary Care Research Forum; 2016.
Zomer E, Osborn D, Nazareth I, Blackburn R, Burton A, Hardoon S, et al. Effectiveness and Cost-effectiveness
of a Cardiovascular Risk Prediction Algorithm for People with Severe Mental Illness. Madrid: European
Congress of Psychiatry (EPA); 2016. URL: www.sciencedirect.com/science/article/pii/S0924933816004375?
via%3Dihub (accessed 18 March 2017).
Burton A, Zomer E, Walters K, Atkins L, Howard M, Michie S, et al. A Systematic Review of Interventions to
Manage Cardiovascular Disease Risk Factors in People with Severe Mental Illnesses. Melbourne, VIC:
15th World Congress on Public Health; 2017.
Zomer E, Osborn D, Nazareth I, Hunter R. Effectiveness and Cost-effectiveness of a Cardiovascular Risk
Prediction Algorithm for People with Severe Mental Illness. Melbourne, VIC: 15th World Congress on
Public Health; 2017.
Books/chapters
Michie S, Atkins L, West R. The Behaviour Change Wheel: A Guide to Designing Interventions. London:
Silverback Publishing; 2014. URL: www.behaviourchangewheel.com (accessed 3 November 2017).
DOI: 10.3310/pgfar07020 PROGRAMME GRANTS FOR APPLIED RESEARCH 2019 VOL. 7 NO. 2
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Osborn et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
93

Appendix 4 Development of the Primrose
intervention and training programme: figures
and tables
The following section presents supplementary information on the development of the Primroseintervention and training programme. Evidence from focus groups, a systematic review and workshops
with academic, clinical and lived experience experts was brought together and considered by a subgroup
of the programme management team. A logic model (Figure 4) was developed using this evidence, to
describe the relationship between factors that might influence the effectiveness and implementation of a
primary care nurse-HCA-delivered behaviour change intervention. The logic model was then used as a
guide to identifying key intervention and training components for delivering CVD prevention for people
with SMI in primary care. Table 15 presents a mapping of the barriers and facilitators identified in the
focus groups to the TDF. Potential intervention components were then identified that could be used to
address or facilitate the enactment of the domains. Table 16 provides a detailed description of the content
in each module of day 1 of the intervention training programme.
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FIGURE 4 Logic model of delivery of a CVD risk management intervention.
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TABLE 15 Mapping barriers and facilitators identified by the focus group study to the TDF to identify Primrose
intervention components
Which barriers need to be
addressed and facilitators
harnessed?
Who needs to be
targeted?
Theoretical domains
in which the barriers
and facilitators lie
Suggested intervention components
to address the barriers and harness
the facilitators
Negative attitudes of some
health professionals towards
CVD intervention in people with
SMI (e.g. losing weight and
stopping smoking)
Health professionals Optimism (pessimism) Nurse training on:
l Experiences of SMI
l Effective interventions for CVD risk
management in SMI
l Examples of service user motivation in
managing their own health= service
user involvement in training
l Peer influence= involve a nurse in
delivering the training
Difficulties for service users to
access GP services
Patients and health
professionals
Opportunity –
environmental context
and resources
Direct telephone number of health
professional
Difficulties in managing a
healthy lifestyle due to the
side effects of antipsychotic
medication
Patients and health
professionals
Knowledge and skills Training health professionals on the
effects of antipsychotics
Difficulties in managing a
healthy lifestyle due to the
impact of mental health
symptoms on the patient’s
ability to engage in healthy
behaviours
Patients and health
professionals
Capability Training – only initiate CVD risk prevention
when the service user is well
Action planning
Recording and reviewing progress
Identifying small achievable goals to work
towards
Coping with setbacks
Difficulties in managing a
healthy lifestyle due to a lack
of incentivised services
Patients and health
professionals
Opportunity –
environmental context
and resources
Local directory of services to refer people
with SMI to
Lack of awareness of increased
risk and effective interventions
for managing CVD risk in
people with SMI
Patients and health
professionals
Knowledge Training on:
l Increased risk of CVD in SMI
l What interventions work for patients
with SMI (e.g. simple behavioural
interventions, NRT, statins)
l Examples of service users managing
their own health – service users
delivering training
l Decision aid on CVD risk factors and
appropriate interventions
Patients not turning up to
scheduled appointments at their
GP practice
Patients and health
professionals
Behavioural regulation Have one named practice nurse/GP
overseeing care to ensure continuity
and to build a relationship
Contact details of supportive others to
follow-up non-attendees
Involving supportive others in
the patient’s care
Patients and health
professionals
Social opportunity/social
influences
Involve supportive others in monitoring
adherence to treatments and progress
with healthy lifestyle goals
Continuity of care Health professionals Physical opportunity Have one named practice nurse/GP
overseeing care to ensure continuity
and to build a relationshipEnvironmental context
and resources
Providing positive feedback to
patients during the appointments
Health professionals Reflective motivation Positive feedback
Reinforcement
Setting small, achievable
patient-led goals
Patients and health
professionals
Capabilty Setting a behavioural goal
Goals
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TABLE 16 The Primrose intervention training programme content
Summary of
training module Content of training module Mode of delivery
Increasing health
professional
awareness on the link
between SMI and
increased risk of CVD
The rationale and reasons for the study and delivering the intervention
in primary care were presented
Lectures by a practice
nurse with expertise
in SMI and the
programme manager
Discussions were held on the different factors that might lead to an
increased risk of CVD in people with SMI and the need to take these
factors into consideration when working with patients
Group discussion
Increasing mental
health awareness
To tackle any potential stigma and increase confidence in working
with people with SMI, we incorporated a session on mental health
awareness and education including:
Lecture by a practice
nurse with expertise
in SMI
l A session on personal experiences of living with bipolar disorder and
losing weight and stopping smoking with the aim of challenging
both stigma, and the potential view that stopping smoking and
losing weight is too difficult to achieve in people with SMI
Lecture by a lived
experience trainer
l The impact of the side effects of psychiatric medications on weight
gain and motivation
l Nurses were also advised to identify a member of staff at the GP
practice to whom they could go to with questions or concerns
about patients
Group discussion
Lowering CVD risk
factors
Nurses/HCAs were prompted to review each patient’s medical record to
establish their CVD risk profile
Lecture by a practice
nurse with expertise
in SMI
They were trained to work through appointment flow charts contained
within the study manual to arrive at an appropriate goal relevant to
both the patient’s risk profile and in collaboration with the patient and
then follow-up and monitor the goal at subsequent appointments
Lecture by health
psychologist
They were trained to follow a decision aid beginning with a review of
cholesterol level and to consider with the patient, potential interventions
that would have the greatest impact on lowering levels of cholesterol
Group discussion
Behaviour change
techniques
Nurses/HCAs were trained to use eight behaviour techniques with the
aim of addressing the barriers and harnessing the facilitators identified
by the focus groups. These were:
Lecture by health
psychologist
1. Setting a behavioural goal
2. Involving supportive others, such as family, friends or support
workers, to help patient’s work towards their goals
3. Action planning in collaboration with the patients to determine
where, when, with whom and for how long activities related to
achieving goals would be undertaken
4. Recording progress towards the goal to give a realistic picture of
progress, increase motivation on seeing evidence of success and
to identify any problems
5. Reviewing progress to identify and solve problems and to praise
progress or effort towards goal achievement
6. Giving positive feedback to promote engagement and encourage
progress
7. Preparing and coping with setbacks to learn from and develop
strategies for coping with situations that may lead to a setback
8. Forming habits so that behaviours become part of a routine and
require less effort to perform
Role-play observation
Role-play delivery
Group discussions
Maintaining
engagement
Nurses/HCAs were trained in ways of keeping patients motivated and
engaged. These included the importance of seeing the same person
throughout the intervention to ensure continuity of care and to establish a
relationship, booking the next appointment with the patient in person and
writing this in their diary or health plan, to offer flexibility of appointment
days and times, to book longer appointments and to give the option of a
telephone consultation if the patient was unable to attend
Lectures by health
psychologist and
programme manager
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